<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523420303068</prism:url><dc:identifier>doi:10.1016/j.ejmech.2020.112337</dc:identifier><eid>1-s2.0-S0223523420303068</eid><prism:doi>10.1016/j.ejmech.2020.112337</prism:doi><pii>S0223-5234(20)30306-8</pii><dc:title>Discovery of simplified benzazole fragments derived from the marine benzosceptrin B as necroptosis inhibitors involving the receptor interacting protein Kinase-1 </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>201</prism:volume><prism:startingPage>112337</prism:startingpage><prism:pageRange>112337</prism:pagerange><articleNumber>112337</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2020-09-01</prism:coverdate><prism:coverDisplayDate>1 September 2020</prism:coverdisplaydate><prism:copyright>© 2020 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Benchekroun, Mohamed</dc:creator><dc:creator>Ermolenko, Ludmila</dc:creator><dc:creator>Tran, Minh Quan</dc:creator><dc:creator>Vagneux, Agathe</dc:creator><dc:creator>Nedev, Hristo</dc:creator><dc:creator>Delehouzé, Claire</dc:creator><dc:creator>Souab, Mohamed</dc:creator><dc:creator>Baratte, Blandine</dc:creator><dc:creator>Josselin, Béatrice</dc:creator><dc:creator>Iorga, Bogdan I.</dc:creator><dc:creator>Ruchaud, Sandrine</dc:creator><dc:creator>Bach, Stéphane</dc:creator><dc:creator>Al-Mourabit, Ali</dc:creator><dc:description>
                  With the aim to develop new chemical tools based on simplified natural metabolites to help deciphering the molecular mechanism of necroptosis, simplified benzazole fragments including 2-aminobenzimidazole and the 2-aminobenzothiazole analogs were prepared during the synthesis of the marine benzosceptrin B. Conpounds inhibiting the RIPK1 protein kinase were discovered. A library of 54 synthetic analogs were prepared and evaluated through a phenotypic screen using the inhibition of the necrotic cell death induced by TNF-α in human Jurkat T cells deficient for the FADD protein. This article reports the design, synthesis and biological evaluation of a series of 2-aminobenzazoles on the necroptotic cell death through the inhibition of RIPK1 protein kinase. The 2-aminobenzimidazole and 2-aminobenzothiazole platforms presented herein can serve as novel chemical tools to study the molecular regulation of necroptosis and further develop lead drug candidates for chronic pathologies involving necroptosis.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>Aminobenzimidazole</dcterms:subject><dcterms:subject>Synthesis</dcterms:subject><dcterms:subject>Necroptosis</dcterms:subject><dcterms:subject>Kinase inhibitors</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523420303068" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523420303068" rel="scidir"/></link></coredata><objects><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="578" height="268" size="30226">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="713" height="715" size="143511">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="60" height="36" size="1235">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="115" height="76" size="3200">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="61" height="29" size="1049">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx9.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="533" height="142" size="28038">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="54" height="35" size="889">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="531" height="281" size="35728">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="622" height="85" size="21663">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-sc2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="45" height="21" size="834">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx8.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="500" height="194" size="38089">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="sc5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="387" height="86" size="9975">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-sc5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="622" height="474" size="64875">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="29" height="21" size="611">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="536" height="221" size="31071">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="61" height="29" size="1079">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx10.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="55" height="21" size="806">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx6.jpg?httpAccept=%2A%2F%2A</object><object ref="sc4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="533" height="184" size="16811">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-sc4.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="622" height="72" size="9887">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-sc3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="669" height="193" size="33732">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="61" height="21" size="841">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx7.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="101" size="4422">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="163" height="163" size="16606">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="fx5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="130" size="4646">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx5.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="145" size="5010">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="fx9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="105" size="3467">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx9.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="58" size="4542">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="fx3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="141" size="4123">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx3.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="116" size="6338">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="sc2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="30" size="3329">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-sc2.sml?httpAccept=%2A%2F%2A</object><object ref="fx8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="203" height="93" size="2477">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx8.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="85" size="8980">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="sc5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="49" size="3002">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-sc5.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="215" height="164" size="9429">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="fx4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="129" height="93" size="1657">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx4.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="90" size="5431">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="fx10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="103" size="3422">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx10.sml?httpAccept=%2A%2F%2A</object><object ref="fx6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="83" size="3446">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx6.sml?httpAccept=%2A%2F%2A</object><object ref="sc4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="76" size="3314">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-sc4.sml?httpAccept=%2A%2F%2A</object><object ref="sc3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="25" size="2001">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-sc3.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="63" size="5723">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="fx7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="75" size="3326">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx7.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2559" height="1186" size="222341">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-sc1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3158" height="3167" size="1144509">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="267" height="158" size="6973">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="509" height="336" size="21057">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="270" height="129" size="5130">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2362" height="629" size="247039">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="242" height="156" size="6027">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2351" height="1246" size="276453">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2756" height="375" size="167145">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-sc2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="203" height="93" size="4009">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2213" height="859" size="319098">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1713" height="380" size="70897">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-sc5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2756" height="2099" size="480881">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="129" height="93" size="2949">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2376" height="980" size="317077">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="273" height="129" size="5191">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="244" height="92" size="4237">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2362" height="817" size="132301">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-sc4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2756" height="320" size="77868">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-sc3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2961" height="854" size="281851">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="270" height="92" size="4700">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-fx7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="5332667">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-mmc1.pdf?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="1120463">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420303068-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85087701245</scopus-id><scopus-eid>2-s2.0-85087701245</scopus-eid><pubmed-id>32659605</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85087701245" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20200625">2020-06-25</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20200625">2020-06-25</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20200710">2020-07-10</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20200710">2020-07-10</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2021-02-19T20:43:29</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523420303068</xocs:eid>
      <xocs:pii-formatted>S0223-5234(20)30306-8</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523420303068</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2020.112337</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.3</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523420X00146</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20210219">2021-02-19T22:08:34.080438Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20200901</xocs:date-search-begin>
      <xocs:year-nav>2020</xocs:year-nav>
      <xocs:indexeddate epoch="1593067854">2020-06-25T06:50:54.736054Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast grantnumber grantsponsor grantsponsorid highlightsabst primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>201</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>201</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 201</xocs:vol-iss-suppl-text>
      <xocs:sort-order>31</xocs:sort-order>
      <xocs:first-fp>112337</xocs:first-fp>
      <xocs:article-number>112337</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>112337</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20200901</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>1 September 2020</xocs:cover-date-text>
      <xocs:cover-date-start>2020-09-01</xocs:cover-date-start>
      <xocs:cover-date-year>2020</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Full papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2020 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>DISCOVERYSIMPLIFIEDBENZAZOLEFRAGMENTSDERIVEDMARINEBENZOSCEPTRINBNECROPTOSISINHIBITORSINVOLVINGRECEPTORINTERACTINGPROTEINKINASE1</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>BENCHEKROUN</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>M</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biological results</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Characterization of the 2-aminobenzazole derivatives as new inhibitors of necroptosis</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>AV123 [<ce:cross-ref id="crosref0310" refid="bib12">12</ce:cross-ref>] and MBM105 (67) are inhibitors of human RIPK1</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>The more selective RIPK1 inhibitor, MBM105, blocks necroptotic but not apoptotic cell death</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Molecular docking</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusion</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Experimental part</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General considerations</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedures for the synthesis of 2-aminobenzimidazoles 12-49</xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Procedure A</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Procedure B</xocs:item-toc-section-title>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.1</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-Butyl-6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine AV123 (12)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.2</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-Ethyl-6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (13)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.3</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>6-Nitro-<ce:italic>N</ce:italic>-propyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (14)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.4</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>6-Nitro-<ce:italic>N</ce:italic>-hexyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (15)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.5</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>6-Nitro-<ce:italic>N</ce:italic>-octyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (16)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.6</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-Isopropyl-6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (17)</ce:bold> [<ce:cross-ref id="crosref0415" refid="bib26">26</ce:cross-ref>]</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.7</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-Allyl-6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (18)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.8</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>6-Nitro-<ce:italic>N</ce:italic>-(prop-2-yn-1-yl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (19)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.9</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-Isobutyl-6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (20)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.10</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-(2-Methoxyethyl)-6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (21)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.11</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-Cyclohexyl-6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (22)</ce:bold> [<ce:cross-ref id="crosref0420" refid="bib27">27</ce:cross-ref>]</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.12</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-Benzyl-6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (23)</ce:bold> [<ce:cross-ref id="crosref0425" refid="bib26">26</ce:cross-ref>]</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.13</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-(6-Nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-yl)benzamide (24)</ce:bold> [<ce:cross-ref id="crosref0430" refid="bib27">27</ce:cross-ref>]</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.14</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>6-Nitro-<ce:italic>N</ce:italic>-phenyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (25)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.15</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-(4-Bromophenyl)-6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (26)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.16</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>4-((6-Nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-yl)amino)benzonitrile (27)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.17</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>6-Nitro-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine (28)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.18</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>6-Nitro-<ce:italic>N</ce:italic>-(4-nitrophenyl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (29)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.19</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>
                           </ce:bold>
                           <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>, <ce:italic>N</ce:italic>
                           </ce:bold>
                           <ce:sup loc="post">
                              <ce:bold>1</ce:bold>
                           </ce:sup>
                           <ce:bold>-Dimethyl-<ce:italic>N</ce:italic>
                           </ce:bold>
                           <ce:sup loc="post">
                              <ce:bold>4</ce:bold>
                           </ce:sup>
                           <ce:bold>-(6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-yl)benzene-1,4-diamine (30)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.20</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>Ethyl (6-nitro-1H-benzo[d]imidazol-2-yl)glycinate (31)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.21</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>6-Bromo-<ce:italic>N</ce:italic>-ethyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (32)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.22</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>6-Bromo-<ce:italic>N</ce:italic>-butyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (33)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.23</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>Methyl 2-(butylamino)-1<ce:italic>H</ce:italic>-benzo[d]imidazole-6-carboxylate (34)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.24</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>Ethyl 2-(butylamino)-1<ce:italic>H</ce:italic>-benzo[d]imidazole-7-carboxylate (35)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.25</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>Methyl 2-(cyclohexylamino)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazole-6-carboxylate (36)</ce:bold> [<ce:cross-ref id="crosref0435" refid="bib28">28</ce:cross-ref>]</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.26</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-isopropyl-7-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (37)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.27</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-Butyl-7-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (38)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.28</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-(2-Methoxyethyl)-7-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (39)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.29</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-Butyl-7-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (40)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.30</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>7-Nitro-<ce:italic>N</ce:italic>-phenyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (41)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.31</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-Benzyl-7-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (42)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.32</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-Cyclohexyl-6-methyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (43)</ce:bold> [<ce:cross-ref id="crosref0440" refid="bib29">29</ce:cross-ref>]</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.33</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>6-Chloro-<ce:italic>N</ce:italic>-cyclohexyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (44)</ce:bold> [<ce:cross-ref id="crosref0445" refid="bib30">30</ce:cross-ref>]</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.34</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>6-Bromo-<ce:italic>N</ce:italic>-cyclohexyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (45)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.35</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-Butyl-6-iodo-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (46)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.36</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-Butyl-6-(1<ce:italic>H</ce:italic>-tetrazol-1-yl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (47)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.37</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>2-(Butylamino)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazole-6-carbonitrile (48)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.2.2.38</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>7-Bromo-<ce:italic>N</ce:italic>-butyl-5-(trifluoromethyl)-1H-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (49)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedures for the Suzuki-Miyaura cross-coupling reaction</xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:bold>6-(2-Chlorophenyl)-<ce:italic>N</ce:italic>-ethyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (50)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:bold>
                           <ce:italic>N</ce:italic>-Ethyl-6-(3-nitrophenyl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (51)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:bold>
                           <ce:italic>N</ce:italic>-Ethyl-6-(3-methoxyphenyl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (52)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:bold>
                           <ce:italic>N</ce:italic>-Butyl-6-(3-nitrophenyl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (53)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.5</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:bold>
                           <ce:italic>N</ce:italic>-Butyl-6-(3-methoxyphenyl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (54)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.6</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:bold>
                           <ce:italic>N</ce:italic>-Butyl-6-(thiophen-3-yl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (55)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.7</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:bold>
                           <ce:italic>N</ce:italic>-Butyl-6-((trimethylsilyl)ethynyl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (56)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.8</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:bold>
                           <ce:italic>N</ce:italic>-Butyl-6-ethynyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (57)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.9</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:bold>6-(1-Benzyl-1H-1,2,3-triazol-4-yl)-N-ethyl-1H-benzo[d]imidazol-2-amine (58)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the amidation with 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD)</xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Procedure A</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Procedure B</xocs:item-toc-section-title>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.4.2.1</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:italic>N</ce:italic>-Ethyl-2-((6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-yl)amino)acetamide (59)</xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.4.2.2</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-Butyl-2-((6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-yl)amino)acetamide (60)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.4.2.3</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>
                              <ce:italic>N</ce:italic>-Benzyl-2-(butylamino)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazole-6-carboxamide (61)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.4.2.4</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>Methyl 2-(butylamino)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazole-6-carboxylate (62)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                     <xocs:item-toc-entry ref-elem="ce:sections">
                        <xocs:item-toc-label>4.1.4.2.5</xocs:item-toc-label>
                        <xocs:item-toc-section-title>
                           <ce:bold>2-(Butylamino)-<ce:italic>N</ce:italic>-(3-phenylpropyl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazole-6-carboxamide (63)</ce:bold>
                        </xocs:item-toc-section-title>
                     </xocs:item-toc-entry>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the synthesis of the 2-aminobenzothiazoles 66 and (67) [<ce:cross-ref id="crosref0450" refid="bib23">23</ce:cross-ref>]</xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:bold>
                           <ce:italic>N-</ce:italic>Butyl-6-nitrobenzo[<ce:italic>d</ce:italic>]thiazol-2-amine (66)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:bold>
                           <ce:italic>N</ce:italic>-Butyl-5-nitrobenzo[<ce:italic>dse</ce:italic>]thiazol-2-amine (67)</ce:bold>
                     </xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biology</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cell cultures</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Reagents</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cell-based assays</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Protein kinase assays</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Molecular docking</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Author contributions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgements</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>LOCKSHIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1964</xocs:ref-pub-year>
            <xocs:ref-first-fp>643</xocs:ref-first-fp>
            <xocs:ref-last-lp>649</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>GALLUZZI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>486</xocs:ref-first-fp>
            <xocs:ref-last-lp>541</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>JOUANLANHOUET</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>2003</xocs:ref-first-fp>
            <xocs:ref-last-lp>2014</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>LECANN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>3050</xocs:ref-first-fp>
            <xocs:ref-last-lp>3068</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>DELEHOUZE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>12931</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>ZHOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>14</xocs:ref-first-fp>
            <xocs:ref-last-lp>23</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>DEGTEREV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>112</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>VANDENABEELE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>185</xocs:ref-first-fp>
            <xocs:ref-last-lp>187</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>TENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>5039</xocs:ref-first-fp>
            <xocs:ref-last-lp>5044</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>ZHUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>1490</xocs:ref-first-fp>
            <xocs:ref-last-lp>1510</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>HARRIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1238</xocs:ref-first-fp>
            <xocs:ref-last-lp>1243</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>HARRIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>2163</xocs:ref-first-fp>
            <xocs:ref-last-lp>2178</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>WEISEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-article-number>e00365</xocs:ref-article-number>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>YOSHIKAWA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>BERGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>HARRIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>5096</xocs:ref-first-fp>
            <xocs:ref-last-lp>5110</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>PUSHPAKOM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>41</xocs:ref-first-fp>
            <xocs:ref-last-lp>58</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>HOFMANS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>BHARATE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>6761</xocs:ref-first-fp>
            <xocs:ref-last-lp>6815</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>APPENZELLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>4874</xocs:ref-first-fp>
            <xocs:ref-last-lp>4877</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>FREI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>5226</xocs:ref-first-fp>
            <xocs:ref-last-lp>5229</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>VERMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>18783</xocs:ref-first-fp>
            <xocs:ref-last-lp>18786</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>HOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>13</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>BELMOKHTAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>3354</xocs:ref-first-fp>
            <xocs:ref-last-lp>3362</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>ESSER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>1153</xocs:ref-first-fp>
            <xocs:ref-last-lp>1154</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>HAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>571</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>7167</xocs:ref-first-fp>
            <xocs:ref-last-lp>7170</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>PUBCHEM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>NCYCLOHEXYL6METHYL1HBENZIMIDAZOL2AMINE</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>PUBCHEM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>6CHLORONCYCLOHEXYL1HBENZIMIDAZOL2AMINE</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>ZEGZOUTI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>560</xocs:ref-first-fp>
            <xocs:ref-last-lp>572</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>VERDONK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>609</xocs:ref-first-fp>
            <xocs:ref-last-lp>623</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>SALI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1993</xocs:ref-pub-year>
            <xocs:ref-first-fp>779</xocs:ref-first-fp>
            <xocs:ref-last-lp>815</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>SURPATEANU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>595</xocs:ref-first-fp>
            <xocs:ref-last-lp>601</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>COLAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>455</xocs:ref-first-fp>
            <xocs:ref-last-lp>462</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>MARTINY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>996</xocs:ref-first-fp>
            <xocs:ref-last-lp>1003</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>SELWA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>829</xocs:ref-first-fp>
            <xocs:ref-last-lp>839</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>SELWA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>273</xocs:ref-first-fp>
            <xocs:ref-last-lp>286</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>CHAPUT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>93</xocs:ref-first-fp>
            <xocs:ref-last-lp>103</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>ELISEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1031</xocs:ref-first-fp>
            <xocs:ref-last-lp>1043</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>PETTERSEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>1605</xocs:ref-first-fp>
            <xocs:ref-last-lp>1612</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>BENCHEKROUNX2020X112337</xocs:refkey3>
         <xocs:refkey4ai>BENCHEKROUNX2020X112337XM</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-agreements>
            <xocs:or-agreement>
               <xocs:or-agreement-name>NR_HAL</xocs:or-agreement-name>
               <xocs:or-agreement-terms>publishAcceptedManuscriptIndexable</xocs:or-agreement-terms>
            </xocs:or-agreement>
         </xocs:or-agreements>
         <xocs:or-agreement-license>http://www.elsevier.com/open-access/userlicense/1.0/</xocs:or-agreement-license>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2021-07-10T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2020 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2020-05-05T07:01:36.538Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency-acronym>CNRS</xocs:funding-agency-acronym>
            <xocs:funding-agency>Centre National de la Recherche Scientifique</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100004794</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/3017382</xocs:funding-agency-country>
         </xocs:funding>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(20)30306-8</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523420303068</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523420303068</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2020.112337</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2021-02-19T22:08:34.080438Z</xocs:timestamp>
         <xocs:cover-date-start>2020-09-01</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/MAIN/application/pdf/e0bab4807b090039bbb7056a0649896b/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>2310125</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>18</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523420303068-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/PREVIEW/image/png/3ebef7c592d80fb8b518d33b235086fc/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>54541</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/sc1/DOWNSAMPLED/image/jpeg/195e164c887b047a87291488224bb1ce/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>30226</xocs:filesize>
               <xocs:pixel-height>268</xocs:pixel-height>
               <xocs:pixel-width>578</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/gr6/DOWNSAMPLED/image/jpeg/ec9de897f4e61c1f9d70d11b8dc5ca81/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>143511</xocs:filesize>
               <xocs:pixel-height>715</xocs:pixel-height>
               <xocs:pixel-width>713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx5/DOWNSAMPLED/image/jpeg/cf0649681f0bcea3281e0a2c6852913e/fx5.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1235</xocs:filesize>
               <xocs:pixel-height>36</xocs:pixel-height>
               <xocs:pixel-width>60</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx2/DOWNSAMPLED/image/jpeg/759a725fb9c1fce6a7fb5f218420b3ab/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3200</xocs:filesize>
               <xocs:pixel-height>76</xocs:pixel-height>
               <xocs:pixel-width>115</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx9/DOWNSAMPLED/image/jpeg/61b2a102deb6a3badcbfcf0703f856fa/fx9.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1049</xocs:filesize>
               <xocs:pixel-height>29</xocs:pixel-height>
               <xocs:pixel-width>61</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/gr2/DOWNSAMPLED/image/jpeg/41d2d792d6226c4528a45a111006098e/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>28038</xocs:filesize>
               <xocs:pixel-height>142</xocs:pixel-height>
               <xocs:pixel-width>533</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx3/DOWNSAMPLED/image/jpeg/115aaf38c2301ff286a59bb36ffb37d5/fx3.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>889</xocs:filesize>
               <xocs:pixel-height>35</xocs:pixel-height>
               <xocs:pixel-width>54</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/gr1/DOWNSAMPLED/image/jpeg/3f8c425728c6c8287641b706e59ecfe0/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>35728</xocs:filesize>
               <xocs:pixel-height>281</xocs:pixel-height>
               <xocs:pixel-width>531</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-sc2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/sc2/DOWNSAMPLED/image/jpeg/d143c130d2cd71165931821df7595ed0/sc2.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>21663</xocs:filesize>
               <xocs:pixel-height>85</xocs:pixel-height>
               <xocs:pixel-width>622</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx8/DOWNSAMPLED/image/jpeg/4acbaa0c879fa4a56154ec764e1b8ab5/fx8.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>834</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>45</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx1/DOWNSAMPLED/image/jpeg/b044d99b5c9d013bdbff6a9a6a3ef5fe/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>38089</xocs:filesize>
               <xocs:pixel-height>194</xocs:pixel-height>
               <xocs:pixel-width>500</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-sc5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/sc5/DOWNSAMPLED/image/jpeg/208cc0fa0fce126241103049ce6e9cb9/sc5.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc5</xocs:file-basename>
               <xocs:filename>sc5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>9975</xocs:filesize>
               <xocs:pixel-height>86</xocs:pixel-height>
               <xocs:pixel-width>387</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/gr3/DOWNSAMPLED/image/jpeg/7dea7ea6f77c81f8f7bbac1d26b5df2b/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>64875</xocs:filesize>
               <xocs:pixel-height>474</xocs:pixel-height>
               <xocs:pixel-width>622</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx4/DOWNSAMPLED/image/jpeg/a7d9035db3f16b9c7124f7682842cd82/fx4.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>611</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>29</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/gr4/DOWNSAMPLED/image/jpeg/04e403de86a4a546aa1330c7f5719e62/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31071</xocs:filesize>
               <xocs:pixel-height>221</xocs:pixel-height>
               <xocs:pixel-width>536</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx10/DOWNSAMPLED/image/jpeg/0e850324605f499050efc4f563f87ce0/fx10.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1079</xocs:filesize>
               <xocs:pixel-height>29</xocs:pixel-height>
               <xocs:pixel-width>61</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx6/DOWNSAMPLED/image/jpeg/fdae43e86070e4909641252de9c5a179/fx6.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>806</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>55</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-sc4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/sc4/DOWNSAMPLED/image/jpeg/efe9ccb2e4f5d3275e0106547f6a4779/sc4.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc4</xocs:file-basename>
               <xocs:filename>sc4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>16811</xocs:filesize>
               <xocs:pixel-height>184</xocs:pixel-height>
               <xocs:pixel-width>533</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-sc3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/sc3/DOWNSAMPLED/image/jpeg/806cb970e38fc46f3e384c9eff465a3b/sc3.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>9887</xocs:filesize>
               <xocs:pixel-height>72</xocs:pixel-height>
               <xocs:pixel-width>622</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/gr5/DOWNSAMPLED/image/jpeg/873e0134a3e3a9429fe567b485680856/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>33732</xocs:filesize>
               <xocs:pixel-height>193</xocs:pixel-height>
               <xocs:pixel-width>669</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx7/DOWNSAMPLED/image/jpeg/66c388d348250c7132b0ddb1251d843b/fx7.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>841</xocs:filesize>
               <xocs:pixel-height>21</xocs:pixel-height>
               <xocs:pixel-width>61</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/sc1/THUMBNAIL/image/gif/c3453e653eab0ff3ab9cf7f32b509466/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4422</xocs:filesize>
               <xocs:pixel-height>101</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/gr6/THUMBNAIL/image/gif/beb1e6f847406b2fe66cc742a38da36f/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>16606</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>163</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx5/THUMBNAIL/image/gif/cfbe08bd20638810deff73c590ee93ab/fx5.sml</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4646</xocs:filesize>
               <xocs:pixel-height>130</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx2/THUMBNAIL/image/gif/9a0ce8ad162f9347430c65b7557dd02e/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5010</xocs:filesize>
               <xocs:pixel-height>145</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx9/THUMBNAIL/image/gif/9bebc2cc0b4ce0f44bc35c4dbbaa4c22/fx9.sml</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3467</xocs:filesize>
               <xocs:pixel-height>105</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/gr2/THUMBNAIL/image/gif/3b84b451129c6a26f2ee2e16e5bda7e3/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4542</xocs:filesize>
               <xocs:pixel-height>58</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx3/THUMBNAIL/image/gif/85f3de9a73f914c84f884540c10f1bbe/fx3.sml</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4123</xocs:filesize>
               <xocs:pixel-height>141</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/gr1/THUMBNAIL/image/gif/1ea8a692b893f6753c338977d128f132/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6338</xocs:filesize>
               <xocs:pixel-height>116</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-sc2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/sc2/THUMBNAIL/image/gif/d1d1397756e1ff33662997cc042b657b/sc2.sml</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3329</xocs:filesize>
               <xocs:pixel-height>30</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx8/THUMBNAIL/image/gif/3884d8d63ce5ee7dee67dbd04057965a/fx8.sml</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2477</xocs:filesize>
               <xocs:pixel-height>93</xocs:pixel-height>
               <xocs:pixel-width>203</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx1/THUMBNAIL/image/gif/f215664aa51f16a1e46be7e5742a30f7/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8980</xocs:filesize>
               <xocs:pixel-height>85</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-sc5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/sc5/THUMBNAIL/image/gif/4c43e541489e903239f8ca4867879644/sc5.sml</xocs:ucs-locator>
               <xocs:file-basename>sc5</xocs:file-basename>
               <xocs:filename>sc5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3002</xocs:filesize>
               <xocs:pixel-height>49</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/gr3/THUMBNAIL/image/gif/47f2ba1993036699976540710bcb1e8a/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9429</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>215</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx4/THUMBNAIL/image/gif/40291823fd5a305c18232d116c596a93/fx4.sml</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1657</xocs:filesize>
               <xocs:pixel-height>93</xocs:pixel-height>
               <xocs:pixel-width>129</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/gr4/THUMBNAIL/image/gif/bb88de38589c2b08467464fe0c5bdcb3/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5431</xocs:filesize>
               <xocs:pixel-height>90</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx10/THUMBNAIL/image/gif/2dced2e1f17cf9694d5de1b2bcceaf33/fx10.sml</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3422</xocs:filesize>
               <xocs:pixel-height>103</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx6/THUMBNAIL/image/gif/1e65e227bec9d2f77fb6524e7354850c/fx6.sml</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3446</xocs:filesize>
               <xocs:pixel-height>83</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-sc4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/sc4/THUMBNAIL/image/gif/7a2486c66ef540509ba24322e8fd6719/sc4.sml</xocs:ucs-locator>
               <xocs:file-basename>sc4</xocs:file-basename>
               <xocs:filename>sc4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3314</xocs:filesize>
               <xocs:pixel-height>76</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-sc3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/sc3/THUMBNAIL/image/gif/b12fd3a1c44c3560e68b170cb2fbee29/sc3.sml</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2001</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/gr5/THUMBNAIL/image/gif/2fbbceabc4e7ba666404ac5d48faeb3e/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5723</xocs:filesize>
               <xocs:pixel-height>63</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx7/THUMBNAIL/image/gif/55623f04551e34407b2d1592460bc60e/fx7.sml</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3326</xocs:filesize>
               <xocs:pixel-height>75</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-sc1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/sc1/HIGHRES/image/jpeg/ff57466f5652e88d73bb74542e09940f/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>222341</xocs:filesize>
               <xocs:pixel-height>1186</xocs:pixel-height>
               <xocs:pixel-width>2559</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/gr6/HIGHRES/image/jpeg/e0ae7c1c7a9ce060f401d9ea7836dc8a/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1144509</xocs:filesize>
               <xocs:pixel-height>3167</xocs:pixel-height>
               <xocs:pixel-width>3158</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx5/HIGHRES/image/jpeg/894fc0bff3001805c95f2c773fb63047/fx5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6973</xocs:filesize>
               <xocs:pixel-height>158</xocs:pixel-height>
               <xocs:pixel-width>267</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx2/HIGHRES/image/jpeg/fe1408f84fe3f00a9994e7b8a8cd43d4/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>21057</xocs:filesize>
               <xocs:pixel-height>336</xocs:pixel-height>
               <xocs:pixel-width>509</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx9/HIGHRES/image/jpeg/c5b2f835a8b0fa620a726671c3f26ab5/fx9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5130</xocs:filesize>
               <xocs:pixel-height>129</xocs:pixel-height>
               <xocs:pixel-width>270</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/gr2/HIGHRES/image/jpeg/efcd482c00f531c9cdb4898ec651a532/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>247039</xocs:filesize>
               <xocs:pixel-height>629</xocs:pixel-height>
               <xocs:pixel-width>2362</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx3/HIGHRES/image/jpeg/49efec74702fe7ff38eee6fb8d45e730/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6027</xocs:filesize>
               <xocs:pixel-height>156</xocs:pixel-height>
               <xocs:pixel-width>242</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/gr1/HIGHRES/image/jpeg/1938ea9f462c1f16aa3b51cbe4c2dc75/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>276453</xocs:filesize>
               <xocs:pixel-height>1246</xocs:pixel-height>
               <xocs:pixel-width>2351</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-sc2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/sc2/HIGHRES/image/jpeg/478e2ebc82c579cc18c675cf7f9fa00b/sc2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>167145</xocs:filesize>
               <xocs:pixel-height>375</xocs:pixel-height>
               <xocs:pixel-width>2756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx8/HIGHRES/image/jpeg/de2196117ee24c38704552e7240d785a/fx8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4009</xocs:filesize>
               <xocs:pixel-height>93</xocs:pixel-height>
               <xocs:pixel-width>203</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx1/HIGHRES/image/jpeg/22c4b9865c2e5ea3e8c5d07feaf56b3a/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>319098</xocs:filesize>
               <xocs:pixel-height>859</xocs:pixel-height>
               <xocs:pixel-width>2213</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-sc5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/sc5/HIGHRES/image/jpeg/35eb6bf9d8f66a163369ebdeb0a785af/sc5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc5</xocs:file-basename>
               <xocs:filename>sc5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>70897</xocs:filesize>
               <xocs:pixel-height>380</xocs:pixel-height>
               <xocs:pixel-width>1713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/gr3/HIGHRES/image/jpeg/32bf082cf79e382014ee043d9db1d037/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>480881</xocs:filesize>
               <xocs:pixel-height>2099</xocs:pixel-height>
               <xocs:pixel-width>2756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx4/HIGHRES/image/jpeg/ffa5bdccc6e9f19d19e980cbd4024ecc/fx4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2949</xocs:filesize>
               <xocs:pixel-height>93</xocs:pixel-height>
               <xocs:pixel-width>129</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/gr4/HIGHRES/image/jpeg/d1823d289a8116323ea28089f5048973/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>317077</xocs:filesize>
               <xocs:pixel-height>980</xocs:pixel-height>
               <xocs:pixel-width>2376</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx10/HIGHRES/image/jpeg/1bf353768772593314f370a92ec4a250/fx10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5191</xocs:filesize>
               <xocs:pixel-height>129</xocs:pixel-height>
               <xocs:pixel-width>273</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx6/HIGHRES/image/jpeg/767de53f8e2f2109c884149c42768047/fx6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4237</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>244</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-sc4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/sc4/HIGHRES/image/jpeg/b84605207b5f8e2c05fa1ef5fd0cb482/sc4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc4</xocs:file-basename>
               <xocs:filename>sc4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>132301</xocs:filesize>
               <xocs:pixel-height>817</xocs:pixel-height>
               <xocs:pixel-width>2362</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-sc3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/sc3/HIGHRES/image/jpeg/a932889c658f533ea96389ebf32fc656/sc3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>77868</xocs:filesize>
               <xocs:pixel-height>320</xocs:pixel-height>
               <xocs:pixel-width>2756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/gr5/HIGHRES/image/jpeg/a47a5521a2bfbba1a381c94d26b0e77f/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>281851</xocs:filesize>
               <xocs:pixel-height>854</xocs:pixel-height>
               <xocs:pixel-width>2961</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-fx7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/fx7/HIGHRES/image/jpeg/97262239bda29742035cca2c08d623d8/fx7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4700</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>270</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-mmc1.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420303068/mmc1/MAIN/application/pdf/8361c381b641696fc0f584fe71c7eb11/mmc1.pdf</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>false</xocs:pdf-optimized>
               <xocs:filesize>5332667</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420303068-am.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10NLJ471ZSD/MAIN/application/pdf/f9c61f082fe6dcf7d68ac22417f4ceec/am.pdf</xocs:ucs-locator>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>false</xocs:pdf-optimized>
               <xocs:filesize>1120463</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>112337</aid>
            <ce:article-number>112337</ce:article-number>
            <ce:pii>S0223-5234(20)30306-8</ce:pii>
            <ce:doi>10.1016/j.ejmech.2020.112337</ce:doi>
            <ce:copyright type="full-transfer" year="2020">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0010" view="all">Chemical structures of selected inhibitors of necroptosis. ∗ Nec-1s (<ce:bold>2</ce:bold>) and Sibiriline (<ce:bold>9</ce:bold>) were used as controls in this study.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0015" role="short">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S0223523420303068/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0015" view="all">Chemical structures of benzosceptrin B (<ce:bold>10</ce:bold>), hit compound <ce:bold>AV123</ce:bold> (<ce:bold>12</ce:bold>) and the general structure of the 2-aminobenzazole derivatives targeted in this work.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0020" role="short">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S0223523420303068/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0020" view="all">Dose-dependent inhibition of TNF-α-induced necroptosis by increasing concentrations of <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0495" refid="bib12">12</ce:cross-ref>] and <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>). (A) After a 24-h incubation of Jurkat FADD deficient cells with or without (w/o) 10 ng/mL TNF-α and increasing concentrations of tested compounds. The effect of the co-treatment on the cell viability was evaluated by MTS reduction assay. Treatments without TNF-α were used to estimate the toxicity of the tested compound. The values were normalized as a percentage of cell viability, considering 100% viable cells in the control treated with DMSO (n = 3, mean ± SD). (B) Evaluation of the toxicity of <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0500" refid="bib12">12</ce:cross-ref>] and <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) on hTERT-immortalized retinal pigment epithelial cell line, hTERT RPE-1. RPE-1 retina cells were exposed for 24-h to increasing concentrations of the tested compound (ranging from 0.01 to 50 μM). Cell viability was assessed and plotted as mentioned here above. A similar experiment was performed to measure cellular death (LDH release assay; left axis). Results are plotted in % of maximal LDH release (cell lysis). Data are mean ± SD (n = 3).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S0223523420303068/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0025" view="all">Effects of <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0505" refid="bib12">12</ce:cross-ref>] and <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) on the catalytic activity of RIPK1 kinase. RIPK1 was assayed in the presence of increasing concentrations (ranging from 0.01 to 100 μM) of <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0510" refid="bib12">12</ce:cross-ref>] and <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>). ATP concentration used in the kinase assays was 155 μM. Kinase activities are expressed in % of RIPK1 maximal activity, i.e. measured with the same amount of DMSO and in the absence of inhibitor. Data are mean ± range, n = 2. We further evaluated the bioactivity of compounds <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0515" refid="bib12">12</ce:cross-ref>] and <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) against a short panel of disease-related serine/threonine protein kinases: three human cyclin dependent kinases (CDK2/Cyclin A, CDK5/p25 and CDK9/Cyclin T), mouse CDC2-like kinase 1 (CLK1), rat dual specificity tyrosine-phosphorylation-regulated kinase 1 A (DYRK1A), human proto-oncogene PIM1, human Janus Kinase 3 (JAK3), human Abelson murine leukemia viral oncogene homolog 1 (ABL1), human mitotic kinases Haspin and Aurora B, casein kinase 1 isoform epsilon (CK1<ce:italic>ε</ce:italic>), receptor-interacting protein 3 (RIPK3). As reported on <ce:cross-ref id="crosref0520" refid="tbl3">Table 3</ce:cross-ref>, <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0525" refid="bib12">12</ce:cross-ref>] and <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) were shown to inhibit DYRK1A with IC<ce:inf loc="post">50</ce:inf> of 1.80 and 2.21 μM, respectively. <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0530" refid="bib12">12</ce:cross-ref>] was shown to be putatively less selective compared to <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) as <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0535" refid="bib12">12</ce:cross-ref>] was also shown to inhibit CDK9/Cyclin T and CLK1 with sub-micromolar IC<ce:inf loc="post">50</ce:inf> of 0.48 and 0.80 μM, respectively.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S0223523420303068/gr4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0030" view="all">
                     <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) does not inhibit TRAIL and staurosporine-induced apoptosis. Apoptosis was induced in Jurkat wild-type cells by treatment with either (panel A) TRAIL-Flag (20 ng.mL-1) or (panel B) staurosporine (STS, 100 nM). Cells were then simultaneously treated by increasing doses of <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) or Z-VAD-fmk (20 μM) as cell-permeant pan-caspase inhibitor. After a 24-h incubation, the effect of the tested compound on the cell viability was evaluated by MTS reduction assay and is expressed in % of survival in cells treated with DMSO. Data are mean ± SD (n = 3).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0035" role="short">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S0223523420303068/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0035" view="all">Docking conformations of selected RIPK1 inhibitors. (<ce:bold>a</ce:bold>, <ce:bold>b</ce:bold>) Docking conformation (brown) superposed on the X-ray structure (cyan, PDB code <ce:inter-ref id="intref0045" xlink:href="pdb:6C3E" xlink:type="simple">6C3E</ce:inter-ref>) [<ce:cross-ref id="crosref0540" refid="bib14">14</ce:cross-ref>]of 2-benzyl-5-nitro-1<ce:italic>H</ce:italic>-benzimidazole in the binding site of RIPK1; (<ce:bold>c</ce:bold>, <ce:bold>d</ce:bold>) Docking conformation of <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0545" refid="bib12">12</ce:cross-ref>] in the binding site of RIPK1; (<ce:bold>e</ce:bold>, <ce:bold>f</ce:bold>) Docking conformation of <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) in the binding site of RIPK1. The protein is represented as pink surface (<ce:bold>a</ce:bold>, <ce:bold>c</ce:bold>, <ce:bold>e</ce:bold>) or cartoon with residues within 5 Å from the ligand visible (<ce:bold>b</ce:bold>, <ce:bold>d</ce:bold>, <ce:bold>f</ce:bold>). Hydrogen bonds are represented as cyan colored springs. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0040" role="short">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S0223523420303068/gr6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0040" view="all">
                     <ce:italic>Reagents and conditions:</ce:italic> a) 1.2 equiv. R<ce:inf loc="post">4</ce:inf>NCS, 1.2 equiv. dialkylcarbodiimide, ACN or Py, 80 °C, 16 h; b) 1.5 equiv. R<ce:inf loc="post">4</ce:inf>NC, 1 mol% Se powder, Py, 90–110 °C, 24 h.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0045" role="short">Scheme 1</ce:alt-text>
               <ce:link locator="sc1" xlink:href="pii:S0223523420303068/sc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch2">
               <ce:label>Scheme 2</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0045" view="all">
                     <ce:italic>Reagents and conditions</ce:italic>: a) R<ce:inf loc="post">2</ce:inf>B(OH)<ce:inf loc="post">2</ce:inf> (1 equiv.), K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (3 equiv.), Pd(PPh<ce:inf loc="post">3</ce:inf>)<ce:inf loc="post">4</ce:inf> (5 mol%, 0.02 mmol), 1,4-dioxane/water : 1/0.1, 16 h; b) R<ce:inf loc="post">2</ce:inf>B(OH)<ce:inf loc="post">2</ce:inf> (1 equiv.), K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (3 equiv.), (5 mol%, 0.02 mmol), 1,4-dioxane/water: 1/0.1, 16 h.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0050" role="short">Scheme 2</ce:alt-text>
               <ce:link locator="sc2" xlink:href="pii:S0223523420303068/sc2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch3">
               <ce:label>Scheme 3</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0050" view="all">
                     <ce:italic>Reagents and conditions:</ce:italic> a) 10 mol% PdCl<ce:inf loc="post">2</ce:inf>(dtbpf) (0.10 equiv.), 20 mol% (CuI (0.20 mmol) TEA (5 equiv.), dry DMF (0.5 mL); b) K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (1.1 equiv.), MeOH/water 1:1; c) BnN<ce:inf loc="post">3</ce:inf> (1.1 equiv.), DMF/water: 1/0.2, 16 h; d) 10 mol% CuSO<ce:inf loc="post">4</ce:inf>.5H<ce:inf loc="post">2</ce:inf>O (0.1 equiv.), 20 mol% Na ascorbate (0.2 equiv.), 16 h.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0055" role="short">Scheme 3</ce:alt-text>
               <ce:link locator="sc3" xlink:href="pii:S0223523420303068/sc3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch4">
               <ce:label>Scheme 4</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="fspara0055" view="all">
                     <ce:italic>Reagents and conditions</ce:italic>: a) TBD (1 equiv.), amine (5 equiv.), ACN or neat.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0060" role="short">Scheme 4</ce:alt-text>
               <ce:link locator="sc4" xlink:href="pii:S0223523420303068/sc4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch5">
               <ce:label>Scheme 5</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="fspara0060" view="all">
                     <ce:italic>Reagents and conditions</ce:italic>: a) DBU, <ce:italic>n</ce:italic>BuNH<ce:inf loc="post">2</ce:inf>, NaHCO<ce:inf loc="post">3</ce:inf>, neat.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0065" role="short">Scheme 5</ce:alt-text>
               <ce:link locator="sc5" xlink:href="pii:S0223523420303068/sc5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl1" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0070">
                  <ce:simple-para id="tspara0010" view="all">Yields of 2-aminobenzimidazoles <ce:bold>12</ce:bold>–<ce:bold>49.</ce:bold>
                  </ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0070" role="short">Table 1</ce:alt-text>
               <tgroup cols="7">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Diaminoarene</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">R<inf loc="post">1</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">R<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">R<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">R<inf loc="post">4</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Benzimi-dazole</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">yield</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>AV123</bold> [<cross-ref id="crosref0550" refid="bib12">12</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">90%<cross-ref id="crosref0555" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Et</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>13</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">70%<cross-ref id="crosref0560" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Pr</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>14</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">48%<cross-ref id="crosref0565" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Hex</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">74%<cross-ref id="crosref0570" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Oct</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>16</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">58%<cross-ref id="crosref0575" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>i</italic>Pr</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>17</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">92%<cross-ref id="crosref0580" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Allyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>18</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">80%<cross-ref id="crosref0585" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Propargyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>19</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">26%<cross-ref id="crosref0590" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>sec</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>20</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24%<cross-ref id="crosref0595" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Methoxyethyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>21</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">36%<cross-ref id="crosref0600" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>c</italic>Hex</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>22</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">66%<cross-ref id="crosref0605" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>23</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">78%<cross-ref id="crosref0610" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Bn</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>24</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">66%<cross-ref id="crosref0615" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Bz</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>25</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">70%<cross-ref id="crosref0620" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>p-</italic>Br-C<inf loc="post">6</inf>H<inf loc="post">4</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>26</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">43%<cross-ref id="crosref0625" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>p-</italic>CN-C<inf loc="post">6</inf>H<inf loc="post">4</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>27</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">87%<cross-ref id="crosref0630" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>p-</italic>CF<inf loc="post">3</inf>-C<inf loc="post">6</inf>H<inf loc="post">4</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>28</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">35%<cross-ref id="crosref0635" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>p-</italic>NO<inf loc="post">2</inf>-C<inf loc="post">6</inf>H<inf loc="post">4</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>29</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">87%<cross-ref id="crosref0640" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>p-</italic>N(Me)<inf loc="post">2</inf>-C<inf loc="post">6</inf>H<inf loc="post">4</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>30</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">70%<cross-ref id="crosref0645" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH<inf loc="post">2</inf>CO<inf loc="post">2</inf>Et</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>31</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">49%<cross-ref id="crosref0650" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11b</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Br</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Et</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>32</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">39%<cross-ref id="crosref0655" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11b</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Br</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>33</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">46%<cross-ref id="crosref0660" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11c</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CO<inf loc="post">2</inf>Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>34</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">82%<cross-ref id="crosref0665" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11d</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CO<inf loc="post">2</inf>Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>35</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">83%<cross-ref id="crosref0670" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11d</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CO<inf loc="post">2</inf>Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>c</italic>Hex</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>36</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">56%<cross-ref id="crosref0675" refid="tbl1fnb">
                              <italic>
                                 <sup loc="post">b</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11e</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>i</italic>Pr</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>37</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">95%<cross-ref id="crosref0680" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11e</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>38</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">95%<cross-ref id="crosref0685" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11e</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Methoxyethyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>39</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">84%<cross-ref id="crosref0690" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11e</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>c</italic>Hex</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>40</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">50%<cross-ref id="crosref0695" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11e</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>41</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">96%<cross-ref id="crosref0700" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11e</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Bn</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>42</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">73%<cross-ref id="crosref0705" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11f</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>c</italic>Hex</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>43</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">74%<cross-ref id="crosref0710" refid="tbl1fnb">
                              <italic>
                                 <sup loc="post">b</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11g</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>c</italic>Hex</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>44</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">82%<cross-ref id="crosref0715" refid="tbl1fnb">
                              <italic>
                                 <sup loc="post">b</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11b</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Br</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>c</italic>Hex</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>45</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">70%<cross-ref id="crosref0720" refid="tbl1fnb">
                              <italic>
                                 <sup loc="post">b</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11h</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>46</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">43%<cross-ref id="crosref0725" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11i</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1λ<sup loc="post">2</sup>-tetrazolyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>47</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">48%<cross-ref id="crosref0730" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11j</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CN</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>48</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14%<cross-ref id="crosref0735" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11k</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Br</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>49</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">39%<cross-ref id="crosref0740" refid="tbl1fna">
                              <italic>
                                 <sup loc="post">a</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl1fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0010" view="all">Prepared according to condition a) in <ce:cross-ref id="crosref0745" refid="sch1">Scheme 1</ce:cross-ref>.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl1fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0015" view="all">Prepared according to condition b) in <ce:cross-ref id="crosref0750" refid="sch1">Scheme 1</ce:cross-ref>.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl2" rowsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0075">
                  <ce:simple-para id="tspara0015" view="all">Primary cell-based screening on the TNF-α-induced necroptosis in Jurkat FADD deficient cells.<ce:cross-ref id="crosref0755" refid="tbl2fna">
                        <ce:sup loc="post">a</ce:sup>
                     </ce:cross-ref>
                  </ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0075" role="short">Table 2</ce:alt-text>
               <ce:link locator="fx2" xlink:href="pii:S0223523420303068/fx2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="8">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <colspec colname="col8" colnum="8"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Cmpd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">X</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">R<inf loc="post">1</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">R<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">R<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">R<inf loc="post">4</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ProtecΔ at 10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">EC<inf loc="post">50</inf> (μM)</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AV123 [<cross-ref id="crosref0760" refid="bib12">12</cross-ref>]</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">56.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.7</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>13</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Et</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>14</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Pr</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>20</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>14.4</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Hex</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">23.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<cross-ref id="crosref0765" refid="tbl2fnb">
                              <italic>
                                 <sup loc="post">b</sup>
                              </italic>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>16</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Oct</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>17</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>i</italic>Pr</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>16.2</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">> <bold>25</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>18</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Allyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>19</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Propargyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>20</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>sec</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>53.7</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>2.2</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>21</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Methoxyethyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>22</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>c</italic>Hex</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>68.1</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>1.04</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>23</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>41.9</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>2.5</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>24</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Bn</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>25</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Bz</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−21.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>26</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>p</italic>-Br-C<inf loc="post">6</inf>H<inf loc="post">4</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−6.1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>27</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>p</italic>-CN-C<inf loc="post">6</inf>H<inf loc="post">4</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−31.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>28</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>p</italic>-CF<inf loc="post">3</inf>-C<inf loc="post">6</inf>H<inf loc="post">4</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−30.8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>29</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>p</italic>-NO<inf loc="post">2</inf>-C<inf loc="post">6</inf>H<inf loc="post">4</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>30</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>p</italic>-(NMe)<inf loc="post">2</inf>-C<inf loc="post">6</inf>H<inf loc="post">4</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>31</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CH<inf loc="post">2</inf>CO<inf loc="post">2</inf>Et</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>32</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Br</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Et</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>33</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Br</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>34</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CO<inf loc="post">2</inf>Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>35</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CO<inf loc="post">2</inf>Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>29.2</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>18.1</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>36</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CO<inf loc="post">2</inf>Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>c</italic>Hex</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>21.7</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>9</bold>
                           <cross-ref id="crosref0770" refid="tbl2fnc">
                              <bold>
                                 <italic>
                                    <sup loc="post">c</sup>
                                 </italic>
                              </bold>
                           </cross-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>37</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>i</italic>Pr</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>38</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>39</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Methoxyethyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−2.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>40</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>c</italic>Hex</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>41</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ph</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>42</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Bn</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>43</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>c</italic>Hex</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>44</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>c</italic>Hex</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>38.2</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>4.4</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>45</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Br</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>c</italic>Hex</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">43.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND<sup loc="post">
                              <italic>b</italic>
                           </sup>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>46</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−16.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>47</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>t</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−1.32</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>48</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1λ<sup loc="post">2</sup>-tetrazolyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>49</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CN</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>23.7</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8.9</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>50</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Br</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>51</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>o</italic>-Cl-C<inf loc="post">6</inf>H<inf loc="post">4</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Et</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−19.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>52</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>m</italic>-NO<inf loc="post">2</inf>-C<inf loc="post">6</inf>H<inf loc="post">4</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Et</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−12.8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>53</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>m</italic>-MeO-C<inf loc="post">6</inf>H<inf loc="post">4</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Et</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−20.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>54</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>m</italic>-NO<inf loc="post">2</inf>-C<inf loc="post">6</inf>H<inf loc="post">4</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−16.8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>55</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>m</italic>-MeO-C<inf loc="post">6</inf>H<inf loc="post">4</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−20.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>56</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2-Thienyl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−18.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>57</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx3" xlink:href="pii:S0223523420303068/fx3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0080" role="short">Image 3</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−21.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>58</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:href="pii:S0223523420303068/fx4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0085" role="short">Image 4</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−10.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>59</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx5" xlink:href="pii:S0223523420303068/fx5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0090" role="short">Image 5</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>60</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx9" xlink:href="pii:S0223523420303068/fx9" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0095" role="short">Image 9</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>61</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx10" xlink:href="pii:S0223523420303068/fx10" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0100" role="short">Image 10</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>62</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx6" xlink:href="pii:S0223523420303068/fx6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0105" role="short">Image 6</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>63</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx7" xlink:href="pii:S0223523420303068/fx7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0110" role="short">Image 7</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−3.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>64</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx8" xlink:href="pii:S0223523420303068/fx8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0115" role="short">Image 8</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>66</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">S</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>28.0</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>6.9</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MBM105 (<bold>67</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">S</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>n</italic>Bu</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>56.1</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>4.7</bold>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Sibiriline (<bold>9</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>57.9</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>1.1</bold>
                        </entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl2fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0020" view="all">The table displays the % of remaining viable cells after co-treatment with 10 μM of the tested compound and with TNF-α (10 ng/mL). Cell viability was measured by MTS reduction assay as mentioned in the Experimental part section. The values were normalized, considering 100% viable cells in the control treated only with DMSO (n = 3). The level of protection against the TNF-α-induced cell death of each tested compounds is estimated using the “protection delta” (ProtecΔ) values. These values are determined by subtracting the smaller number (value obtained with TNF-α and without the tested compound) from the larger one (value obtained for co-treatment with TNF-α and with the tested compound). In some cases, the tested compounds can be toxic and thus we may have to subtract the larger one from the smaller one. This might result in a negative number. The EC<ce:inf loc="post">50</ce:inf> of the more effective molecules (ProtecΔ>16) were determined from the dose-response curves using Graphpad PRISM software (data are mean, n = 3). ND, not determined.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl2fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0025" view="all">A treatment with more than 10 μM of compounds <ce:bold>15</ce:bold> and <ce:bold>45</ce:bold> compound decreased strongly the viability of Jurkat FADD deficient cells. It was thus impossible to determine an EC<ce:inf loc="post">50</ce:inf> value for this compound.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl2fnc">
                  <ce:label>c</ce:label>
                  <ce:note-para id="ntpara0030" view="all">A treatment with more than 25 μM of compound <ce:bold>36</ce:bold> was shown to have a negative effect on the viability of Jurkat FADD deficient cells that could correspond to a toxic effect. Nevertheless, it was possible to calculate an EC<ce:inf loc="post">50</ce:inf> from the dose-response curve.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl3" rowsep="0">
               <ce:label>Table 3</ce:label>
               <ce:caption id="cap0080">
                  <ce:simple-para id="tspara0020" view="all">Inhibitory activities of <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0775" refid="bib12">12</ce:cross-ref>] and <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) against a short panel of disease-related protein kinases. The table displays the IC<ce:inf loc="post">50</ce:inf> values determined from the dose-response curves. ATP concentration used in the kinase assays was 10 μM (values are means, n = 2). Kinases are from human origin unless specified: (<ce:italic>Mm</ce:italic>), <ce:italic>Mus musculus</ce:italic>; (<ce:italic>Rn</ce:italic>), <ce:italic>Rattus norvegicus</ce:italic>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0120" role="short">Table 3</ce:alt-text>
               <tgroup cols="13">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <colspec colname="col8" colnum="8"/></colspec>
                  <colspec colname="col9" colnum="9"/></colspec>
                  <colspec colname="col10" colnum="10"/></colspec>
                  <colspec colname="col11" colnum="11"/></colspec>
                  <colspec colname="col12" colnum="12"/></colspec>
                  <colspec colname="col13" colnum="13"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Cpd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CDK2/CyclinA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CDK5/p25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CDK9/CyclinT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <italic>(Mm)</italic> CLK1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <italic>(Rn)</italic> DYRK1A</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">HASPIN</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Pim1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CK1<italic>ε</italic>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAK3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ABL1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">RIPK3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">AURKB</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>AV123</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>0.48</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>0.80</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>1.80</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>MBM105</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>2.21</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10 μM</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Research paper</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Discovery of simplified benzazole fragments derived from the marine benzosceptrin B as necroptosis inhibitors involving the receptor interacting protein Kinase-1</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523420303068-233934fc5a6e0807f898d70141d42632">
                  <ce:given-name>Mohamed</ce:given-name>
                  <ce:surname>Benchekroun</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523420303068-578eb4ff0facde18d857ffda53603382">
                  <ce:given-name>Ludmila</ce:given-name>
                  <ce:surname>Ermolenko</ce:surname>
                  <ce:cross-ref id="crosref0015" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523420303068-3307150bab21723416cf004c3a149942">
                  <ce:given-name>Minh Quan</ce:given-name>
                  <ce:surname>Tran</ce:surname>
                  <ce:cross-ref id="crosref0020" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523420303068-90e03a28fd0e48c96b90c8405fd6eace">
                  <ce:given-name>Agathe</ce:given-name>
                  <ce:surname>Vagneux</ce:surname>
                  <ce:cross-ref id="crosref0025" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au5" author-id="S0223523420303068-8b70fd6e52e022aa897e035c384cdeca">
                  <ce:given-name>Hristo</ce:given-name>
                  <ce:surname>Nedev</ce:surname>
                  <ce:cross-ref id="crosref0030" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6" author-id="S0223523420303068-8e5f0f639e75e51d16b1d2fed5bbed76">
                  <ce:given-name>Claire</ce:given-name>
                  <ce:surname>Delehouzé</ce:surname>
                  <ce:cross-ref id="crosref0035" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0040" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au7" author-id="S0223523420303068-3abc3ea34b8dd1a855927edb4bd09dbe">
                  <ce:given-name>Mohamed</ce:given-name>
                  <ce:surname>Souab</ce:surname>
                  <ce:cross-ref id="crosref0045" refid="aff4">
                     <ce:sup loc="post">d</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au8" author-id="S0223523420303068-81ff34cbfb419078ad3ecdec3cd0398b">
                  <ce:given-name>Blandine</ce:given-name>
                  <ce:surname>Baratte</ce:surname>
                  <ce:cross-ref id="crosref0050" refid="aff4">
                     <ce:sup loc="post">d</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au9" author-id="S0223523420303068-3da3a751ce75d6e02cff670b536b7714">
                  <ce:given-name>Béatrice</ce:given-name>
                  <ce:surname>Josselin</ce:surname>
                  <ce:cross-ref id="crosref0055" refid="aff4">
                     <ce:sup loc="post">d</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au10" author-id="S0223523420303068-1a65e230e484ae813c364efc03b3a453">
                  <ce:given-name>Bogdan I.</ce:given-name>
                  <ce:surname>Iorga</ce:surname>
                  <ce:cross-ref id="crosref0060" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au11" author-id="S0223523420303068-18533a5b60851776b525eafed0374940">
                  <ce:given-name>Sandrine</ce:given-name>
                  <ce:surname>Ruchaud</ce:surname>
                  <ce:cross-ref id="crosref0065" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au12" author-id="S0223523420303068-f53ed141de91246c90854d13922b7b80">
                  <ce:given-name>Stéphane</ce:given-name>
                  <ce:surname>Bach</ce:surname>
                  <ce:cross-ref id="crosref0070" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0075" refid="aff4">
                     <ce:sup loc="post">d</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0080" refid="cor2">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au13" author-id="S0223523420303068-2efc72415ddc9be3636884e829d8591d">
                  <ce:given-name>Ali</ce:given-name>
                  <ce:surname>Al-Mourabit</ce:surname>
                  <ce:cross-ref id="crosref0085" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0090" refid="cor1">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523420303068-3bf954b30975eecf33b8c8d66d7ca409">
                  <ce:label>a</ce:label>
                  <ce:textfn>Université Paris-Saclay, CNRS, Institut de Chimie des Substances Naturelles, Gif-sur-Yvette, 91190, France</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Université Paris-Saclay</sa:organization>
                     <sa:organization>CNRS</sa:organization>
                     <sa:organization>Institut de Chimie des Substances Naturelles</sa:organization>
                     <sa:city>Gif-sur-Yvette</sa:city>
                     <sa:postal-code>91190</sa:postal-code>
                     <sa:country>France</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">Universite Paris-Saclay, CNRS, Institut de Chimie des Substances Naturelles, Gif-sur-Yvette, 91190, France</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S0223523420303068-d0b3d550e28b4445595d9ec9fd4fe0ca">
                  <ce:label>b</ce:label>
                  <ce:textfn>SeaBeLife Biotech, Place Georges Teissier, 29680, Roscoff, France</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>SeaBeLife Biotech</sa:organization>
                     <sa:address-line>Place Georges Teissier</sa:address-line>
                     <sa:city>Roscoff</sa:city>
                     <sa:postal-code>29680</sa:postal-code>
                     <sa:country>France</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">SeaBeLife Biotech, Place Georges Teissier, 29680 Roscoff, France</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff3" affiliation-id="S0223523420303068-b03bd8455da66f968ce4ff4c56b21499">
                  <ce:label>c</ce:label>
                  <ce:textfn>Sorbonne Université, CNRS, UMR 8227, Integrative Biology of Marine Models Laboratory (LBI2M), Station Biologique de Roscoff, 29680, Roscoff, France</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Sorbonne Université</sa:organization>
                     <sa:organization>CNRS</sa:organization>
                     <sa:organization>UMR 8227</sa:organization>
                     <sa:organization>Integrative Biology of Marine Models Laboratory (LBI2M)</sa:organization>
                     <sa:organization>Station Biologique de Roscoff</sa:organization>
                     <sa:city>Roscoff</sa:city>
                     <sa:postal-code>29680</sa:postal-code>
                     <sa:country>France</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0020">Sorbonne Universite, CNRS, UMR 8227, Integrative Biology of Marine Models Laboratory (LBI2M), Station Biologique de Roscoff, 29680 Roscoff, France</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff4" affiliation-id="S0223523420303068-2d1df05456646a8c55da93ac0a2887b6">
                  <ce:label>d</ce:label>
                  <ce:textfn>Sorbonne Université, CNRS, FR 2424, Plateforme de criblage KISSf (Kinase Inhibitor Specialized Screening Facility), Station Biologique de Roscoff, 29680, Roscoff, France</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Sorbonne Université</sa:organization>
                     <sa:organization>CNRS</sa:organization>
                     <sa:organization>FR 2424</sa:organization>
                     <sa:organization>Plateforme de criblage KISSf (Kinase Inhibitor Specialized Screening Facility), Station Biologique de Roscoff</sa:organization>
                     <sa:city>Roscoff</sa:city>
                     <sa:postal-code>29680</sa:postal-code>
                     <sa:country>France</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0025">Sorbonne Universite, CNRS, FR 2424, Plateforme de criblage KISSf (Kinase Inhibitor Specialized Screening facility), Station Biologique de Roscoff, 29680 Roscoff, France</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author. Sorbonne Université, CNRS, UMR 8227, Integrative Biology of Marine Models Laboratory (LBI2M), Station Biologique de Roscoff, 29680, Roscoff, France.</ce:text>
                  <sa:affiliation>
                     <sa:organization>Sorbonne Université</sa:organization>
                     <sa:organization>CNRS</sa:organization>
                     <sa:organization>UMR 8227</sa:organization>
                     <sa:organization>Integrative Biology of Marine Models Laboratory (LBI2M)</sa:organization>
                     <sa:organization>Station Biologique de Roscoff</sa:organization>
                     <sa:city>Roscoff</sa:city>
                     <sa:postal-code>29680</sa:postal-code>
                     <sa:country>France</sa:country>
                  </sa:affiliation>
               </ce:correspondence>
            </ce:author-group>
            <ce:date-received day="13" month="3" year="2020"/></ce:date-received>
            <ce:date-revised day="4" month="4" year="2020"/></ce:date-revised>
            <ce:date-accepted day="13" month="4" year="2020"/></ce:date-accepted>
            <ce:abstract id="abs0010" xml:lang="en" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">With the aim to develop new chemical tools based on simplified natural metabolites to help deciphering the molecular mechanism of necroptosis, simplified benzazole fragments including 2-aminobenzimidazole and the 2-aminobenzothiazole analogs were prepared during the synthesis of the marine benzosceptrin B. Conpounds inhibiting the RIPK1 protein kinase were discovered. A library of 54 synthetic analogs were prepared and evaluated through a phenotypic screen using the inhibition of the necrotic cell death induced by TNF-α in human Jurkat T cells deficient for the FADD protein. This article reports the design, synthesis and biological evaluation of a series of 2-aminobenzazoles on the necroptotic cell death through the inhibition of RIPK1 protein kinase. The 2-aminobenzimidazole and 2-aminobenzothiazole platforms presented herein can serve as novel chemical tools to study the molecular regulation of necroptosis and further develop lead drug candidates for chronic pathologies involving necroptosis.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:href="pii:S0223523420303068/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords id="kwrds0010" xml:lang="en" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Aminobenzimidazole</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Synthesis</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Necroptosis</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Kinase inhibitors</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0030" view="all">The regulation of cell death is crucial for the homeostasis control for all living beings. The concept of programmed cell death (PCD), that emerged early in the 1960s, referred to the sequence of molecular events that lead to death of the cell [<ce:cross-ref id="crosref0095" refid="bib1">1</ce:cross-ref>]. This physiological process, which occurs in the absence of any exogenous perturbations, is notably essential for the development of multicellular organisms and for maintaining the tissue homeostasis in the whole organism. The “regulated cell death” (RCD) was then introduced to define the molecular processes that were initiated from perturbations of intracellular or extracellular micro-environment, when adaptive responses are incapable of restoring cellular homeostasis. As defined by the Nomenclature Committee on Cell Death (NCCD), the major RCD subroutines includes extrinsic and intrinsic apoptosis, entotic cell death, NETotic cell death, lysosome-dependent cell death, autophagy-dependent cell death, immunogenic cell death, mitotic death, pyroptosis, parthanatos, mitochondrial permeability transition (MPT)-driven necrosis, ferroptosis and necroptosis [<ce:cross-ref id="crosref0100" refid="bib2">2</ce:cross-ref>].</ce:para>
                  <ce:para id="p0035" view="all">Necroptosis is a RCD that has attracted increasing consideration regarding its involvement in numerous pathologies including ischemia-reperfusion injuries (including stroke, myocardial infarction, resuscitation, solid organ transplantation or heart surgery) in brain, heart and kidney, inflammatory diseases, sepsis, retinal disorders, neurodegenerative diseases, infectious disorders and liver disease [<ce:cross-refs id="crosrefs0010" refid="bib3 bib4 bib5">3–5</ce:cross-refs>]. Necroptosis may be activated upon stimulation by the cytokines TNF-α (Tumor Necrosis Factor-α), FasL (Fas Ligand) and TRAIL (tumor-necrosis-factor related apoptosis inducing ligand) and relies on the activity of two serine-threonine kinases, RIPK1 (Receptor-Interacting Protein Kinase-1) and RIPK3, and on the pseudo-kinase MLKL (Mixed Lineage Kinase domain-Like). After the stimulation of receptors by the corresponding cytokines, necroptosis may occur under apoptotic deficient conditions: e.g. deficiency in caspase-8 or in Fas-Associated protein with Death Domain - FADD protein (see Zhou and Yuan, 2014, for review [<ce:cross-ref id="crosref0105" refid="bib6">6</ce:cross-ref>]). The enzymatic inhibition of caspases by zVAD.fmk was used in 2005 by Degterev et al. to identify the first small-molecule inhibitor of necroptosis, the necrostatin-1 (Nec-1, <ce:bold>1</ce:bold>) [<ce:cross-ref id="crosref0110" refid="bib7">7</ce:cross-ref>]. Nec-1, bearing a methyl-thiohydantoin-tryptophan (MTH-Trp) scaffold, was characterized in a phenotypic screen for small-molecules able to inhibit the necrotic cell death induced by TNF-α in human monocytic U937 cells. The chlorinated analogue of Nec-1, Nec-1s (<ce:bold>2</ce:bold>), was then described to be endowed with a better pharmacokinetic profile, an increased specificity for RIPK1 over a broad range of kinases and an absence of indoleamine-2,3-dioxygenase (IDO)- inhibitory activity [<ce:cross-ref id="crosref0115" refid="bib8">8</ce:cross-ref>]. Necrostatins served as privileged tools to better understand the necroptosis cascade. However, their development as drugs was hampered due especially to poor SAR profile as well as unfavorable pharmacokinetic factors [<ce:cross-ref id="crosref0120" refid="bib9">9</ce:cross-ref>].</ce:para>
                  <ce:para id="p0040" view="all">Following the necrostatins, several inhibitors of necroptosis were subsequently described over the last decade [<ce:cross-ref id="crosref0125" refid="bib10">10</ce:cross-ref>].Representative examples are given in <ce:cross-ref id="crosref0130" refid="fig1">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>. For instance, GSK has disclosed a chemical series of benzo[<ce:italic>b</ce:italic>] [<ce:cross-ref id="crosref0135" refid="bib1">1</ce:cross-ref>,<ce:cross-ref id="crosref0140" refid="bib4">4</ce:cross-ref>]oxazepin-4-one analogs [<ce:cross-ref id="crosref0145" refid="bib11">11</ce:cross-ref>] that proved to be effective anti-necroptosis agents [<ce:cross-ref id="crosref0150" refid="bib12">12</ce:cross-ref>]] Among them, the clinical candidate GSK2982772 (<ce:bold>3</ce:bold>) completed the phase 2 clinical studies for psoriasis, rheumatoid arthritis, and ulcerative colitis [<ce:cross-ref id="crosref0155" refid="bib13">13</ce:cross-ref>]. Subsequently, Takeda researchers have discovered new brain-penetrating necroptosis inhibitors based on the benzo[<ce:italic>b</ce:italic>] [<ce:cross-ref id="crosref0160" refid="bib1">1</ce:cross-ref>,<ce:cross-ref id="crosref0165" refid="bib4">4</ce:cross-ref>]oxazepin-4-one core of lead compound <ce:bold>3</ce:bold>. Subsequently, lead optimization efforts furnished compound <ce:bold>4</ce:bold> having a potent cellular anti-necroptotic action in vitro for the treatment of neurodegenerative diseases. Moreover, compound <ce:bold>4</ce:bold> was able to significantly diminish disease progression in an experimental autoimmune encephalomyelitis (EAE) murine model of multiple sclerosis [<ce:cross-ref id="crosref0170" refid="bib14">14</ce:cross-ref>]. In order to find additional chemotypes, Harris et al. initiated a high throughput screen on the GSK compound collection to identify novel inhibitors targeting the allosteric binding site in RIPK1. This has led to the discovery of the 4,5-dihydropyrazole GSK963 (<ce:bold>5</ce:bold>) [<ce:cross-ref id="crosref0175" refid="bib15">15</ce:cross-ref>] which furnished after lead optimization efforts compounds <ce:bold>6</ce:bold> and <ce:bold>7</ce:bold>, orally bioavailable and highly selective RIPK1 inhibitors [<ce:cross-ref id="crosref0180" refid="bib16">16</ce:cross-ref>]. Following an original drug repurposing strategy [<ce:cross-ref id="crosref0185" refid="bib17">17</ce:cross-ref>], Augustyns and colleagues have devised a series of new Tozasertib analogs as inhibitors of necroptotic cell death. Tozasertib is a Type I pan-Aurora kinase inhibitor that was also found to inhibit the mTNF-induced necroptosis. Interestingly, compound <ce:bold>8</ce:bold> did not inhibit the Aurora kinases while strongly inhibiting RIPK1. Compound <ce:bold>8</ce:bold> was also potent <ce:italic>in vivo</ce:italic> in a TNF-induced systemic inflammatory response syndrome (SIRS) mouse model [<ce:cross-ref id="crosref0190" refid="bib18">18</ce:cross-ref>]. Finally, one of us and colleagues screened a kinase-focused library and discovered 4-(1<ce:italic>H</ce:italic>-pyrrolo[2,3-<ce:italic>b</ce:italic>]pyridin-2-yl)phenol (<ce:bold>9</ce:bold>), dubbed Sibiriline, as a new RIPK1 inhibitor. Sibiriline was shown to protect mice from immune-mediated acute hepatitis by significantly decreasing serum aspartate aminotransferase (AST) and alanine amino transferase (ALT) levels and liver injury [<ce:cross-ref id="crosref0195" refid="bib4">4</ce:cross-ref>].</ce:para>
                  <ce:para id="p0045" view="all">Therefore, substantial breakthroughs in the knowledge of the medicinal chemistry of necroptosis through the discovery of new-programmed cell death inhibitors or activators are expected not only to lead to original and effective drugs, but also to decipher various molecular mechanisms involved in PCD pathways. Taking into account these latter developments and our interest in necroptotic cell death mechanisms using kinase inhibitors as molecular probes, we recently turned our attention to marine natural products and their simplified fragments. Of particular interest, some marine metabolites bearing the 2-aminoimidazole or the 2-aminobenzimidazole moieties were found to modulate the enzymatic activity of several kinases. For example, the marine natural product 10<ce:italic>Z</ce:italic>-hymenialdisine showed potent activity on several serine/threonine kinases such as GSK-3β, CDK1 (cyclin-dependent kinase 1), CDK2, CDK5, CK1 (casein kinase-1) and MAPKK-1 (Mitogen-activated protein kinase kinase 1) that are involved in the cell life cycle [<ce:cross-ref id="crosref0200" refid="bib19">19</ce:cross-ref>].</ce:para>
                  <ce:para id="p0050" view="all">In a synthetic project targeting the total synthesis of the marine Benzosceptrin B (<ce:bold>10</ce:bold>) [<ce:cross-ref id="crosref0205" refid="bib20">20</ce:cross-ref>] that inhibits kinase CK1δ with an IC<ce:inf loc="post">50</ce:inf> of 0.68 μM, we explored the kinase activity of several truncated fragments based on the 2-aminobenzimidazole sub-structure. Indeed, structural simplification of natural products is nowadays a well-established strategy to circumvent limitations such as narrow synthetic accessibility, unfavorable pharmacokinetics and poor drug-likeness [<ce:cross-ref id="crosref0210" refid="bib21">21</ce:cross-ref>,<ce:cross-ref id="crosref0215" refid="bib22">22</ce:cross-ref>].</ce:para>
                  <ce:para id="p0055" view="all">In this study, we used the FADD-deficient Jurkat T cells treated with 10 ng/mL human TNF-α as in vitro model of necroptosis induction. As described in Delehouzé et al. this forward chemical biology approach can be used to screen chemical libraries for characterization of RIPK1 inhibitors [<ce:cross-ref id="crosref0220" refid="bib5">5</ce:cross-ref>]. Among the various simplified fragments of benzosceptrin C we have screened (undisclosed results), compound <ce:bold>AV123</ce:bold> (<ce:bold>12</ce:bold>) demonstrated a clear inhibition of TNF-α induced necroptosis with an EC<ce:inf loc="post">50</ce:inf> of 1.7 μM, highlighting the simple benzazole core as a promising chemical platform for necroptosis and RIPK1 inhibition. The goal of this study was to identify further benzosceptrin B-inspired fragments that are easy to diversify in order to evaluate RIPK1 as a key target in necroptosis inhibition. We therefore launched a medicinal chemistry project aimed at finding further necroptosis inhibitors based on the 2-aminobenzazole scaffold of the hit compound <ce:bold>AV123</ce:bold> (<ce:bold>12</ce:bold>) (<ce:cross-ref id="crosref0225" refid="fig2">Fig. 2</ce:cross-ref>
                     <ce:float-anchor refid="fig2"/></ce:float-anchor>). We show herein that: (i) RIPK1 is targeted by the more potent hits; (ii) these new RIPK1 inhibitors were shown to block necroptotic but not apoptotic cell death.</ce:para>
               </ce:section>
               <ce:section id="sec2" role="results" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Results and discussion</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">Chemistry</ce:section-title>
                     <ce:para id="p0060" view="all">Initially, we were concerned that the structural complexity of the kinase inhibitor benzosceptrin B make it unsuitable for further development. Thus, we decided to further explore the simplified hit compound <ce:bold>AV123</ce:bold> (<ce:bold>12</ce:bold>) and its 2-aminobenzimidazole analogs <ce:bold>13</ce:bold>–<ce:bold>49</ce:bold> that were prepared according to two standard procedures (<ce:cross-ref id="crosref0230" refid="sch1">Scheme 1</ce:cross-ref>
                        <ce:float-anchor refid="sch1"/></ce:float-anchor> and <ce:cross-ref id="crosref0235" refid="tbl1">Table 1</ce:cross-ref>
                        <ce:float-anchor refid="tbl1"/></ce:float-anchor>). The first procedure involves the reaction of 2-aminobenzimidazoles <ce:bold>10a-k</ce:bold> with selected isothiocyanates in presence of a desulfurization reagent such as dicyclohexylcarbodiimide (DCC) or diisopropylcarbodiimide (DIC) in acetonitrile. The second procedure involves the reaction of diaminoarenes <ce:bold>11b</ce:bold>, <ce:bold>11f</ce:bold> and <ce:bold>11g</ce:bold> with selected commercially available isocyanides in presence of a catalytic amount of elemental selenium. Compounds were obtained in overall satisfactory yields (<ce:cross-ref id="crosref0240" refid="tbl1">Table 1</ce:cross-ref>).</ce:para>
                     <ce:para id="p0065" view="all">Substituent effects on the phenyl ring of <ce:bold>AV123</ce:bold> were then examined. For this purpose, the nitro group found in the R<ce:inf loc="post">2</ce:inf> position of <ce:bold>AV123</ce:bold> was replaced by aryl substituents. Compounds <ce:bold>50</ce:bold>–<ce:bold>55</ce:bold> (<ce:cross-ref id="crosref0245" refid="sch2">Scheme 2</ce:cross-ref>
                        <ce:float-anchor refid="sch2"/></ce:float-anchor>) were prepared from the above brominated compounds <ce:bold>32</ce:bold>–<ce:bold>33</ce:bold> and selected commercially available boronic acids using the Suzuki-Miyaura cross-coupling reaction. Two conditions palladium/base combinations were used (Pd(PPh<ce:inf loc="post">3</ce:inf>)<ce:inf loc="post">4</ce:inf>/K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> or PdCl<ce:inf loc="post">2</ce:inf>(dtbpf))/K<ce:inf loc="post">3</ce:inf>PO<ce:inf loc="post">4</ce:inf> in 1,4-dioxane/water : 1/0.1).</ce:para>
                     <ce:para id="p0070" view="all">The triazolyl-containing compound <ce:bold>58</ce:bold> was obtained through the acetylenic intermediate <ce:bold>57</ce:bold> (<ce:cross-ref id="crosref0250" refid="sch3">Scheme 3</ce:cross-ref>
                        <ce:float-anchor refid="sch3"/></ce:float-anchor>). First, a Sonogashira cross-coupling reaction between the brominated compound <ce:bold>33</ce:bold> and trimethylsilylacetylene furnished the silylated acetylenic intermediate <ce:bold>56</ce:bold> which was subsequently desilylated to furnish <ce:bold>57</ce:bold> which was subsequently treated with benzyl azide then CuSO<ce:inf loc="post">4</ce:inf>.5H<ce:inf loc="post">2</ce:inf>O/sodium ascorbate to give <ce:bold>58</ce:bold> in a one-pot fashion.</ce:para>
                     <ce:para id="p0075" view="all">Selected 2-aminobenzimidazole esters <ce:bold>31</ce:bold> and <ce:bold>34</ce:bold> (<ce:cross-ref id="crosref0255" refid="sch4">Scheme 4</ce:cross-ref>
                        <ce:float-anchor refid="sch4"/></ce:float-anchor>) were directly coupled with appropriate amines using 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD), as an activator of the ester functionality, in acetonitrile to give the amides <ce:bold>59</ce:bold>–<ce:bold>63</ce:bold>.</ce:para>
                     <ce:para id="p0080" view="all">The reaction of the commercially available 2-chlorobenzothiazoles <ce:bold>64</ce:bold> and <ce:bold>65</ce:bold> with <ce:italic>n</ce:italic>-butylamine in the presence of DBU and NaHCO<ce:inf loc="post">3</ce:inf> afforded the corresponding 2-aminobenzothiazoles regioisomers <ce:bold>66</ce:bold> and <ce:bold>67</ce:bold> in good yields (<ce:cross-ref id="crosref0260" refid="sch5">Scheme 5</ce:cross-ref>
                        <ce:float-anchor refid="sch5"/></ce:float-anchor>) [<ce:cross-ref id="crosref0265" refid="bib23">23</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">Biological results</ce:section-title>
                     <ce:section id="sec2.2.1" view="all">
                        <ce:label>2.2.1</ce:label>
                        <ce:section-title id="sectitle0050">Characterization of the 2-aminobenzazole derivatives as new inhibitors of necroptosis</ce:section-title>
                        <ce:para id="p0085" view="all">To evaluate the antinecroptotic activity of the selected compounds, the regulated necrosis was induced by TNF-α in human FADD-deficient Jurkat T cells resistant to extrinsic apoptosis (<ce:cross-ref id="crosref0270" refid="tbl2">Table 2</ce:cross-ref>
                           <ce:float-anchor refid="tbl2"/></ce:float-anchor>
                           <ce:float-anchor refid="tbl3"/></ce:float-anchor>). Structure-activity relationships studies revealed that only few modifications were tolerated at the R<ce:inf loc="post">1</ce:inf>, R<ce:inf loc="post">2</ce:inf>, R<ce:inf loc="post">3</ce:inf> and R<ce:inf loc="post">4</ce:inf> positions of the benzimidazole core. For instance, a complete loss of necroptotic activity was observed when replacing the nitro group at R<ce:inf loc="post">2</ce:inf> by any aryl/heteroaryl (compounds <ce:bold>47</ce:bold>, <ce:bold>50</ce:bold>, <ce:bold>51</ce:bold>, <ce:bold>52</ce:bold>, <ce:bold>53</ce:bold>, <ce:bold>54</ce:bold>, <ce:bold>55</ce:bold>, <ce:bold>56</ce:bold>, <ce:bold>58</ce:bold>), ester (compound <ce:bold>34</ce:bold>), amide (compounds <ce:bold>61</ce:bold>–<ce:bold>63</ce:bold>) or alkynyl groups (compounds <ce:bold>56</ce:bold> and <ce:bold>57</ce:bold>). Nevertheless, compound <ce:bold>44</ce:bold> bearing a chloro-substituent and <ce:bold>48</ce:bold> bearing a cyano substituent at R<ce:inf loc="post">2</ce:inf> showed an EC<ce:inf loc="post">50</ce:inf> of 4.4 μM and 8.9 μM, respectively. Varying the substitution at R<ce:inf loc="post">4</ce:inf> while fixing R<ce:inf loc="post">1</ce:inf> = H, R<ce:inf loc="post">2</ce:inf> = NO<ce:inf loc="post">2</ce:inf> and R<ce:inf loc="post">3</ce:inf> = H, showed that the <ce:italic>n</ce:italic>-butyl found in <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0275" refid="bib12">12</ce:cross-ref>] or the <ce:italic>sec</ce:italic>-butyl groups in compound compound <ce:bold>20</ce:bold> were the most promising compounds. Moreover, the switch from the 2-aminobenzimidazole to the 2-aminobenzothiazole nucleus proved to be beneficial for the anti-necroptotic activity. Indeed, the structurally related benzothiazoles <ce:bold>66</ce:bold> (R<ce:inf loc="post">1</ce:inf> = H, R<ce:inf loc="post">2</ce:inf> = NO<ce:inf loc="post">2</ce:inf>, R<ce:inf loc="post">3</ce:inf> = H, R<ce:inf loc="post">4</ce:inf> = <ce:italic>n</ce:italic>Bu) and <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) (R<ce:inf loc="post">1</ce:inf> = H, R<ce:inf loc="post">2</ce:inf> = H, R<ce:inf loc="post">3</ce:inf> = NO<ce:inf loc="post">2</ce:inf>, R<ce:inf loc="post">4</ce:inf> = <ce:italic>n</ce:italic>Bu) showed an EC<ce:inf loc="post">50</ce:inf> of 6.9 and 4.7 μM, respectively. As a result, the 2-aminobenzimidazole <ce:bold>AV123</ce:bold> and the 2-aminobenzothiazole <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) emerged as promising hit molecules. They are potent inhibitors of cell-death phenotype but also poorly toxic. Four other compounds, namely <ce:bold>20</ce:bold>, <ce:bold>22</ce:bold>, <ce:bold>23</ce:bold> and <ce:bold>44</ce:bold>, were also shown to be potent inhibitors of necroptosis but they are toxic when used above 10 μM concentration (see <ce:cross-ref id="crosref0280" refid="appsec1">Supplementary Fig. 1</ce:cross-ref> in Supporting Information for details). Even if <ce:bold>AV123</ce:bold> inhibited the cell viability of FADD-deficient Jurkat cells at the highest doses tested (>25 μM), we decided to select this compound because it emerged as the most potent inhibitor of necroptosis (EC<ce:inf loc="post">50</ce:inf> = 1.7 μM). The ability of the selected molecules to inhibit necroptosis was also compared to known inhibitors of RIPK1 kinase, Nec-1s and Sibiriline.</ce:para>
                        <ce:para id="p0090" view="all">As shown on <ce:cross-ref id="crosref0285" refid="fig3">Fig. 3</ce:cross-ref>
                           <ce:float-anchor refid="fig3"/></ce:float-anchor>, panel <ce:bold>A</ce:bold>, <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0290" refid="bib12">12</ce:cross-ref>] and <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) efficiently blocked necroptosis in a dose-dependent manner, and with an efficacy almost similar to Sibiriline. Moreover, cell viability analysis of retina cell line grown in presence of <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0295" refid="bib12">12</ce:cross-ref>] and <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) for 24 h indicated that none of the two compounds exhibited toxicity to RPE-1 cells at concentrations from 0.01 to 50 μM (<ce:cross-ref id="crosref0300" refid="fig2">Fig. 2</ce:cross-ref>, panel <ce:bold>B</ce:bold>). The bioactivities of <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0305" refid="bib12">12</ce:cross-ref>] and <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) were studied in the work reported here.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.2" view="all">
                        <ce:label>2.2.2</ce:label>
                        <ce:section-title id="sectitle0055">AV123 [<ce:cross-ref id="crosref0310" refid="bib12">12</ce:cross-ref>] and MBM105 (67) are inhibitors of human RIPK1</ce:section-title>
                        <ce:para id="p0095" view="all">In order to decipher the mechanism of action of <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0315" refid="bib12">12</ce:cross-ref>] and <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>), the RIPK1 enzymatic activity was monitored in the presence of the compounds. The catalytic activity of RIPK1 was quantified by monitoring the phosphorylation of myelin basic protein (MBP), a known substrate of RIPK1 (KinaseProfiler™ assay, Eurofins Discovery, Celle-L’Evescault, France). As shown in <ce:cross-ref id="crosref0320" refid="fig4">Fig. 4</ce:cross-ref>
                           <ce:float-anchor refid="fig4"/></ce:float-anchor>, <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0325" refid="bib12">12</ce:cross-ref>] and <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) efficiently inhibit the phosphorylation of MBP by RIPK1 in a dose-dependent manner with IC<ce:inf loc="post">50</ce:inf> equal to 12.12 and 2.89 μM, respectively. The inhibition of the enzymatic activity by <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0330" refid="bib12">12</ce:cross-ref>] was also observed using an in vitro auto-phosphorylation assay using recombinant full-length RIPK1 (GST-tagged). This assay showed an inhibition of RIPK1 auto-phosphorylation by <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0335" refid="bib12">12</ce:cross-ref>] in a dose-dependent manner. Taken altogether, these data demonstrated that the selected molecules <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0340" refid="bib12">12</ce:cross-ref>] and <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) are inhibitors of RIPK1 kinase activity. In a recent paper, a RIPK1 inhitor including similar benzothiozole motif was described [<ce:cross-ref id="crosref0345" refid="bib24">24</ce:cross-ref>].</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.3" view="all">
                        <ce:label>2.2.3</ce:label>
                        <ce:section-title id="sectitle0060">The more selective RIPK1 inhibitor, MBM105, blocks necroptotic but not apoptotic cell death</ce:section-title>
                        <ce:para id="p0100" view="all">To further analyze the bioactivity of <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>), we next tested its ability to inhibit apoptotic cell death. As shown by the results reported on <ce:cross-ref id="crosref0350" refid="fig4">Fig. 4</ce:cross-ref>, <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) did not rescue WT Jurkat cells from death-receptor (DR)-induced apoptosis (induction by treatment with the cytokine TRAIL) or DR-independent induced apoptosis (induction by treatment with the pan-kinase inhibitor, Staurosporine, STS). In the same conditions, the pan-caspase inhibitor Z-VAD-fmk was shown to inhibit both ways of apoptosis induction. As STS is known to induce both caspase-dependent and caspase-independent cell-death modalities [<ce:cross-ref id="crosref0355" refid="bib25">25</ce:cross-ref>], the inhibition of staurosporine-induced cell-death by Z-VAD-fmk was less potent compared to TRAIL-induced apoptosis (<ce:cross-ref id="crosref0360" refid="fig5">Fig. 5</ce:cross-ref>
                           <ce:float-anchor refid="fig5"/></ce:float-anchor>). Note here that the specificity toward necroptosis was also observed for Sibiriline and necrostatin-1 by Le Cann et al. [<ce:cross-ref id="crosref0365" refid="bib4">4</ce:cross-ref>] Overall, these data indicate that the lead compound <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) is selective towards necroptosis.</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title id="sectitle0065">Molecular docking</ce:section-title>
                     <ce:para id="p0105" view="all">The interaction of RIPK1 with representative inhibitors synthesized in this work was studied using molecular docking calculations. First, the reliability of our protocol was evaluated by docking the compound 2-benzyl-5-nitro-1<ce:italic>H</ce:italic>-benzimidazole in the binding site of RIPK1 (PDB code <ce:inter-ref id="intref0010" xlink:href="pdb:6C3E" xlink:type="simple">6C3E</ce:inter-ref>) [<ce:cross-ref id="crosref0370" refid="bib14">14</ce:cross-ref>]. As shown in <ce:cross-ref id="crosref0375" refid="fig6">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="fig6"/></ce:float-anchor>a and b; the docking conformation reproduces well the X-ray structure of the ligand, with a root-mean-square deviation (RMSD) of 0.59 Å. The ligand is stabilized by hydrogen bond interactions of N-3 with backbone NH of Asp156 and of NH-1 with backbone O of Val76, as well as mainly hydrophobic interactions between the phenyl ring and a subpocket defined by the side chains of residues Leu70, Val75, Ile154, Leu129, Val134, Phe162, Ser161, His136 and Asp156 (<ce:cross-ref id="crosref0380" refid="fig6">Fig. 6</ce:cross-ref>a and b). Compound <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0385" refid="bib12">12</ce:cross-ref>] binds in a similar manner, with the NH-nBu substituent in the hydrophobic pocket and the hydrogen bond of N-3 with backbone NH of Asp156 (<ce:cross-ref id="crosref0390" refid="fig6">Fig. 6</ce:cross-ref>c and d). This latter interaction seems to control the global orientation of the ligand in the binding site, positioning the nitro group between the side chains of Leu90 and Met92, slightly shifted upwards compared with the reference ligand. The same conformation is observed for <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>), again strongly influenced by the hydrogen bond of N-3 with backbone NH of Asp156 (<ce:cross-ref id="crosref0395" refid="fig6">Fig. 6</ce:cross-ref>e and f). Overall, these complexes show a very good shape complementarity between the protein and the ligand (<ce:cross-ref id="crosref0400" refid="fig6">Fig. 6</ce:cross-ref>a, c, e), with a good tolerance of the nitro group in the positions 5 and 6.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0070">Conclusion</ce:section-title>
                  <ce:para id="p0110" view="all">In this study, we identified the first marine-derived compounds as RIPK1 inhibitors that can block necroptotic cell death. This new series of derivatives are based on the 2-aminobenzazole scaffold, a building brick of the larger benzosceptrin B extracted from a marine sponge. Among the 54 compounds synthesized, the 2-aminobenzimidazole <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0405" refid="bib12">12</ce:cross-ref>] and the 2-aminobenzothiazole <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) significantly blocked the necroptotic cell-death induced by TNF-α in human FADD-deficient Jurkat T cells with EC<ce:inf loc="post">50</ce:inf> values in the low micromolar range (1.7 and 4.7 μM, respectively). We have shown also that the inhibition of the catalytic activity of RIPK1 can explain the cellular effect observed. In particular, hit compound <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) showed the best inhibitory effect against HsRIPK1, with an IC<ce:inf loc="post">50</ce:inf> value of 2.89 μM. This compound is also rather selective toward a panel of 12 disease-related protein kinases. In vitro studies on human RPE1 retina cells and Jurkat wild-type lymphocyte cells confirmed their interest. Indeed, <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) is non-cytotoxic and blocks the necroptotic but not the apoptotic cell death. Thus, the 2-aminobenzothiazole <ce:bold>MBM105</ce:bold> (<ce:bold>67</ce:bold>) represents an attractive chemical probe for the study of necroptosis but also serves as a new chemical platform for further development of innovative therapeutic modalities.</ce:para>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0075">Experimental part</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0080">Chemistry</ce:section-title>
                     <ce:section id="sec4.1.1" view="all">
                        <ce:label>4.1.1</ce:label>
                        <ce:section-title id="sectitle0085">General considerations</ce:section-title>
                        <ce:para id="p0115" view="all">All reagents were of analytical grade and were used without further purification. All reactions were monitored by TLC using pre-coated silica gel aluminium plates (Macherey–Nagel) and visualized by UV light (254 nm). Flash column chromatography was carried out with silica gel 60 (70–230 mesh, Macherey–Nagel). <ce:sup loc="post">1</ce:sup>H and <ce:sup loc="post">13</ce:sup>C NMR spectra were acquired at 300 and 75 MHz, respectively, on Bruker spectrometers: Avance 300 MHz (QNP-<ce:sup loc="post">13</ce:sup>C, <ce:sup loc="post">31</ce:sup>P, <ce:sup loc="post">19</ce:sup>F -probe or Dual <ce:sup loc="post">13</ce:sup>C probe) and Avance 500 MHz (BBO-ATM probe or BBI-ATM probe). Chemical shifts (d) are reported in parts per million (ppm) relative to the residual solvent signals, and coupling constants (J) are reported in hertz (Hz). The following abbreviations are used: s, singlet; d, doublet; dd, doublet of doublet; t, triplet; q, quadruplet; quintuplet, quint; dhept, doublet of heptuplet; m, multiplet. IR spectra were recorded on a PerkinElmer Spectrum 65 spectrophotometer using an attenuated total reflectance (ATR) device (<ce:italic>ν</ce:italic> in cm-1). High-resolution MS data were obtained on a Waters LCT Micromass spectrometer in positive electrospray ionization-time of flight (ESI-TOF) mode. Reported yields are unoptimized.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.2" view="all">
                        <ce:label>4.1.2</ce:label>
                        <ce:section-title id="sectitle0090">General procedures for the synthesis of 2-aminobenzimidazoles 12-49</ce:section-title>
                        <ce:section id="sec4.1.2.1" view="all">
                           <ce:label>4.1.2.1</ce:label>
                           <ce:section-title id="sectitle0095">Procedure A</ce:section-title>
                           <ce:para id="p0120" view="all">A mixture of the corresponding substituted-phenylenediamine (limiting reagent), isothiocyanate (1.2 equiv.) and dialkylcarbodiimide (1.2 equiv.) was stirred in pyridine or acetonitrile (3 mL) at 80 °C for 16 h. After, the reaction mixture was evaporated to remove volatiles. The residue was either purified by flash column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>/CH<ce:inf loc="post">3</ce:inf>OH : 95/5) or filtrated and washed with a 1/1 mixture of Et<ce:inf loc="post">2</ce:inf>O and acetonitrile (3 × 10 mL).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.2" view="all">
                           <ce:label>4.1.2.2</ce:label>
                           <ce:section-title id="sectitle0100">Procedure B</ce:section-title>
                           <ce:para id="p0125" view="all">A mixture of the corresponding <ce:italic>o</ce:italic>-phenylenediamine (limiting reagent), isonitrile (1.5 equiv), 1 mol% elemental selenium powder and pyridine (0.2 mL) were added at rt. The mixture was then charged with oxygen (1 atm) and stirred at the appropriate temperature for 24 h. After the reaction time, the reaction was filtered to remove solid particles. The filtrate was dried to remove volatiles. The residue was purified by flash column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>/CH<ce:inf loc="post">3</ce:inf>OH : 95/5).</ce:para>
                           <ce:section id="sec4.1.2.2.1" view="all">
                              <ce:label>4.1.2.2.1</ce:label>
                              <ce:section-title id="sectitle0105">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-Butyl-6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine AV123 (12)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0130" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (459 mg, 3 mmol), <ce:italic>n</ce:italic>-butyl isothiocyanate (434 μL, 3.6 mmol), diisopropylcarbodiimide (561 μL, 3.6 mmol) were reacted in pyridine (1 mL) according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded <ce:bold>AV123</ce:bold> [<ce:cross-ref id="crosref0410" refid="bib12">12</ce:cross-ref>] (632 mg, 90%) as a yellow amorphous solid. IR (neat): 3279, 2955, 2937, 1650, 1470, 1320, 1254, 1064, 991 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.27 (s, 1H), 7.93 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 7.88 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 1H), 7.45 (s, 1H), 7.20 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 3.47–3.16 (m, 2H), 1.65–1.45 (m, 1H), 1.35 (dq, <ce:italic>J</ce:italic> = 14.1, 7.2 Hz, 1H), 0.90 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 1H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 159.3, 150.8, 138.9, 133.2, 117.6, 113.1, 104.2, 41.8, 31.3, 19.5, 13.6. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">11</ce:inf>H<ce:inf loc="post">15</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">3</ce:inf>. 235.1195, Found: 235.1195.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.2" view="all">
                              <ce:label>4.1.2.2.2</ce:label>
                              <ce:section-title id="sectitle0110">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-Ethyl-6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (13)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0135" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (459 mg, 3 mmol), ethyl isothiocyanate (315 μL, 3.6 mmol), diisopropylcarbodiimide (557 μL, 3.6 mmol) were reacted in pyridine according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>13</ce:bold> (436 mg, 70%) as a light yellow foam. IR (neat): 3270, 2983, 1661, 1608, 1582, 1473, 1256, 1123, 1060, 1018 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 8.00 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 7.94 (dd, <ce:italic>J</ce:italic> = 8.7, 2.2 Hz, 1H), 7.20 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 3.42 (q, <ce:italic>J</ce:italic> = 7.1 Hz, 2H), 1.28 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 160.0, 146.7, 142.8, 134.3, 118.5, 112.4, 107.9, 38.9, 15.6. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">9</ce:inf>H<ce:inf loc="post">11</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">2</ce:inf> 207.0882. Found 207.0873.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.3" view="all">
                              <ce:label>4.1.2.2.3</ce:label>
                              <ce:section-title id="sectitle0115">
                                 <ce:bold>6-Nitro-<ce:italic>N</ce:italic>-propyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (14)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0140" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (306 mg, 2 mmol), propyl isothiocyanate (250 μL, 2.4 mmol), diisopropylcarbodiimide (372 μL, 2.4 mmol) were reacted in acetonitrile according to the for the synthesis of the 2-aminobenzimidazoles. The resulting solid was filtrated and washed with a 8:2 mixture of Et<ce:inf loc="post">2</ce:inf>O and acetonitrile (3 × 10 mL) to afford compound <ce:bold>14</ce:bold> (211 mg, 48%) as a yellow amorphous solid. IR (neat): 3330, 2959, 1659, 1581, 1471, 1446, 1255, 1220, 1061, 992, 883 cm<ce:sup loc="post">−1</ce:sup>.<ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) <ce:italic>δ</ce:italic> 11.28 (s, 1H), 7.93 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 7.87 (dd, <ce:italic>J</ce:italic> = 8.7, 2.3 Hz, 1H), 7.37 (s, 1H), 7.19 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 3.28 (dd, <ce:italic>J</ce:italic> = 13.1, 6.7 Hz, 2H), 1.70–1.47 (m, 2H), 0.91 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 3H).<ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 158.99, 116.93, 112.16, 105.17, 43.87, 22.45, 11.21. Some quaternary carbons and aromatic CH too broad to be seen due to very slow relaxation. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">10</ce:inf>H<ce:inf loc="post">13</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">2</ce:inf> 221.1039. Found: 221.1037.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.4" view="all">
                              <ce:label>4.1.2.2.4</ce:label>
                              <ce:section-title id="sectitle0120">
                                 <ce:bold>6-Nitro-<ce:italic>N</ce:italic>-hexyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (15)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0145" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (459 mg, 3 mmol), <ce:italic>n</ce:italic>-hexyl isothiocyanate (591 μL, 3.6 mmol), diisopropylcarbodiimide (557 μL, 3.6 mmol) were reacted in pyridine according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>15</ce:bold> (584 mg, 74%) as a yellow amorphous solid. IR (neat): 3337, 3107, 2955, 2856, 1660, 1586, 1465, 1263, 1067, 944 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.27 (s, 1H), 7.94 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 7.87 (dd, <ce:italic>J</ce:italic> = 8.7, 2.3 Hz, 1H), 7.35 (s, 1H), 7.19 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 3.31 (dd, <ce:italic>J</ce:italic> = 12.8, 6.8 Hz, 2H), 1.69–1.42 (m, 2H), 1.46–1.16 (m, 6H), 0.84 (t, <ce:italic>J</ce:italic> = 6.8 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 158.94, 159.58, 116.85, 112.23, 104.91, 42.13, 30.96, 29.16, 25.98, 22.03, 13.81. Some quaternary carbons and aromatic CH too broad to be seen due to very slow relaxation. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">19</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">2</ce:inf> 263.1508. Found: 263.1495.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.5" view="all">
                              <ce:label>4.1.2.2.5</ce:label>
                              <ce:section-title id="sectitle0125">
                                 <ce:bold>6-Nitro-<ce:italic>N</ce:italic>-octyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (16)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0150" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (459 mg, 3 mmol), <ce:italic>n</ce:italic>-octyl isothiocyanate (678 μL, 3.6 mmol), diisopropylcarbodiimide (557 μL, 3.6 mmol) were reacted in pyridine according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>16</ce:bold> (508 mg, 58%) as a yellow amorphous solid. IR (neat): 3348, 2923, 2853, 1660, 1586, 1466, 1269, 1067, 944 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.27 (s, 1H), 7.93 (s, 1H), 7.87 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.29 (m, 1H), 7.20 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 1.76–1.41 (m, 2H), 1.41–1.08 (m, 12H), 0.94–0.68 (m, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 158.94, 139.56, 116.76, 111.49, 105.48, 42.12, 31.18, 29.19, 28.68, 28.64, 26.31, 22.01, 13.84. Some quaternary carbons and aromatic CH too broad to be seen due to very slow relaxation. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">22</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">2</ce:inf> 291.1821. Found: 291.1825.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.6" view="all">
                              <ce:label>4.1.2.2.6</ce:label>
                              <ce:section-title id="sectitle0130">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-Isopropyl-6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (17)</ce:bold> [<ce:cross-ref id="crosref0415" refid="bib26">26</ce:cross-ref>]</ce:section-title>
                              <ce:para id="p0155" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (459 mg, 3 mmol), isopropyl isothiocyanate (384 μL, 3.6 mmol), diisopropylcarbodiimide (557 μL, 3.6 mmol) were reacted in pyridine according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded <ce:bold>17</ce:bold> (607 mg, 92%) as a light yellow amorphous solid. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 8.00 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 7.94 (dd, <ce:italic>J</ce:italic> = 8.7, 2.2 Hz, 1H), 7.20 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 3.98 (m, 1H), 1.29 (d, <ce:italic>J</ce:italic> = 6.6 Hz, 6H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 159.3, 149.6, 142.9, 135.0, 118.4, 112.4, 107.9, 46.0, 23.3.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.7" view="all">
                              <ce:label>4.1.2.2.7</ce:label>
                              <ce:section-title id="sectitle0135">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-Allyl-6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (18)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0160" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (459 mg, 3 mmol), allyl isothiocyanate (352 μL, 3.6 mmol), diisopropylcarbodiimide (557 μL, 3.6 mmol) were reacted in pyridine according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>18</ce:bold> (522 mg, 80%) as a light yellow amorphous solid. IR (neat): 3280, 2976, 1665, 1606, 1583, 1475, 1319, 1256, 1219, 1062, 1004, 922, 880, 816 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 8.02 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 7.96 (dd, <ce:italic>J</ce:italic> = 8.8, 2.3 Hz, 1H), 7.22 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 5.99 (m, 1H), 5.29 (m, 1H), 5.16 (m, 1H), 4.02 (m, 2H). 2H missing due to chemical exchange with MeOD. <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 158.7, 139.7, 135.4, 116.9, 115.3, 112.6, 105.1, 44.3. Some quaternary carbons and aromatic CH too broad to be seen due to very slow relaxation. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">10</ce:inf>H<ce:inf loc="post">11</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">2</ce:inf>: 219.0867. Found 219.0882.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.8" view="all">
                              <ce:label>4.1.2.2.8</ce:label>
                              <ce:section-title id="sectitle0140">
                                 <ce:bold>6-Nitro-<ce:italic>N</ce:italic>-(prop-2-yn-1-yl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (19)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0165" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (306 mg, 2 mmol), propargyl isothiocyanate (226 μL, 2.4 mmol), diisopropylcarbodiimide (372 μL, 2.4 mmol) were reacted in acetonitrile according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>19</ce:bold> (133 mg, 26%) as a yellow amorphous solid. IR (neat): 3332, 3266, 2903, 2740, 2643, 1574, 1466, 1320, 1066, 1037, 867, 819 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) <ce:italic>δ</ce:italic> 11.48 (s, 1H), 8.00 (s, 1H), 7.94–7.82 (m, 1H), 7.85–7.40 (m, 1H), 7.28 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 4.16 (d, <ce:italic>J</ce:italic> = 3.2 Hz, 2H), 3.16 (s, 1H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 117.47, 115.46, 113.83, 109.91, 108.58, 104.75, 81.45, 73.38, 31.57. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd. for C<ce:inf loc="post">10</ce:inf>H<ce:inf loc="post">9</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">2</ce:inf> 217.0726. Found: 217.0718.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.9" view="all">
                              <ce:label>4.1.2.2.9</ce:label>
                              <ce:section-title id="sectitle0145">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-Isobutyl-6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (20)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0170" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (306 mg, 2 mmol), isobutyl isothiocyanate (291 μL, 2.4 mmol), diisopropylcarbodiimide (372 μL, 2.4 mmol) were reacted in acetonitrile according to the procedure A for the synthesis of the 2-aminobenzimidazoles. The resulting solid was filtrated and washed with a 8:2 mixture of Et<ce:inf loc="post">2</ce:inf>O and acetonitrile (3 × 10 mL) to afford compound <ce:bold>20</ce:bold> (114 mg, 24%) as a yellow amorphous solid. IR (neat): 3354, 3110, 2964, 1613, 1592, 1289, 1065, 1020, 816 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.19 (s, 1H), 7.93 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 7.87 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.43 (s, 1H), 7.19 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 3.14 (t, <ce:italic>J</ce:italic> = 6.4 Hz, 2H), 1.88 (dp, <ce:italic>J</ce:italic> = 13.4, 6.7 Hz, 1H), 0.91 (d, <ce:italic>J</ce:italic> = 6.7 Hz, 6H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 117.58, 113.00, 104.65, 49.63, 27.97, 22.66, 19.94. Some quaternary carbons and aromatic CH too broad to be seen due to very slow relaxation. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd. for C<ce:inf loc="post">11</ce:inf>H<ce:inf loc="post">15</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">2</ce:inf> 235.1195. Found: 235.1185.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.10" view="all">
                              <ce:label>4.1.2.2.10</ce:label>
                              <ce:section-title id="sectitle0150">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-(2-Methoxyethyl)-6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (21)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0175" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (164 mg, 1.5 mmol), 2-methoxyethyl isothiocyanate (195 μL, 1.8 mmol), dicyclohexylcarbodiimide (371 mg, 1.8 mmol) were reacted in pyridine according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>21</ce:bold> (126 mg, 36%) as a light yellow solid. IR (neat): 3287, 2922, 2828, 1657, 1584, 1466, 1261, 1103, 1061 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (500 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.21 (s, 1H), 7.94 (t, <ce:italic>J</ce:italic> = 9.1 Hz, 1H), 7.88 (dd, <ce:italic>J</ce:italic> = 8.7, 2.2 Hz, 1H), 7.43 (s, 1H), 7.22 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 3.50 (m, 2H), 3.29 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 117.4, 113.3, 109.2, 104.5, 70.6, 58.0, 41.8. Some quaternary carbons and aromatic CH too broad to be seen due to very slow relaxation. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">10</ce:inf>H<ce:inf loc="post">13</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">2</ce:inf> 237.0988. Found 237.0989.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.11" view="all">
                              <ce:label>4.1.2.2.11</ce:label>
                              <ce:section-title id="sectitle0155">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-Cyclohexyl-6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (22)</ce:bold> [<ce:cross-ref id="crosref0420" refid="bib27">27</ce:cross-ref>]</ce:section-title>
                              <ce:para id="p0180" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (229 mg, 1 mmol), cyclohexyl isocyanide (280 μL, 1.5 mmol), elemental selenium (1 mg, 1 mol%) and oxygen (1 atm) were reacted at 90 °C in pyridine (0.2 mL) according to the procedure B for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>22</ce:bold> (172 mg, 66%) as a pale yellow amorphous solid. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 8.02 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.97 (d, <ce:italic>J</ce:italic> = 1.2 Hz, 1H), 7.22 (dd, <ce:italic>J</ce:italic> = 7.9, 1.2 Hz, 1H), 3.63 (m, 1H), 2.06–1.37 (m, 10H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 150.6, 142.5, 139.0, 134.0, 117.7, 113.3, 104.2, 51.0, 32.7, 25.2, 24.6.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.12" view="all">
                              <ce:label>4.1.2.2.12</ce:label>
                              <ce:section-title id="sectitle0160">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-Benzyl-6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (23)</ce:bold> [<ce:cross-ref id="crosref0425" refid="bib26">26</ce:cross-ref>]</ce:section-title>
                              <ce:para id="p0185" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (459 mg, 3 mmol), phenyl isothiocyanate (430 μL, 3.6 mmol), diisopropylcarbodiimide (557 μL, 3.6 mmol) were reacted in pyridine according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>23</ce:bold> (624 mg, 78%) as a light yellow amorphous solid. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 12.87 (s, 1H), 12.43 (s, 1H), 8.37 (d, <ce:italic>J</ce:italic> = 1.9 Hz, 1H), 8.18–7.94 (m, 3H), 7.75–7.46 (m, 4H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 166.7, 150.9, 141.9, 132.8, 132.5, 128.5, 128.3, 117.4.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.13" view="all">
                              <ce:label>4.1.2.2.13</ce:label>
                              <ce:section-title id="sectitle0165">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-(6-Nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-yl)benzamide (24)</ce:bold> [<ce:cross-ref id="crosref0430" refid="bib27">27</ce:cross-ref>]</ce:section-title>
                              <ce:para id="p0190" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (459 mg, 3 mmol), benzyl isothiocyanate (477 μL, 3.6 mmol), diisopropylcarbodiimide (557 μL, 3.6 mmol) were reacted in pyridine according to procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>25</ce:bold> (561 mg, 66%) as a light yellow amorphous solid. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, MeOD) <ce:italic>δ</ce:italic> 8.03 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 8.00–7.88 (m, 1H), 7.46–7.29 (m, 4H), 7.29–7.13 (m, 2H), 4.61 (s, 2H), 2H missing due to chemical exchange with MeOD. <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, MeOD) <ce:italic>δ</ce:italic> 140.0, 129.6, 128.3, 128.4, 118.3, 112.5, 107.8, 47.3. Some quaternary carbons and aromatic CH too broad to be seen due to very slow relaxation. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">13</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">2</ce:inf> 269.1039. Found 269.1036.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.14" view="all">
                              <ce:label>4.1.2.2.14</ce:label>
                              <ce:section-title id="sectitle0170">
                                 <ce:bold>6-Nitro-<ce:italic>N</ce:italic>-phenyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (25)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0195" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (459 mg, 3 mmol), benzoyl isothiocyanate (484 μL, 3.6 mmol), diisopropylcarbodiimide (557 μL, 3.6 mmol) were reacted in pyridine according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>25</ce:bold> (528 mg, 70%) as a light yellow amorphous solid. IR (neat): 3287, 2975, 2868, 1642, 1577, 1455, 1318, 1256, 1061, 996 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.44 (s, 1H), 9.94 (s, 1H), 8.15 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 7.97 (dd, <ce:italic>J</ce:italic> = 8.7, 2.3 Hz, 1H), 7.75 (dd, <ce:italic>J</ce:italic> = 8.6, 1.0 Hz, 2H), 7.43 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.38–7.25 (m, 2H), 7.00 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 1H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 139.7, 128.9, 121.7, 117.9, 117.0. Some quaternary carbons and aromatic CH too broad to be seen due to very slow relaxation. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">11</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">3</ce:inf> 283.0831. Found 283.0835.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.15" view="all">
                              <ce:label>4.1.2.2.15</ce:label>
                              <ce:section-title id="sectitle0175">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-(4-Bromophenyl)-6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (26)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0200" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (306 mg, 2 mmol), 4-bromophenyl isothiocyanate (513 mg, 2.4 mmol), diisopropylcarbodiimide (372 μL, 2.4 mmol) were reacted in acetonitrile according to the procedure A for the synthesis of the 2-aminobenzimidazoles. The resulting solid was filtrated and washed with a 8:2 mixture of Et<ce:inf loc="post">2</ce:inf>O and acetonitrile (3 × 10 mL) to afford compound <ce:bold>26</ce:bold> (286 mg, 43%) as a yellow amorphous solid. IR (neat): 3279, 2845, 1661, 1572, 1491, 1315, 1273, 1072, 1010, 891 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) <ce:italic>δ</ce:italic> 11.52 (s, 1H), 10.07 (s, 1H), 8.16 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 7.98 (dd, <ce:italic>J</ce:italic> = 8.8, 2.3 Hz, 1H), 7.81–7.71 (m, 2H), 7.59–7.48 (m, 2H), 7.45 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 153.73, 141.05, 139.20, 131.58, 119.74, 117.05, 112.99. Some quaternary carbons and aromatic CH too broad to be seen due to very slow relaxation. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">9</ce:inf>
                                 <ce:sup loc="post">79</ce:sup>BrN<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">2</ce:inf> 332.9987. Found: 332.9991.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.16" view="all">
                              <ce:label>4.1.2.2.16</ce:label>
                              <ce:section-title id="sectitle0180">
                                 <ce:bold>4-((6-Nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-yl)amino)benzonitrile (27)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0205" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (306 mg, 2 mmol), (218 mg, 2 mmol), 4-cyanophenyl isothiocyanate (384 mg, 2.4 mmol), diisopropylcarbodiimide (372 μL, 2.4 mmol) were reacted in acetonitrile according to the procedure A for the synthesis of the 2-aminobenzimidazoles. The resulting solid was filtrated and washed with a 8:2 mixture of Et<ce:inf loc="post">2</ce:inf>O and acetonitrile (3 × 10 mL) to afford compound <ce:bold>27</ce:bold> (488 mg, 87%) as a yellow amorphous solid. IR (neat): 3274, 2842, 2226, 1658, 1562, 1505, 1320, 1233, 1178, 1066, 1020 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.68 (s, 1H), 10.50 (s, 1H), 8.23 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 8.07–7.89 (m, 3H), 7.89–7.71 (m, 2H), 7.52 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO) <ce:italic>δ</ce:italic> 144.0, 133.4, 119.4, 117.6, 102.8. Some quaternary carbons and aromatic CH too broad to be seen due to very slow relaxation. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">10</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">2</ce:inf> 280.0834. Found: 280.0840.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.17" view="all">
                              <ce:label>4.1.2.2.17</ce:label>
                              <ce:section-title id="sectitle0185">
                                 <ce:bold>6-Nitro-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine (28)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0210" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (306 mg, 2 mmol), (218 mg, 2 mmol), 4-(trifluoromethyl)-phenyl isothiocyanate (487 mg, 2.4 mmol), diisopropylcarbodiimide (372 μL, 2.4 mmol) were reacted in acetonitrile according to the procedure A for the synthesis of the 2-aminobenzimidazoles. The resulting solid was filtrated and washed with a 8:2 mixture of Et<ce:inf loc="post">2</ce:inf>O and acetonitrile (3 × 10 mL) to afford compound <ce:bold>28</ce:bold> (224 mg, 35%) as a yellow amorphous solid. IR (neat): 3317, 1615, 1572, 1320, 1284, 1098, 1066, 1015, 822 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.64 (s, 1H), 10.37 (s, 1H), 8.21 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 8.07–7.91 (m, 3H), 7.70 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.50 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 153.25, 143.35, 141.19, 116.19, 121.40 (q, <ce:italic>J</ce:italic> = 40 Hz, 1C), 117.43, 117.12. Some quaternary carbons and aromatic CH too broad to be seen due to very slow relaxation. <ce:sup loc="post">19</ce:sup>F NMR (282 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>
                                 <ce:italic>) δ</ce:italic> – 59.96 (s, 3F). HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">10</ce:inf>F<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">2</ce:inf>Na 364.0997. Found: 364.0998.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.18" view="all">
                              <ce:label>4.1.2.2.18</ce:label>
                              <ce:section-title id="sectitle0190">
                                 <ce:bold>6-Nitro-<ce:italic>N</ce:italic>-(4-nitrophenyl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (29)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0215" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (306 mg, 2 mmol), (218 mg, 2 mmol), 4-nitrophenyl isothiocyanate (487 mg, 2.4 mmol), diisopropylcarbodiimide (372 μL, 2.4 mmol) were reacted in acetonitrile according to the procedure A for the synthesis of the 2-aminobenzimidazoles. The resulting solid was filtrated and washed with a 8:2 mixture of Et<ce:inf loc="post">2</ce:inf>O and acetonitrile (3 × 10 mL) to afford compound <ce:bold>29</ce:bold> (488 mg, 87%) as a yellow solid. IR (neat): 3389, 3305, 3108, 2919, 1578, 1485, 1321, 1290, 1251, 1114, 1072 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.42 (s, 1H), 8.24 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 3H), 8.10–7.85 (m, 4H), 7.52 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 153.01, 146.36, 143.02, 141.30, 140.48, 137.00, 125.24, 117.09, 116.91, 113.12, 108.68. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">10</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">4</ce:inf> 300.0733. Found: 300.0737.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.19" view="all">
                              <ce:label>4.1.2.2.19</ce:label>
                              <ce:section-title id="sectitle0195">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>
                                 </ce:bold>
                                 <ce:sup loc="post">
                                    <ce:bold>1</ce:bold>
                                 </ce:sup>
                                 <ce:bold>, <ce:italic>N</ce:italic>
                                 </ce:bold>
                                 <ce:sup loc="post">
                                    <ce:bold>1</ce:bold>
                                 </ce:sup>
                                 <ce:bold>-Dimethyl-<ce:italic>N</ce:italic>
                                 </ce:bold>
                                 <ce:sup loc="post">
                                    <ce:bold>4</ce:bold>
                                 </ce:sup>
                                 <ce:bold>-(6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-yl)benzene-1,4-diamine (30)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0220" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (306 mg, 2 mmol), 4-dimethylaminophenyl isothiocyanate (427 mg, 2.4 mmol), diisopropylcarbodiimide (372 μL, 2.4 mmol) were reacted in acetonitrile according to the procedure A for the synthesis of the 2-aminobenzimidazoles. The resulting solid was filtrated and washed with a 8:2 mixture of Et<ce:inf loc="post">2</ce:inf>O and acetonitrile (3 × 10 mL) to afford compound <ce:bold>30</ce:bold> (416 mg, 70%) as a red amorphous solid. IR (neat): 3408, 2796, 1669, 1572, 1490, 1472, 1310, 1258, 1225, 1070, 945, 812 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) <ce:italic>δ</ce:italic> 11.25 (s, 1H), 9.58 (s, 1H), 8.05 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 7.93 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 7.48 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H), 7.33 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 6.78 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 2H), 2.87 (s, 6H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 146.78, 129.18, 120.68, 117.55, 113.24, 104.84, 40.61. Some quaternary carbons and aromatic CH too broad to be seen due to very slow relaxation. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">16</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">4</ce:inf> 298.1304. Found: 298.1306.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.20" view="all">
                              <ce:label>4.1.2.2.20</ce:label>
                              <ce:section-title id="sectitle0200">
                                 <ce:bold>Ethyl (6-nitro-1H-benzo[d]imidazol-2-yl)glycinate (31)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0225" view="all">4-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (613 g, 4 mmol), Ethyl isothiocyanatoacetate (601 μL, 4.8 mmol), diisopropylcarbodiimide (743 μL, 4.8 mmol) were reacted in acetonitrile according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>31</ce:bold> (523 g, 49%) as a brown amorphous solid. <ce:sup loc="post">
                                    <ce:bold>1</ce:bold>
                                 </ce:sup>
                                 <ce:bold>H NMR (300 MHz, MeOD)</ce:bold> 
                                 <ce:italic>δ</ce:italic> 8.07 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 7.99 (dd, <ce:italic>J</ce:italic> = 8.7, 2.2 Hz, 1H), 7.27 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 4.23 (q, <ce:italic>J</ce:italic> = 7.1 Hz, 2H), 4.20 (s, 2H), 1.29 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 3H). <ce:sup loc="post">
                                    <ce:bold>13</ce:bold>
                                 </ce:sup>
                                 <ce:bold>C NMR (75 MHz, MeOD)</ce:bold> 
                                 <ce:italic>δ</ce:italic> 118.4, 62.4, 44.9, 14.4. Some quaternary carbons are not visible.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.21" view="all">
                              <ce:label>4.1.2.2.21</ce:label>
                              <ce:section-title id="sectitle0205">
                                 <ce:bold>6-Bromo-<ce:italic>N</ce:italic>-ethyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (32)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0230" view="all">4-Bromo-<ce:italic>o</ce:italic>-phenylenediamine (561 mg, 3 mmol), ethyl isothiocyanate (315 μL, 3.6 mmol), diisopropylcarbodiimide (557 μL, 3.6 mmol) were reacted in pyridine according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>32</ce:bold> (284 mg, 39%) as a deep red amorphous solid. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.36 (t, <ce:italic>J</ce:italic> = 9.1 Hz, 1H), 7.22–7.04 (m, 2H), 6.89 (s, 1H), 5.48 (s, 1H), 3.42 (q, <ce:italic>J</ce:italic> = 7.2 Hz, 2H), 1.21 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 3H).<ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 155.2, 138.9, 135.8, 123.8, 115.2, 113.6, 112.9, 38.1, 15.0. Some quaternary carbons and aromatic CH too broad to be seen due to very slow relaxation. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">9</ce:inf>H<ce:inf loc="post">11</ce:inf>
                                 <ce:sup loc="post">79</ce:sup>BrN<ce:inf loc="post">3</ce:inf>: 240.0136, found: 240.0146.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.22" view="all">
                              <ce:label>4.1.2.2.22</ce:label>
                              <ce:section-title id="sectitle0210">
                                 <ce:bold>6-Bromo-<ce:italic>N</ce:italic>-butyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (33)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0235" view="all">4-Bromo-<ce:italic>o</ce:italic>-phenylenediamine (2 g, 10.7 mmol), <ce:italic>n</ce:italic>-butyl isothiocyanate (1.5 mL, 12.8 mmol), diisopropylcarbodiimide (2 mL, 12.8 mmol) were reacted in acetonitrile according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>33</ce:bold> (1.33 g, 46%) as a deep red hygroscopic solid. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 9.26 (s, 1H), 7.40 (d, <ce:italic>J</ce:italic> = 1.2 Hz, 1H), 7.14 (m, 2H), 5.38 (s, 1H), 3.41 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 2H), 1.70–1.41 (m, 2H), 1.39–1.22 (q, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 0.85 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H).<ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 156.4, 139.7, 136.5, 123.4, 115.1, 113.2, 112.8, 43.1, 31.9, 20.0, 13.7. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">11</ce:inf>H<ce:inf loc="post">15</ce:inf>
                                 <ce:sup loc="post">79</ce:sup>BrN<ce:inf loc="post">4</ce:inf>: 268.0449, found: 268.0444.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.23" view="all">
                              <ce:label>4.1.2.2.23</ce:label>
                              <ce:section-title id="sectitle0215">
                                 <ce:bold>Methyl 2-(butylamino)-1<ce:italic>H</ce:italic>-benzo[d]imidazole-6-carboxylate (34)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0240" view="all">Methyl 3,4-diaminobenzoate (664 g, 4 mmol), <ce:italic>n</ce:italic>-butyl isothiocyanate (435 μL, 4.8 mmol), diisopropylcarbodiimide (743 μL, 4.8 mmol) were reacted in acetonitrile according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>34</ce:bold> (813 mg, 82%) as a white amorphous solid. IR (neat): 3332, 3102, 2938, 1685, 1653, 1567, 1432, 1276, 1205, 1131, 1099, 999 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.98 (s, 1H), 7.70 (d, <ce:italic>J</ce:italic> = 1.6 Hz, 1H), 7.58 (dd, <ce:italic>J</ce:italic> = 8.2, 1.6 Hz, 1H), 7.15 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 6.97 (s, 1H), 3.80 (s, 3H), 3.27 (q, <ce:italic>J</ce:italic> = 7.3 Hz, 2H), 1.63–1.43 (m, 2H), 1.36 (dq, <ce:italic>J</ce:italic> = 14.2, 7.2 Hz, 2H), 0.91 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 167.1, 157.5, 121.7, 112.1, 51.5, 31.4, 19.5, 13.7. Some quaternary carbons and aromatic CH too broad to be seen due to very slow relaxation. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">18</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf>: 248.1399, found: 248.1398.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.24" view="all">
                              <ce:label>4.1.2.2.24</ce:label>
                              <ce:section-title id="sectitle0220">
                                 <ce:bold>Ethyl 2-(butylamino)-1<ce:italic>H</ce:italic>-benzo[d]imidazole-7-carboxylate (35)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0245" view="all">Ethyl 2,3-diaminobenzoate (665 g, 4 mmol), <ce:italic>n</ce:italic>-butyl isothiocyanate (435 μL, 4.8 mmol), diisopropylcarbodiimide (743 μL, 4.8 mmol) were reacted in acetonitrile according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>35</ce:bold> (820 g, 83%) as a brown amorphous solid. IR (neat): 3336, 2956, 1701, 1578, 1436, 1258, 1199, 1147, 1055, 1034 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 9.43 (s, 1H), 7.63–7.50 (m, 2H), 7.14–6.99 (m, 1H), 5.83 (s, 1H), 3.84 (s, 3H), 3.46 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 2H), 1.66–1.49 (m, 2H), 1.43–1.27 (m, 2H), 0.87 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 167.5, 156.2, 144.0, 134.5, 120.6, 120.0, 111.0, 51.8, 42.8, 31.9, 23.4, 20.0, 13.7. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd. for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">18</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf> 248.1399. Found: 248.1393.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.25" view="all">
                              <ce:label>4.1.2.2.25</ce:label>
                              <ce:section-title id="sectitle0225">
                                 <ce:bold>Methyl 2-(cyclohexylamino)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazole-6-carboxylate (36)</ce:bold> [<ce:cross-ref id="crosref0435" refid="bib28">28</ce:cross-ref>]</ce:section-title>
                              <ce:para id="p0250" view="all">Methyl 3,4-diaminobenzoate (249 mg, 1 mmol), cyclohexyl isocyanide (280 μL, 1.5 mmol), elemental selenium (1 mg, 1 mol%) and oxygen (1 atm) were reacted at 90 °C in pyridine (0.2 mL) according to the procedure B for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>36</ce:bold> (154 mg, 56%) as a white amorphous solid. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 7.82 (d, <ce:italic>J</ce:italic> = 1.4 Hz, 1H), 7.71 (dd, <ce:italic>J</ce:italic> = 8.2, 1.4 Hz, 1H), 7.19 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 3.87 (s, 3H, H16), 3.61 (m, 1H, H11), 2.06–1.35 (m, 10H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 169.9, 145.2, 142.1, 134.7, 128.7, 124.0, 117.5, 113.1, 52.8, 52.4, 34.6, 26.9, 26.3.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.26" view="all">
                              <ce:label>4.1.2.2.26</ce:label>
                              <ce:section-title id="sectitle0230">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-isopropyl-7-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (37)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0255" view="all">3-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (459 mg, 3 mmol), phenyl isothiocyanate (384 μL, 3.6 mmol), diisopropylcarbodiimide (557 μL, 3.6 mmol) were reacted in pyridine according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>37</ce:bold> (630 mg, 95%) as a yellow solid. IR (neat): 3227, 3042, 2973, 1605, 1580, 1507, 1256, 1172, 1127, 1059 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.29 (s, 1H), 7.67 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H), 7.55 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 1H), 7.09 (t, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 6.27 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 1H), 3.98 (m, 1H), 1.23 (d, <ce:italic>J</ce:italic> = 6.5 Hz, 6H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 156.34, 147.23, 130.48, 128.74, 121.12, 119.95, 113.45, 43.96, 22.62. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd. for C<ce:inf loc="post">10</ce:inf>H<ce:inf loc="post">13</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">2</ce:inf> 221.1039. Found: 221.1034.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.27" view="all">
                              <ce:label>4.1.2.2.27</ce:label>
                              <ce:section-title id="sectitle0235">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-Butyl-7-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (38)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0260" view="all">3-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (459 mg, 3 mmol), <ce:italic>n</ce:italic>-butyl isothiocyanate (434 μL, 3.6 mmol), diisopropylcarbodiimide (557 μL, 3.6 mmol) were reacted in pyridine according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>38</ce:bold> (665 mg, 95%) as a yellow amorphous solid. IR (neat): 3385, 2960, 2928, 1608, 1582, 1503, 1335, 1261, 1181 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.47 (s, 1H), 7.68 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 7.55 (d, <ce:italic>J</ce:italic> = 7.4 Hz, 1H), 7.09 (t, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 6.41 (s, 1H), 3.54–3.23 (m, 2H), 1.56 (dd, <ce:italic>J</ce:italic> = 14.0, 6.9 Hz, 2H), 1.36 (dd, <ce:italic>J</ce:italic> = 14.4, 7.2 Hz, 2H), 0.92 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 157.72, 147.68, 130.94, 129.44, 121.53, 120.44, 113.90, 42.20, 31.78, 19.95, 14.14. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd. for C<ce:inf loc="post">11</ce:inf>H<ce:inf loc="post">15</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">2</ce:inf> 235.1195. Found: 235.1193.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.28" view="all">
                              <ce:label>4.1.2.2.28</ce:label>
                              <ce:section-title id="sectitle0240">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-(2-Methoxyethyl)-7-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (39)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0265" view="all">3-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (459 mg, 3 mmol), 2-methoxyethyl isothiocyanate (391 μL, 3.6 mmol), diisopropylcarbodiimide (557 μL, 3.6 mmol) were reacted in pyridine according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>39</ce:bold> (590 mg, 84%) as a red-orange amorphous solid. IR (neat): 3266, 2916, 2831, 1666, 1498, 1333, 1270, 1190, 1103 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.51 (s, 1H), 7.66 (t, <ce:italic>J</ce:italic> = 14.1 Hz, 1H), 7.55 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 1H), 7.10 (t, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 6.52 (s, 1H), 3.60–3.44 (m, 4H), 3.30 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 157.08, 146.96, 130.52, 128.86, 121.19, 120.00, 113.57, 70.56, 57.97. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd. for C<ce:inf loc="post">10</ce:inf>H<ce:inf loc="post">13</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">3</ce:inf> 237.0988. Found: 237.0983.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.29" view="all">
                              <ce:label>4.1.2.2.29</ce:label>
                              <ce:section-title id="sectitle0245">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-Butyl-7-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (40)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0270" view="all">3-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (459 mg, 3 mmol), cyclohexyl isothiocyanate (510 μL, 3.6 mmol), diisopropylcarbodiimide (557 μL, 3.6 mmol) were reacted in pyridine according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>40</ce:bold> (394 mg, 50%) as a yellow amorphous solid. IR (neat): 3287, 2932, 2850, 1649, 1581, 1512, 1339, 1259, 1173, 1109, 1062 cm<ce:sup loc="post">−1</ce:sup>.<ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.27 (s, 1H), 7.67 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H), 7.55 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 1H), 7.09 (t, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 6.38 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 3.69 (s, 1H), 1.97 (d, <ce:italic>J</ce:italic> = 9.8 Hz, 2H), 1.82–1.62 (m, 2H), 1.47–1.15 (m, 6H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 156.27, 147.19, 130.42, 128.75, 121.05, 119.98, 113.40, 50.50, 32.43, 25.14, 24.13. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd. for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">17</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">2</ce:inf> 261.1352. Found: 261.1357.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.30" view="all">
                              <ce:label>4.1.2.2.30</ce:label>
                              <ce:section-title id="sectitle0250">
                                 <ce:bold>7-Nitro-<ce:italic>N</ce:italic>-phenyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (41)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0275" view="all">3-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (459 mg, 3 mmol), phenyl isothiocyanate (430 μL, 3.6 mmol), diisopropylcarbodiimide (557 μL, 3.6 mmol) were reacted in pyridine according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>41 AV118</ce:bold> (730 mg, 96%) as an orange-red amorphous solid. IR (neat): 3434, 3371, 3082, 1648, 1570, 1335, 1232, 1148, 1051, 987 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.60 (s, 1H), 9.15 (s, 1H), 7.87–7.66 (m, 4H), 7.46–7.29 (m, 2H), 7.27–7.11 (m, 1H), 7.01 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 1H).<ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 152.4, 146.4, 139.3, 131.0, 129.0, 127.5, 122.8, 121.6, 120.5, 117.2, 115.2. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd. for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">11</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">2</ce:inf> 255.0882. Found: 255.0880.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.31" view="all">
                              <ce:label>4.1.2.2.31</ce:label>
                              <ce:section-title id="sectitle0255">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-Benzyl-7-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (42)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0280" view="all">3-Nitro-<ce:italic>o</ce:italic>-phenylenediamine (459 mg, 3 mmol), benzyl isothiocyanate (477 μL, 3.6 mmol), diisopropylcarbodiimide (557 μL, 3.6 mmol) were reacted in pyridine according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>42</ce:bold> (586 mg, 73%) as an orange-red amorphous solid. IR (neat): 3375, 3074, 2964, 2869, 1656, 1584, 1495, 1332, 1274, 1221, 1113, 982, 910 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.66 (s, 1H), 7.70 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H), 7.55 (d, <ce:italic>J</ce:italic> = 7.3 Hz, 1H), 7.41–7.30 (m, 4H), 7.25 (ddd, <ce:italic>J</ce:italic> = 6.9, 3.8, 1.5 Hz, 1H), 7.10 (t, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 6.96–6.80 (m, 1H), 4.62 (d, <ce:italic>J</ce:italic> = 6.2 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 157.18, 146.93, 139.56, 130.62, 128.94, 128.32, 127.05, 126.88, 121.30, 120.04, 113.68, 45.47. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd. for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">13</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">2</ce:inf> 269.1039. Found: 269.1038.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.32" view="all">
                              <ce:label>4.1.2.2.32</ce:label>
                              <ce:section-title id="sectitle0260">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-Cyclohexyl-6-methyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (43)</ce:bold> [<ce:cross-ref id="crosref0440" refid="bib29">29</ce:cross-ref>]</ce:section-title>
                              <ce:para id="p0285" view="all">4-Methyl-<ce:italic>o</ce:italic>-phenylenediamine (183 mg, 1 mmol), cyclohexyl isocyanide (280 μL, 1.5 mmol), elemental selenium (1 mg, 1 mol%) and oxygen (1 atm) were reacted at 90 °C in pyridine (0.2 mL) according to the procedure B for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>43</ce:bold> (170 mg, 74%) as a brown amorphous solid.<ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 7.03 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 6.98 (d, <ce:italic>J</ce:italic> = 1.2 Hz, 1H), 6.75 (dd, <ce:italic>J</ce:italic> = 7.9, 1.2 Hz, 1H), 3.55 (m, 1H), 2.32 (s, 3H), 2.01–1.30 (m, 10H).<ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 156.2, 139.3, 137.0, 130.8, 122.2, 113.1, 112.3, 52.8, 34.7, 26.9, 26.2, 21.8.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.33" view="all">
                              <ce:label>4.1.2.2.33</ce:label>
                              <ce:section-title id="sectitle0265">
                                 <ce:bold>6-Chloro-<ce:italic>N</ce:italic>-cyclohexyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (44)</ce:bold> [<ce:cross-ref id="crosref0445" refid="bib30">30</ce:cross-ref>]</ce:section-title>
                              <ce:para id="p0290" view="all">4-Chloro-<ce:italic>o</ce:italic>-phenylenediamine (214 mg, 1 mmol), cyclohexyl isocyanide (280 μL, 1.5 mmol), elemental selenium (1 mg, 1 mol%) and oxygen (1 atm) were reacted at 90 °C in pyridine (0.2 mL) according to the procedure B for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>44</ce:bold> (204 mg, 82%) as a pale yellow solid. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 7.14 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 7.08 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 1H), 6.90 (dd, <ce:italic>J</ce:italic> = 8.3, 2.0 Hz, 1H), 3.57 (s, 1H), 2.05–1.36 (m, 10H).<ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 157.2, 143.7, 140.8, 126.6, 121.0, 113.1, 112.9, 52.9, 34.7, 26.9, 26.3.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.34" view="all">
                              <ce:label>4.1.2.2.34</ce:label>
                              <ce:section-title id="sectitle0270">
                                 <ce:bold>6-Bromo-<ce:italic>N</ce:italic>-cyclohexyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (45)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0295" view="all">4-Bromo-<ce:italic>o</ce:italic>-phenylenediamine (214 mg, 1 mmol), cyclohexyl isocyanide (280 μL, 1.5 mmol), elemental selenium (1 mg, 1 mol%) and oxygen (1 atm) were reacted at 100 °C in pyridine (0.2 mL) according to the procedure B for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>45</ce:bold> (206 mg, 70%) as a black oil. IR (neat): 2971, 2901, 1632, 1572, 1463, 1394, 1259, 1066, 1048, 879, 798 cm<ce:sup loc="post">−1</ce:sup>.<ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 7.23 (d, <ce:italic>J</ce:italic> = 1.9 Hz, 1H), 7.04 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 1H), 6.95 (dd, <ce:italic>J</ce:italic> = 8.3, 1.9 Hz, 1H), 6.69 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 3.54 (m, 1H), 1.93–1.25 (m, 10H).<ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 155.6, 143.9, 135.5, 121.0, 115.8, 114.6, 113.4, 50.9, 32.9, 25.3, 24.7. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">17</ce:inf>BrN<ce:inf loc="post">3</ce:inf> 294.0606. Found 294.0602.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.35" view="all">
                              <ce:label>4.1.2.2.35</ce:label>
                              <ce:section-title id="sectitle0275">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-Butyl-6-iodo-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (46)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0300" view="all">4-Iodo-<ce:italic>o</ce:italic>-phenylenediamine (306 mg, 2 mmol), (218 mg, 2 mmol), <ce:italic>n</ce:italic>-butyl isothiocyanate (289 μL, 2.4 mmol), diisopropylcarbodiimide (372 μL, 2.4 mmol) were reacted in acetonitrile according to the procedure A for the synthesis of the 2-aminobenzimidazoles. The resulting solid was filtrated and washed with a 8:2 mixture of Et<ce:inf loc="post">2</ce:inf>O and acetonitrile (3 × 10 mL) to afford compound <ce:bold>46</ce:bold> (273 mg, 43%) as a brown foam. <ce:bold>IR (neat):</ce:bold> 3395, 2955, 2927, 1629, 1594, 1568, 1458, 1264, 1014, 902 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.84 (s, 1H), 7.43 (d, <ce:italic>J</ce:italic> = 1.5 Hz, 1H), 7.14 (dd, <ce:italic>J</ce:italic> = 8.1, 1.6 Hz, 1H), 6.96 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 6.85–6.67 (m, 1H), 3.28 (q, <ce:italic>J</ce:italic> = 6.7 Hz, 2H), 1.64–1.45 (m, 2H), 1.45–1.24 (m, 2H), 0.90 (t, <ce:italic>J</ce:italic> = 7.0 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 156.07, 127.03, 119.90, 113.35, 81.48, 41.88, 31.45, 19.55, 13.71. Some quaternary carbons and aromatic CH too broad to be seen due to very slow relaxation. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd. for C<ce:inf loc="post">11</ce:inf>H<ce:inf loc="post">14</ce:inf>
                                 <ce:sup loc="post">127</ce:sup>IN<ce:inf loc="post">3</ce:inf> 316.0311. Found: 316.0326.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.36" view="all">
                              <ce:label>4.1.2.2.36</ce:label>
                              <ce:section-title id="sectitle0280">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-Butyl-6-(1<ce:italic>H</ce:italic>-tetrazol-1-yl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (47)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0305" view="all">4-(1<ce:italic>H</ce:italic>-Tetrazol-1-yl)benzene-1,2-diamine (352 mg, 2 mmol), <ce:italic>n</ce:italic>-butyl isothiocyanate (288 μL, 2.4 mmol), diisopropylcarbodiimide (372 μL, 2.4 mmol) were reacted in acetonitrile according to the procedure A for the synthesis of the 2-aminobenzimidazoles. The resulting solid was filtrated and washed with a 8:2 mixture of Et<ce:inf loc="post">2</ce:inf>O and acetonitrile (3 × 10 mL) to afford compound <ce:bold>47</ce:bold> (250 mg, 48%) as a beige foam. <ce:bold>IR (neat):</ce:bold> 2958, 2930, 1678, 1586, 1462, 1404, 1276, 1090, 1002, 918 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) <ce:italic>δ</ce:italic> 11.17 (s, 1H), 9.94 (s, 1H), 7.57 (d, <ce:italic>J</ce:italic> = 1.8 Hz, 1H), 7.40–7.20 (m, 2H), 6.94 (t, <ce:italic>J</ce:italic> = 5.6 Hz, 1H), 3.30 (dd, <ce:italic>J</ce:italic> = 12.8, 6.9 Hz, 2H), 1.66–1.44 (m, 2H), 1.36 (dq, <ce:italic>J</ce:italic> = 14.2, 7.2 Hz, 2H), 0.96–0.81 (m, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 171.92, 157.30, 142.14, 139.52, 126.12, 112.47, 111.14, 105.13, 41.86, 31.39, 19.52, 13.67. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">12</ce:inf>H<ce:inf loc="post">16</ce:inf>N<ce:inf loc="post">7</ce:inf> 258.1467. Found: 258.1463.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.37" view="all">
                              <ce:label>4.1.2.2.37</ce:label>
                              <ce:section-title id="sectitle0285">
                                 <ce:bold>2-(Butylamino)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazole-6-carbonitrile (48)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0310" view="all">4-Cyano-<ce:italic>o</ce:italic>-phenylenediamine (266 mg, 2 mmol), <ce:italic>n</ce:italic>-butyl isothiocyanate (289 μL, 2.4 mmol), diisopropylcarbodiimide (372 μL, 2.4 mmol) were reacted in acetonitrile according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>48</ce:bold> (58 mg, 14%) as a white amorphous solid. IR (neat): 3267, 2949, 2867, 2213, 1663, 1605, 1568, 1287, 1126, 997 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO) <ce:italic>δ</ce:italic> 11.16 (s, 1H), 7.46 (s, 1H), 7.32–7.12 (m, 2H), 7.06 (s, 1H), 3.39–3.14 (m, 2H), 1.66–1.44 (m, 2H), 1.44–1.24 (m, 2H), 0.88 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 157.62, 123.88, 120.87, 113.32, 41.79, 31.34, 19.49, 13.65. Some quaternary carbons and aromatic CH too broad to be seen due to very slow relaxation. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd. for C<ce:inf loc="post">12</ce:inf>H<ce:inf loc="post">15</ce:inf>N<ce:inf loc="post">4</ce:inf> 215.1297. Found: 215.1301.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.2.2.38" view="all">
                              <ce:label>4.1.2.2.38</ce:label>
                              <ce:section-title id="sectitle0290">
                                 <ce:bold>7-Bromo-<ce:italic>N</ce:italic>-butyl-5-(trifluoromethyl)-1H-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (49)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0315" view="all">3-Bromo-5-(trifluoromethyl)benzene-1,2-diamine (510 mg, 2 mmol), <ce:italic>n</ce:italic>-butyl isothiocyanate (289 μL, 2.4 mmol), diisopropylcarbodiimide (372 μL, 2.4 mmol) were reacted in acetonitrile according to the procedure A for the synthesis of the 2-aminobenzimidazoles. Flash column chromatography afforded compound <ce:bold>49</ce:bold> (264 mg, 39%) as a white amorphous solid. IR (neat): 3413, 2933, 1641, 1598, 1425, 1313, 1111, 963 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.34 (s, 1H), 7.38 (m, 3H), 3.32 (dd, <ce:italic>J</ce:italic> = 12.9, 6.8 Hz, 2H), 1.67–1.47 (m, 2H), 1.43–1.25 (m, 2H), 0.89 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 157.73, 145.50, 133.96, 126.35, 122.76, 119.65, 106.28, 104.71, 41.83, 31.40, 19.44, 13.58.<ce:sup loc="post">19</ce:sup>F NMR (282 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>
                                 <ce:italic>) δ</ce:italic> – 58.53 (s, 3F). HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">12</ce:inf>H<ce:inf loc="post">14</ce:inf>
                                 <ce:sup loc="post">79</ce:sup>BrF<ce:inf loc="post">3</ce:inf>N<ce:inf loc="post">3</ce:inf> 336.0323. Found: 336.0326.</ce:para>
                           </ce:section>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.3" view="all">
                        <ce:label>4.1.3</ce:label>
                        <ce:section-title id="sectitle0295">General procedures for the Suzuki-Miyaura cross-coupling reaction</ce:section-title>
                        <ce:para id="p0320" view="all">A mixture of aryl bromide (1 equiv.), boronic acid (1 equiv.) and base (3 equiv.) in dioxanne (1 mL) and water (0.1 mL) was degassed under a flow of Argon for 5 min. Palladium catalyst (5 mol%) was then added and the reaction mixture was heated at 80 °C for 16 h. The reaction mixture was allowed to cool to room temperature then concentrated under reduced pressure. The crude was purified by flash column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>/CH<ce:inf loc="post">3</ce:inf>OH : 95/5).</ce:para>
                        <ce:section id="sec4.1.3.1" view="all">
                           <ce:label>4.1.3.1</ce:label>
                           <ce:section-title id="sectitle0300">
                              <ce:bold>6-(2-Chlorophenyl)-<ce:italic>N</ce:italic>-ethyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (50)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0325" view="all">6-Bromo-<ce:italic>N</ce:italic>-ethyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (108 mg, 0.45 mmol), (2-chlorophenyl)boronic acid (70 mg, 0.45 mmol), K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (186 mg, 1.35 mmol) and Pd(PPh<ce:inf loc="post">3</ce:inf>)<ce:inf loc="post">3</ce:inf> (26 mg, 0.02 mmol, 5 mol%) were reacted in dioxanne (3 mL) and water (1 mL) according to the general procedure for the Suzuki cross-couplings. Flash column chromatography afforded compound <ce:bold>50</ce:bold> (33 mg, 27%) as a brown foam. IR (neat): 3055, 2925, 1634, 1578, 1598, 1460, 1269, 1034 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 8.17 (s, 1H), 7.55–7.15 (m, 6H), 7.12 (dd, <ce:italic>J</ce:italic> = 8.1, 1.6 Hz, 1H), 5.70 (s, 1H), 3.47 (q, <ce:italic>J</ce:italic> = 7.2 Hz, 1H), 1.20 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 155.2, 141.4, 137.4, 132.7, 132.2, 131.8, 129.9, 128.0, 126.7, 122.6, 113.2, 111.8, 38.2, 15.2. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">15</ce:inf>
                              <ce:sup loc="post">35</ce:sup>ClN<ce:inf loc="post">4</ce:inf> 272.0955. Found 272.0966.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.2" view="all">
                           <ce:label>4.1.3.2</ce:label>
                           <ce:section-title id="sectitle0305">
                              <ce:bold>
                                 <ce:italic>N</ce:italic>-Ethyl-6-(3-nitrophenyl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (51)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0330" view="all">6-Bromo-<ce:italic>N</ce:italic>-ethyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (108 mg, 0.45 mmol), (3-nitrophenyl)boronic acid (75 mg, 0.45 mmol), K<ce:inf loc="post">3</ce:inf>PO<ce:inf loc="post">4</ce:inf> (286 mg, 1.35 mmol) and PdCl<ce:inf loc="post">2</ce:inf>(dtbpf) (15 mg, 0.02 mmol, 5 mol%) were reacted in dioxanne and water according to the general procedure for the Suzuki cross-couplings. Flash column chromatography afforded compound <ce:bold>51</ce:bold> (21 mg, 16%) as a yellow foam. IR (neat): 3075, 2926, 1603, 1519, 1467, 1342, 1267, 1034 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 8.48–8.36 (m, 1H), 8.23–8.09 (m, 1H), 8.09–7.96 (m, 1H), 7.64 (dd, <ce:italic>J</ce:italic> = 16.3, 8.3 Hz, 1H), 7.57 (s, 1H), 7.50–7.33 (m, 2H), 3.49 (q, <ce:italic>J</ce:italic> = 7.2 Hz, 2H), 1.36 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 2H). 2H missing due to chemical exchange. <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 155.6, 150.2, 144.6, 140.3, 136.3, 134.1, 131.1, 129.2, 128.1, 122.4, 122.2, 113.2, 111.2, 38.8, 15.1. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m/z</ce:italic> calcd. for C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">15</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">2</ce:inf> 283.1195. Found 283.1184.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.3" view="all">
                           <ce:label>4.1.3.3</ce:label>
                           <ce:section-title id="sectitle0310">
                              <ce:bold>
                                 <ce:italic>N</ce:italic>-Ethyl-6-(3-methoxyphenyl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (52)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0335" view="all">6-Bromo-<ce:italic>N</ce:italic>-ethyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (108 mg, 0.45 mmol), (3-methoxyphenyl)boronic acid (68 mg, 0.45 mmol), K<ce:inf loc="post">3</ce:inf>PO<ce:inf loc="post">4</ce:inf> (286 mg, 1.35 mmol) and PdCl<ce:inf loc="post">2</ce:inf>(dtbpf) (15 mg, 0.02 mmol, 5 mol%) were reacted in dioxanne and water according to the general procedure for the Suzuki cross-couplings. Flash column chromatography afforded compound <ce:bold>52</ce:bold> (40 mg, 33%) as a light brown foam. IR (neat): 3386, 2931, 2833, 1635, 1575, 1465, 1269, 1220, 1163, 1047, 1023 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.51 (s, 1H), 7.42–7.24 (m, 3H), 7.24–7.08 (m, 2H), 6.90–6.78 (m, 1H), 6.35 (s, 1H), 5.19 (s, 1H), 3.83 (s, 3H), 3.48 (q, <ce:italic>J</ce:italic> = 7.2 Hz, 2H), 1.23 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 159.9, 155.8, 143.7, 137.9, 134.1, 126.6, 120.3, 119.7, 112.9, 112.4, 111.9, 110.6, 55.2, 38.1, 15.2. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m/z</ce:italic> calcd. for C<ce:inf loc="post">16</ce:inf>H<ce:inf loc="post">18</ce:inf>N<ce:inf loc="post">3</ce:inf>O 268.1450. Found 268.1443.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.4" view="all">
                           <ce:label>4.1.3.4</ce:label>
                           <ce:section-title id="sectitle0315">
                              <ce:bold>
                                 <ce:italic>N</ce:italic>-Butyl-6-(3-nitrophenyl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (53)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0340" view="all">6-Bromo-<ce:italic>N</ce:italic>-butyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (107 mg, 0.4 mmol), (3-nitrophenyl)boronic acid (67 mg, 0.4 mmol), K<ce:inf loc="post">3</ce:inf>PO<ce:inf loc="post">4</ce:inf> (286 mg, 1.2 mmol) and PdCl<ce:inf loc="post">2</ce:inf>(dtbpf) (14 mg, 0.02 mmol, 5 mol%) were reacted in dioxanne and water according to the general procedure for the Suzuki cross-couplings. Flash column chromatography afforded compound <ce:bold>53</ce:bold> (19 mg, 16%) as a yellow foam. IR (neat): 3392, 2927, 1635, 1600, 1581, 1524, 1463, 1344, 1270, 1099 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, Acetone-<ce:italic>d6</ce:italic>) <ce:italic>δ</ce:italic> 8.42 (t, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 8.17–7.98 (m, 2H), 7.69 (t, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 7.56 (d, <ce:italic>J</ce:italic> = 1.2 Hz, 1H), 7.42–7.22 (m, 2H), 6.41 (s, 1H), 3.49 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 2H), 1.76–1.58 (m, 2H), 1.53–1.33 (m, 2H), 0.93 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (300 MHz, Acetone-<ce:italic>d6</ce:italic>) <ce:italic>δ</ce:italic> 157.5, 149.8, 145.2, 141.0, 140.4, 133.7, 130.8, 121.8, 121.4, 119.9, 113.0, 111.0, 43.3, 32.8, 20.7, 14.1. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">19</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">2</ce:inf> 311.1508. Found 311.1513.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.5" view="all">
                           <ce:label>4.1.3.5</ce:label>
                           <ce:section-title id="sectitle0320">
                              <ce:bold>
                                 <ce:italic>N</ce:italic>-Butyl-6-(3-methoxyphenyl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (54)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0345" view="all">6-Bromo-<ce:italic>N</ce:italic>-butyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (107 mg, 0.4 mmol), (3-methoxyphenyl)boronic acid (61 mg, 0.4 mmol), K<ce:inf loc="post">3</ce:inf>PO<ce:inf loc="post">4</ce:inf> (255 mg, 1.2 mmol) and PdCl<ce:inf loc="post">2</ce:inf>(dtbpf) (14 mg, 0.02 mmol, 5 mol%) were reacted in dioxanne and water according to the general procedure for the Suzuki cross-couplings. Flash column chromatography afforded compound <ce:bold>54</ce:bold> (61 mg, 52%) as a light brown foam. IR (neat): 3058, 2955, 1636, 1577, 1464, 1270, 1221, 1163, 1047, 1034 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.53 (s, 1H), 7.43–7.23 (m, 3H), 7.24–7.06 (m, 2H), 6.92–6.79 (m, 1H), 5.24 (s, 2H), 3.85 (s, 3H), 3.42 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 2H), 1.61 (dt, <ce:italic>J</ce:italic> = 14.9, 7.4 Hz, 2H), 1.47–1.29 (m, 2H), 0.89 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 159.9, 155.4, 143.7, 137.4, 134.3, 129.6, 128.6, 120.4, 119.7, 112.8, 112.4, 111.9, 110.8, 55.2, 43.2, 31.9, 20.0, 13.7. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m/z</ce:italic> calcd for C<ce:inf loc="post">18</ce:inf>H<ce:inf loc="post">22</ce:inf>N<ce:inf loc="post">3</ce:inf>O 296.1763. Found 296.1762.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.6" view="all">
                           <ce:label>4.1.3.6</ce:label>
                           <ce:section-title id="sectitle0325">
                              <ce:bold>
                                 <ce:italic>N</ce:italic>-Butyl-6-(thiophen-3-yl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (55)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0350" view="all">6-Bromo-<ce:italic>N</ce:italic>-butyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (107 mg, 0.4 mmol), thiophen-3-ylboronic acid (51 mg, 0.4 mmol), K<ce:inf loc="post">3</ce:inf>PO<ce:inf loc="post">4</ce:inf> (255 mg, 1.2 mmol) and PdCl<ce:inf loc="post">2</ce:inf>(dtbpf) (14 mg, 0.02 mmol, 5 mol%) were reacted in dioxanne and water according to the general procedure for the Suzuki cross-couplings. Flash column chromatography afforded compound <ce:bold>55</ce:bold> (75 mg, 69%) as a light brown foam. IR (neat): 3389, 3100, 2927, 1634, 1575, 1459, 1363, 1271, 1229, 1032 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.55 (s, 1H), 7.48 (s, 1H), 7.39–7.29 (m, 5H), 5.15 (s, 1H), 3.43 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 2H), 1.66–1.46 (m, 2H), 1.40–1.23 (m, 2H), 0.85 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 156.0, 143.2, 137.8, 129.0, 126.6, 125.9, 119.6, 118.8, 109.9, 43.1, 31.9, 20.0, 13.7. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m/z</ce:italic> calcd. for C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">18</ce:inf>N<ce:inf loc="post">3</ce:inf>S 272.1221. Found 272.1217.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.7" view="all">
                           <ce:label>4.1.3.7</ce:label>
                           <ce:section-title id="sectitle0330">
                              <ce:bold>
                                 <ce:italic>N</ce:italic>-Butyl-6-((trimethylsilyl)ethynyl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (56)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0355" view="all">A mixture of compound <ce:bold>32</ce:bold> (536 mg, 2 mmol, 1 equiv.), trimethylsilylacetylene (831 μL, 6 mmol, 3 equiv.) and triethylamine (836 μL, 6 mmol, 5 equiv.) in dry DMF (0.5 mL) was degassed under a flow of Argon for 5 min. PdCl<ce:inf loc="post">2</ce:inf>(dtbpf) (68 mg, 0.1 mmol, 10 mol%) and CuI (38 mg, 0.2 mmol, 20 mol%) were then added and the reaction mixture was heated at 60 °C for 16 h. The reaction mixture was allowed to cool to room temperature then concentrated under reduced pressure. The crude was purified by flash column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>/CH<ce:inf loc="post">3</ce:inf>OH : 95/5) to afford compound <ce:bold>56</ce:bold> (324 mg, 57%) as a brown foam. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 9.54 (s, 1H), 7.45–6.58 (m, 3H), 5.29 (s, 1H), 3.49–2.90 (m, 2H), 1.48–1.15 (m, 2H), 1.13–0.78 (m, 2H), 0.70–0.34 (m, 3H), −0.03 (s, 9H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 156.5, 138.4, 136.4, 125.4, 114.8, 111.8, 106.4, 91.6, 84.8, 42.9, 31.7, 19.8, 13.5, 0.0. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m/z</ce:italic> calcd. For C<ce:inf loc="post">16</ce:inf>H<ce:inf loc="post">24</ce:inf>N<ce:inf loc="post">3</ce:inf>
                              <ce:sup loc="post">28</ce:sup>Si 286.1740. Found 286.1752.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.8" view="all">
                           <ce:label>4.1.3.8</ce:label>
                           <ce:section-title id="sectitle0335">
                              <ce:bold>
                                 <ce:italic>N</ce:italic>-Butyl-6-ethynyl-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-amine (57)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0360" view="all">Compound <ce:bold>56</ce:bold> (251 mg, 0.88 mmol) and K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (134 mg, 0.97 mmol) were reacted in MeOH/water: 1/1 (1 mL) at room temperature for 16 h. The reaction mixture was then concentrated under reduced pressure. The crude was purified by flash column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>/CH<ce:inf loc="post">3</ce:inf>OH : 95/5) to afford compound <ce:bold>57</ce:bold> (140 mg, 86%) as a yellow foam. IR (neat): 3397, 3285, 2957, 2102, 1632, 1593, 1571, 1462, 1273, 1218, 1118 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.35 (s, 1H), 7.33–7.14 (m, 2H), 5.34 (s, 1H), 5.10 (s, 1H), 3.41 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 2H), 3.00 (s, 1H), 1.79–1.48 (m, 2H), 1.45–1.23 (m, 2H), 0.89 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 156.1, 139.7, 136.9, 125.6, 115.4, 113.7, 112.4, 85.0, 75.0, 43.1, 20.0, 13.7.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.9" view="all">
                           <ce:label>4.1.3.9</ce:label>
                           <ce:section-title id="sectitle0340">
                              <ce:bold>6-(1-Benzyl-1H-1,2,3-triazol-4-yl)-N-ethyl-1H-benzo[d]imidazol-2-amine (58)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0365" view="all">A mixture of benzyl bromide (52 μL, 0.44 mmol, 1.1 equiv.), NaN<ce:inf loc="post">3</ce:inf> (29 mg, 0.44 mmol, 1.1 equiv.) was stirred in DMF (0.5 mL) and water (0.1 mL) at room temperature for 16 h. Once the intermediate azide is formed (TLC control using Heptane/EtOAc: 8/2), compound <ce:bold>57</ce:bold> (85 mg, 0.40 mmol, 1 equiv.), CuSO<ce:inf loc="post">4</ce:inf>.5H<ce:inf loc="post">2</ce:inf>O (10 mg, 0.04 mmol, 10 mol%) and sodium ascorbate (16 mg, 0.08 mmol, 20 mol%) were added. The reaction mixture was stirred for further 16 h at room temperature. Afterward, the reaction mixture was concentrated under reduced pressure and the crude purified by flash column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>/CH<ce:inf loc="post">3</ce:inf>OH: 95/5) to afford compound <ce:bold>58</ce:bold> (56 mg, 40%) as a brown foam. IR (neat): 3031, 2926, 2164, 1671, 1456, 1222, 1071 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 8.39–8.24 (m, 1H), 7.77 (s, 1H), 7.60 (t, <ce:italic>J</ce:italic> = 10.9 Hz, 1H), 7.43–7.29 (m, 6H), 5.62 (s, 2H), 1.68 (dt, <ce:italic>J</ce:italic> = 14.4, 7.0 Hz, 2H), 1.55–1.35 (m, 2H), 0.99 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). 2H missing due to chemical exchange with MeOD. <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 153.7, 149.2, 136.8, 133.8, 133.6, 130.1, 129.6, 129.1, 126.7, 122.1, 121.8, 112.8, 109.5, 55.1, 44.1, 32.1, 21.0, 14.1. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m/z</ce:italic> calcd For C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">23</ce:inf>N<ce:inf loc="post">6</ce:inf> 347.1984. Found 347.1977.</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.4" view="all">
                        <ce:label>4.1.4</ce:label>
                        <ce:section-title id="sectitle0345">General procedure for the amidation with 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD)</ce:section-title>
                        <ce:section id="sec4.1.4.1" view="all">
                           <ce:label>4.1.4.1</ce:label>
                           <ce:section-title id="sectitle0350">Procedure A</ce:section-title>
                           <ce:para id="p0370" view="all">A mixture of 2-aminobenzimidazole (limiting reagent) and triazabicyclodecene (TBD, 1 equiv.) was stirred in DMF (1 mL) until the formation of a heavy precipitate, then amine (1.2 equiv.) was added and the reaction mixture was at 90 °C for 16 h under air. After, the reaction mixture was evaporated to remove volatiles. The residue was either purified by flash column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>/CH<ce:inf loc="post">3</ce:inf>OH : 95/5).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.2" view="all">
                           <ce:label>4.1.4.2</ce:label>
                           <ce:section-title id="sectitle0355">Procedure B</ce:section-title>
                           <ce:para id="p0375" view="all">A mixture of 2-aminobenzimidazole (limiting reagent), triazabicyclodecene (TBD, 1 equiv.) and amine (5 equiv.) was stirred at 90 °C for 16 h under air. After, the reaction mixture was evaporated to remove volatiles. The residue was either purified by flash column chromatography on silica gel (CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>/CH<ce:inf loc="post">3</ce:inf>OH: 95/5).</ce:para>
                           <ce:section id="sec4.1.4.2.1" view="all">
                              <ce:label>4.1.4.2.1</ce:label>
                              <ce:section-title id="sectitle0360">
                                 <ce:italic>N</ce:italic>-Ethyl-2-((6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-yl)amino)acetamide (59)</ce:section-title>
                              <ce:para id="p0380" view="all">Ethyl (6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-yl)glycinate (70 mg, 0.3 mmol), triazabicyclodecene (42 mg, 0.3 mmol) and ethylamine (100 μL, 1.5 mmol, 5 equiv.) were reacted according to the procedure B. Flash column chromatography afforded compound <ce:bold>59</ce:bold> (54 mg, 62%) as a orange amorphous solid. IR (neat): 3363, 3240, 2922, 1673, 1615, 1515, 1451, 1329, 1242, 1122, 1042 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, Acetone-<ce:italic>d6</ce:italic>) <ce:italic>δ</ce:italic> 8.04 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 7.93 (dd, <ce:italic>J</ce:italic> = 8.7, 2.3 Hz, 1H), 7.51 (s, 1H), 7.28 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 6.88 (s, 1H), 4.15 (s, 2H), 3.32–3.22 (m, 1H), 1.10 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, Acetone-<ce:italic>d6</ce:italic>) <ce:italic>δ</ce:italic> 169.7, 159.3, 144.1, 142.0, 139.2, 139.4, 117.6, 112.8, 107.9, 46.5, 34.7, 15.1. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd For C<ce:inf loc="post">11</ce:inf>H<ce:inf loc="post">14</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">3</ce:inf> 264.1097. Found: 264.1106.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.4.2.2" view="all">
                              <ce:label>4.1.4.2.2</ce:label>
                              <ce:section-title id="sectitle0365">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-Butyl-2-((6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-yl)amino)acetamide (60)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0385" view="all">Ethyl (6-nitro-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazol-2-yl)glycinate (70 mg, 0.3 mmol), triazabicyclodecene (42 mg, 0.3 mmol) and <ce:italic>n</ce:italic>-butylamine (148 μL, 1.5 mmol, 5 equiv.) were reacted according to the procedure B for the amidation. Flash column chromatography afforded compound <ce:bold>60</ce:bold> (37 mg, 42%) as a yellow amorphous solid. IR (neat): 3267, 2956, 2928, 1592, 1530, 1461, 1279, 1092 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, Acetone-<ce:italic>d6</ce:italic>) <ce:italic>δ</ce:italic> 10.71 (s, 1H), 8.06 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 7.94 (s, 1H), 7.47 (s, 1H), 7.29 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 6.84 (s, 1H), 4.14 (s, 2H), 3.40–3.09 (m, 2H), 1.57–1.42 (m, 2H), 1.40–1.15 (m, 2H), 0.89 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, Acetone-<ce:italic>d6</ce:italic>) <ce:italic>δ</ce:italic> 168.3, 157.8, 146.5, 143.7, 139.7, 119.4, 114.0, 109.3, 46.6, 39.5, 32.4, 20.6, 14.0. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd. For C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">18</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">3</ce:inf> 292.140. Found: 292.1407.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.4.2.3" view="all">
                              <ce:label>4.1.4.2.3</ce:label>
                              <ce:section-title id="sectitle0370">
                                 <ce:bold>
                                    <ce:italic>N</ce:italic>-Benzyl-2-(butylamino)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazole-6-carboxamide (61)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0390" view="all">2-(Butylamino)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazole-6-carboxylate (74 mg, 0.3 mmol), triazabicyclodecene (42 mg, 0.3 mmol) and benzylamine (68 μL, 1.5 mmol, 5 equiv.) were reacted according to the procedure B for the amidation. Flash column chromatography afforded compound <ce:bold>61</ce:bold> (62 mg, 64%) as a white foam. IR (neat): 3256, 2925, 1606, 1562, 1460, 1280, 1218, 1026 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.90 (s, 1H), 8.78 (t, <ce:italic>J</ce:italic> = 6.0 Hz, 1H), 7.69 (s, 1H), 7.51 (s, 1H), 7.41–7.23 (m, 4H), 7.28–7.16 (m, 1H), 7.12 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 6.79 (s, 1H), 4.47 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 2H), 3.33–3.19 (m, 2H), 1.56 (dt, <ce:italic>J</ce:italic> = 14.8, 7.3 Hz, 2H), 1.45–1.26 (m, 2H), 0.91 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, DMSO‑<ce:italic>d</ce:italic>
                                 <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 167.07, 157.07, 140.2, 128.1, 127.1, 126.5, 119.8, 113.2, 107.9, 42.5, 41.9, 31.5, 19.5, 13.7. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd For C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">23</ce:inf>N<ce:inf loc="post">4</ce:inf>O 323.1872. Found 323.1862.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.4.2.4" view="all">
                              <ce:label>4.1.4.2.4</ce:label>
                              <ce:section-title id="sectitle0375">
                                 <ce:bold>Methyl 2-(butylamino)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazole-6-carboxylate (62)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0395" view="all">2-(Butylamino)-1<ce:italic>H</ce:italic>-benzo[d]imidazole-6-carboxylate (111 mg, 0.45 mmol), triazabicyclodecene (63 mg, 0.45 mmol) and 2-phenylethylamine (68 μL, 0.45 mmol, 1.2 equiv.) were reacted according to the procedure A for the amidation. Flash column chromatography afforded compound <ce:bold>62</ce:bold> (21 mg, 14%) as a white foam. IR (neat): 3323, 3212, 2959, 1646, 1604, 1539, 1476, 1282, 1219, 1135, 1135 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 7.65 (d, <ce:italic>J</ce:italic> = 1.4 Hz, 1H), 7.46 (m, 1H), 7.39–7.13 (m, 6H), 3.71–3.52 (m, 2H), 3.48–3.35 (m, 2H), 3.02–2.86 (m, 2H), 1.74–1.56 (m, 2H), 1.56–1.38 (m, 2H), 1.00 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). 3H missing due to chemical exchange with MeOD. <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 168.7, 154.7, 145.0, 141.3, 129.9, 129.5, 127.3, 121.1, 120.1, 155.0, 112.3, 111.6, 43.6, 42.7, 36.7, 33.0, 21.0, 13.9. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd For C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">25</ce:inf>N<ce:inf loc="post">4</ce:inf>O 337.2028. Found 337.2034.</ce:para>
                           </ce:section>
                           <ce:section id="sec4.1.4.2.5" view="all">
                              <ce:label>4.1.4.2.5</ce:label>
                              <ce:section-title id="sectitle0380">
                                 <ce:bold>2-(Butylamino)-<ce:italic>N</ce:italic>-(3-phenylpropyl)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazole-6-carboxamide (63)</ce:bold>
                              </ce:section-title>
                              <ce:para id="p0400" view="all">2-(Butylamino)-1<ce:italic>H</ce:italic>-benzo[<ce:italic>d</ce:italic>]imidazole-6-carboxylate (74 mg, 0.3 mmol), triazabicyclodecene (42 mg, 0.3 mmol) and 3-phenylpropylamine (213 μL, 1.5 mmol, 5 equiv.) were reacted according to the procedure B for the amidation. Flash column chromatography afforded compound <ce:bold>63</ce:bold> (48 mg, 46%) as a pink foam. IR (neat): 3267, 2956, 2928, 1592, 1530, 1461, 1279, 1092 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 7.69 (d, <ce:italic>J</ce:italic> = 1.6 Hz, 1H), 7.51 (dd, <ce:italic>J</ce:italic> = 8.3, 1.7 Hz, 1H), 7.30–7.04 (m, 6H), 3.48–3.26 (m, 4H), 2.75–2.58 (m, 2H), 2.00–1.81 (m, 2H), 1.71–1.52 (m, 2H), 1.51–1.33 (m, 2H), 0.97 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). 3H missing due to chemical exchange with MeOD. <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CD<ce:inf loc="post">3</ce:inf>OD) <ce:italic>δ</ce:italic> 171.3, 158.5, 143.1, 129.4, 127.5, 126.9, 121.1, 112.4, 111.6, 43.6, 40.8, 34.4, 33.0, 32.5, 21.1, 14.2. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                                 <ce:italic>m/z</ce:italic> calcd. For C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">27</ce:inf>N<ce:inf loc="post">4</ce:inf>O 351.2185. Found 351.2168.</ce:para>
                           </ce:section>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.5" view="all">
                        <ce:label>4.1.5</ce:label>
                        <ce:section-title id="sectitle0385">General procedure for the synthesis of the 2-aminobenzothiazoles 66 and (67) [<ce:cross-ref id="crosref0450" refid="bib23">23</ce:cross-ref>]</ce:section-title>
                        <ce:para id="p0405" view="all">A mixture of the corresponding 2-chloro-6-nitrobenzo[<ce:italic>d</ce:italic>]thiazole <ce:bold>64</ce:bold> or 2-chloro-5-nitrobenzo[<ce:italic>d</ce:italic>]thiazole <ce:bold>65</ce:bold> (429, mg, 2 mmol), DBU (30 μL, 0.2 mmol, 10 mol%), NaHCO<ce:inf loc="post">3</ce:inf> (190 mg, 1.8 mmol, 0.9 equiv.) was vigorously stirred with a spatula then left on standing for 5 min until the reaction mixture became a thick solid. The resulting solid was washed with water and then recrystallized from ethanol.</ce:para>
                        <ce:section id="sec4.1.5.1" view="all">
                           <ce:label>4.1.5.1</ce:label>
                           <ce:section-title id="sectitle0390">
                              <ce:bold>
                                 <ce:italic>N-</ce:italic>Butyl-6-nitrobenzo[<ce:italic>d</ce:italic>]thiazol-2-amine (66)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0410" view="all">2-Chloro-6-nitrobenzo[<ce:italic>d</ce:italic>]thiazole (429 mg, 2 mmol, DBU (30 μL, 0.2 mmol, 10 mol%), NaHCO<ce:inf loc="post">3</ce:inf> (190 mg, 1.8 mmol, 0.9 equiv.) were reacted following the general procedure for the synthesis of the 2-aminobenzothiazoles. Recrystallization from ethanol afforded compound <ce:bold>66</ce:bold> (303 mg, 60%) as a yellow solid. IR (neat): 3096, 2957, 2862, 1624, 1562, 1456, 1328, 1286, 1214, 1124, 1037 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 8.50 (t, <ce:italic>J</ce:italic> = 2.6 Hz, 1H), 8.27–8.10 (m, 1H), 7.46 (dd, <ce:italic>J</ce:italic> = 8.9, 2.8 Hz, 1H), 6.78 (s, 1H), 3.46 (td, <ce:italic>J</ce:italic> = 7.1, 2.7 Hz, 2H), 1.72 (qd, <ce:italic>J</ce:italic> = 7.7, 2.6 Hz, 2H), 1.54–1.31 (m, 2H), 0.97 (td, <ce:italic>J</ce:italic> = 7.3, 2.8 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 171.8, 157.6, 141.8, 130.4, 122.6, 117.6, 117.4, 45.8, 31.3, 20.0, 13.6. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m/z</ce:italic> calcd For C<ce:inf loc="post">11</ce:inf>H<ce:inf loc="post">14</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf>S 252.0807. Found: 252.0804.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.2" view="all">
                           <ce:label>4.1.5.2</ce:label>
                           <ce:section-title id="sectitle0395">
                              <ce:bold>
                                 <ce:italic>N</ce:italic>-Butyl-5-nitrobenzo[<ce:italic>dse</ce:italic>]thiazol-2-amine (67)</ce:bold>
                           </ce:section-title>
                           <ce:para id="p0415" view="all">2-Chloro-5-nitrobenzo[<ce:italic>d</ce:italic>]thiazole (429 mg, 2 mmol), DBU (30 μL, 0.2 mmol, 10 mol%), NaHCO<ce:inf loc="post">3</ce:inf> (190 mg, 1.8 mmol, 0.9 equiv.) were reacted following the general procedure for the synthesis of the 2-aminobenzothiazoles. Recrystallization from ethanol afforded <ce:bold>(67)</ce:bold> (294 mg, 58%) as a brown solid. IR (neat): 3010, 2855, 1611, 1504, 1329, 1290, 1080, 1058, 944 cm<ce:sup loc="post">−1</ce:sup>. <ce:sup loc="post">1</ce:sup>H NMR (300 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 8.25 (d, <ce:italic>J</ce:italic> = 27.6 Hz, 1H), 7.96 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.70 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 6.77 (s, 1H), 3.47 (t, <ce:italic>J</ce:italic> = 7.1 Hz, 2H), 1.74 (dt, <ce:italic>J</ce:italic> = 14.8, 7.3 Hz, 2H), 1.48 (dq, <ce:italic>J</ce:italic> = 14.3, 7.3 Hz, 2H), 0.99 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (75 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 169.9, 153.1, 146.9, 120.8, 116.1, 113.2, 45.7, 31.5, 20.0, 13.7. HRMS ESI-TOF [<ce:italic>M</ce:italic>+H]<ce:sup loc="post">+</ce:sup> 
                              <ce:italic>m/z</ce:italic> calcd. For C<ce:inf loc="post">11</ce:inf>H<ce:inf loc="post">14</ce:inf>N<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">2</ce:inf>S 252.0807. Found: 252.0801.</ce:para>
                        </ce:section>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0400">Biology</ce:section-title>
                     <ce:section id="sec4.2.1" view="all">
                        <ce:label>4.2.1</ce:label>
                        <ce:section-title id="sectitle0405">Cell cultures</ce:section-title>
                        <ce:para id="p0420" view="all">The human cell lines FADD-deficient Jurkat I 2.1, Jurkat wild-type A3 and RPE-1 hTERT, were obtained from ATCC (American Type Culture Collection, Rockville, MD, USA). Jurkat cells were cultured in RPMI containing glutamax (Invitrogen) supplemented with 10% FCS for Jurkat wild-type or 15% FCS for FADD-deficient Jurkat cells. RPE-1 hTERT cells were cultured in DMEM-F12 containing Glutamax (Invitrogen) supplemented with 10% FCS. All cells were cultured under a 5% CO<ce:inf loc="post">2</ce:inf> atmosphere at 37 °C.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.2" view="all">
                        <ce:label>4.2.2</ce:label>
                        <ce:section-title id="sectitle0410">Reagents</ce:section-title>
                        <ce:para id="p0425" view="all">Recombinant human Flag-tagged TRAIL (TRAIL-Flag) and z-VAD-fmk were obtained from Enzo Life Sciences (Villeurbanne, France). Necrostatin-1s (Nec-1s) were from Calbiochem (VWR International, Fontenay-sous-Bois, France). Sibiriline (Sib) was a kind gift of SeaBeLife Biotech SAS (Roscoff, France). The cytokine TNF-α used for the cell-based assay was obtained from Invitrogen (Carlsbad, CA, USA).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.3" view="all">
                        <ce:label>4.2.3</ce:label>
                        <ce:section-title id="sectitle0415">Cell-based assays</ce:section-title>
                        <ce:para id="p0430" view="all">The cell-based screening assay used for the characterization of necroptosis inhibitors has been previously described in Delehouzé et al. [<ce:cross-ref id="crosref0455" refid="bib5">5</ce:cross-ref>] and Le Cann et al. [<ce:cross-ref id="crosref0460" refid="bib4">4</ce:cross-ref>] The cell-death by necroptosis was induced in Jurkat FADD-deficient cells by addition of 10 ng/mL of human recombinant TNF-α (Invitrogen). The chemical compounds tested here were formatted at 10 mM in 100% DMSO in 96-well plates. The quantification of the cell viability was used as the main parameter to detect bioactive compounds. The cell viability was evaluated by detection of MTS reduction according to the manufacturer’s instructions (CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay, Promega, Fitchburg, WI, USA) (see Delehouzé et al. [<ce:cross-ref id="crosref0465" refid="bib5">5</ce:cross-ref>] for experimental details). As the reduction of tetrazolium reagents can be occasionally observed under conditions in which cell death does not occur, we also used the lactate dehydrogenase (LDH) release assay, as independent cell death assay. The % of maximal cell death was determined by using the CyQUANT™ LDH Cytotoxicity Assay Kit (Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s instructions.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.4" view="all">
                        <ce:label>4.2.4</ce:label>
                        <ce:section-title id="sectitle0420">Protein kinase assays</ce:section-title>
                        <ce:para id="p0435" view="all">Kinase enzymatic activities were assayed in 384-well plates using the ADP-Glo™ assay kit according the recommendations of the manufacturer (Promega, Madison, WI). This assay provides a homogeneous and high-throughput screening method to measure kinase activity by quantifying the amount of ADP produced during a kinase reaction [<ce:cross-ref id="crosref0470" refid="bib31">31</ce:cross-ref>]. The reactions were carried in the presence of 10 μM ATP. The transmitted signal was measured using the Envision (PerkinElmer, Waltham, MA) microplate luminometer and expressed in Relative Light Unit (RLU). Peptide substrates were obtained from Proteogenix (Schiltigheim, France). These experiments were performed on the Kinase Inhibitor Specialized Screening facility (KISSf, FR2424, Station Biologique, Roscoff, France).</ce:para>
                        <ce:para id="p0440" view="all">The following <ce:bold>buffers</ce:bold> were used: <ce:bold>(A)</ce:bold> 10 mM MgCl<ce:inf loc="post">2</ce:inf>, 1 mM EGTA, 1 mM DTT, 25 mM Tris-HCl pH 7.5, 50 μg/mL heparin; <ce:bold>(B)</ce:bold> 25 mM MOPS, pH7.2, 12.5 mM β-glycerophosphate, 25 mM MgCl<ce:inf loc="post">2</ce:inf>, 5 mM EGTA, 2 mM EDTA, 0.25 mM DTT; <ce:bold>(C)</ce:bold> 5 mM MOPS pH 7.2, 2.5 mM β-glycerophosphate, 4 mM MgCl<ce:inf loc="post">2</ce:inf>, 2.5 mM MnCl<ce:inf loc="post">2</ce:inf>, 1 mM EGTA, 0.5 mM EDTA, 50 μg/mL BSA, 0.05 mM DTT.</ce:para>
                        <ce:para id="p0445" view="all">The following <ce:bold>protein kinases</ce:bold> were analyzed during this study: <ce:bold>AuroraB</ce:bold> (human, recombinant, expressed by baculovirus in Sf9 insect cells, SignalChem, product #A31-10G) was assayed in buffer B with 0.16 μg/μL of myelin basic protein (MBP) as substrate; <ce:bold>CDK2/CyclinA</ce:bold> (cyclin-dependent kinase-2, human, kindly provided by Dr. A. Echalier-Glazer, Leicester, UK) was assayed in buffer A with 0.8 μg/μL of histone H1 as substrate; <ce:bold>CDK5/p25</ce:bold> (human, recombinant, expressed in bacteria) was assayed in buffer A with 0.8 μg/μL of histone H1 as substrate; <ce:bold>CDK9/CyclinT</ce:bold> (human, recombinant, expressed by baculovirus in Sf9 insect cells) was assayed in buffer A with 0.27 μg/μL of the following peptide: YSPTSPSYSPTSPSYSPTSPSKKKK, as substrate; <ce:bold>CK1ε</ce:bold> (human, recombinant, expressed by baculovirus in Sf9 insect cells) was assayed in buffer A with 0.022 μg/μL of the following peptide: RRKHAAIGSpAYSITA (“Sp” stands for phosphorylated serine) as CK1-specific substrate; <ce:bold>HASPIN-kd</ce:bold> (human, kinase domain, amino acids 470 to 798, recombinant, expressed in bacteria) was assayed in buffer A with 0.007 μg/μL of Histone H3(1–21) peptide (ARTKQTARKSTGGKAPRKQLA) as substrate; <ce:bold>Pim-1</ce:bold> (human proto-oncogene, recombinant, expressed in bacteria) was assayed in buffer A with 0.083 μg/μL of histone H1 (Sigma #H5505) as substrate; <ce:bold>RIPK3</ce:bold> (human, recombinant, expressed by baculovirus in Sf9 insect cells) was assayed in buffer C with 0.1 μg/μL of MBP as substrate; <ce:bold>
                              <ce:italic>Mm</ce:italic>CLK1</ce:bold> (from <ce:italic>Mus musculus</ce:italic>, recombinant, expressed in bacteria) was assayed in buffer A with 0.017 μg/μL of the following peptide: GRSRSRSRSRSR as substrate; <ce:bold>
                              <ce:italic>Rn</ce:italic>DYRK1A-kd</ce:bold> (<ce:italic>Rattus norvegicu</ce:italic>s, amino acids 1 to 499 including the kinase domain, recombinant, expressed in bacteria, DNA vector kindly provided by Dr. W. Becker, Aachen, Germany) was assayed in buffer A with 0.033 μg/μL of the following peptide: KKISGRLSPIMTEQ as substrate; <ce:bold>ABL1</ce:bold> (human, amino acids 118 to 535, recombinant, expressed by baculovirus in Sf9 insect cells) were assayed in buffer A with 0.17 μg/μL of the following peptide (dubbed ABLtide): EAIYAAPFAKKK as ABL1-selective substrate; <ce:bold>JAK3</ce:bold> (human, C-terminal fragment, amino acids 781–1124, recombinant, expressed by baculovirus in Sf9 insect cells) were assayed in buffer A with 0.17 μg/μL of the following peptide (dubbed JAK3tide): GGEEEEYFELVKKKK as JAK3-selective substrate.</ce:para>
                        <ce:para id="p0450" view="all">To validate each kinase assay, the following model inhibitors were used under the same conditions than the tested compounds: Barasertib (AZD1152-HQPA, #S1147, Selleckchem) for AuroraB; Staurosporine from <ce:italic>Streptomyces</ce:italic> sp. (#S5921, purity ≥95%, Sigma-Aldrich) for CK1<ce:italic>ε</ce:italic>; Indirubin-3′-oxime (#I0404, Sigma-Aldrich) for CDK2/CyclinA, CDK5/p25, CDK9/CyclinT, <ce:italic>Rn</ce:italic>DYRK1A and <ce:italic>Mm</ce:italic>CLK1; CHR-6494 (#SML0648, Sigma-Aldrich) for HASPIN; Tofacitinib (CP-690550, #S2789, Selleckchem) for JAK3; Imatinib mesylate (STI571, #S1026, Selleckchem) for ABL1; GSK′872 (GSK2399872 A, #S8465, Selleckchem) for RIPK3; SGI-1776 (#S2198, Selleckchem) for Pim1.</ce:para>
                        <ce:para id="p0455" view="all">The catalytic activity of <ce:bold>RIPK1</ce:bold> was detected by Eurofins Discovery (Celle-L’Evescault, France) using a radiometric assay. Briefly, human RIPK1-kd (amino acids 8 to 322 including the kinase domain, recombinant) was assayed in 8 mM MOPS pH 7.0, 0.2 mM EDTA, 10 mM magnesium acetate with 0.33 mg/mL of MBP as substrate. The reaction was initiated by the addition of the Mg/[γ-<ce:sup loc="post">33</ce:sup>P]ATP mix (155 μM is the Km value used as ATP final concentration). After incubation for 120 min at room temperature, the reaction is stopped by the addition of phosphoric acid to a concentration of 0.5%. 10 μL of the stopped reaction is spotted onto a P30 filtermat and washed four times for 4 min in 0.425% phosphoric acid and once in methanol prior to drying and scintillation counting. This assay was validated using the Cdk1/2 Inhibitor III (CAS 443798-55-8) as control inhibitor.</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.3" view="all">
                     <ce:label>4.3</ce:label>
                     <ce:section-title id="sectitle0425">Molecular docking</ce:section-title>
                     <ce:para id="p0460" view="all">Three-dimensional structures of ligands were generated using CORINA 4.2.0 (<ce:inter-ref id="intref0015" xlink:href="http://www.molecular-networks.com" xlink:type="simple">http://www.molecular-networks.com</ce:inter-ref>). Two tautomers were considered for the benzimidazole core of each ligand. Molecular docking calculations were carried out using GOLD software [<ce:cross-ref id="crosref0475" refid="bib32">32</ce:cross-ref>] and GoldScore scoring function, with the structure of RIPK1 (PDB code <ce:inter-ref id="intref0020" xlink:href="pdb:6C3E" xlink:type="simple">6C3E</ce:inter-ref>) [<ce:cross-ref id="crosref0480" refid="bib14">14</ce:cross-ref>] as receptor. This structure was selected considering the similarity of the ligand with the structures reported in our study, as well as the conformation of residues Met67, Met92 and Phe162 in the binding pocket. The chain A of this structure was used, the missing loops and atoms being completed using MODELLER [<ce:cross-ref id="crosref0485" refid="bib33">33</ce:cross-ref>].The binding site was defined as a sphere with 15 Å radius around the carbonyl oxygen of Asp156. In agreement with our previous studies [<ce:cross-refs id="crosrefs0020" refid="bib34 bib35 bib36 bib37 bib38 bib39 bib40">34–40</ce:cross-refs>] showing that an enhanced conformational search is beneficial, especially for large molecules, a search efficiency of 200% was used to better explore the ligand conformational space. All other parameters were used with the default values and 10 poses were generated for each ligand.</ce:para>
                     <ce:para id="p0465" view="all">Molecular modeling images were generated using UCSF Chimera [<ce:cross-ref id="crosref0490" refid="bib41">41</ce:cross-ref>].</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec5" view="all">
                  <ce:section-title id="sectitle0430">Author contributions</ce:section-title>
                  <ce:para id="p0470" view="all">Mohamed Benchekroun synthesized a part of compounds and co-wrote the manuscript. Ludmila Ermolenko prepared some analogs Minh Quan Tran and Agathe Vagneux: participated in the synthetic part. Claire Delehouzé, Mohamed Souab, Blandine Baratte et Béatrice Josselin: performed the experiments. Claire Delehouzé, Sandrine Ruchaud and Stéphane Bach, analyzed the results. Stéphane Bach supervised the screening and biological evaluation and co-wrote the manuscript. Hristo Nedev carried out the molecular modeling experiments and analyzed the results Bogdan I. Iorga, analyzed the molecular modeling results and co-wrote the manuscript. Ali Al-Mourabit conceived and directed the project, supervised the findings of this work and wrote the manuscript.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0010" view="all">
               <ce:section-title id="sectitle0435">Declaration of competing interest</ce:section-title>
               <ce:para id="p0475" view="all">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0440">Acknowledgements</ce:section-title>
               <ce:para id="p0480" view="all">Financial support from <ce:grant-sponsor id="gs1" sponsor-id="https://doi.org/10.13039/501100004794" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">CNRS</ce:grant-sponsor> is gratefully acknowledged. The authors thank the Cancéropôle Grand-Ouest (“Marines Molecules, Metabolism and Cancer” network), IBiSA (French Infrastructures en sciences du vivant: biologie, santé et agronomie) and Biogenouest (Western France life science and environment core facility network) for supporting the KISSf screening facility, FR2424 (Roscoff, France). S. Bach is supported by <ce:grant-sponsor id="gs3" sponsor-id="https://doi.org/10.13039/501100001665" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">ANR/Investissements d’Avenir program via the OCEANOMICs project</ce:grant-sponsor> (grant #<ce:grant-number refid="gs3">ANR-11-BTBR-0008</ce:grant-number>) and <ce:grant-sponsor id="gs12" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">French Institut National du Cancer</ce:grant-sponsor> (INCa PLBIO2012, “NECROTRAIL” project, grant #<ce:grant-number refid="gs12">2012-115</ce:grant-number>).</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0445">Supplementary data</ce:section-title>
                  <ce:para id="p0485" view="all">The following is the Supplementary data to this article:<ce:display>
                        <ce:e-component id="ec1">
                           <ce:caption id="cap0010">
                              <ce:simple-para id="espara0010" view="all">copies of <ce:sup loc="post">1</ce:sup>H and <ce:sup loc="post">13</ce:sup>C NMR spectra and figures.</ce:simple-para>
                           </ce:caption>
                           <ce:link locator="mmc1" xlink:href="pii:S0223523420303068/mmc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:type="simple"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0450">Supplementary data</ce:section-title>
                  <ce:para id="p0490" view="all">Supplementary data to this article can be found online at <ce:inter-ref id="intref0025" xlink:href="https://doi.org/10.1016/j.ejmech.2020.112337" xlink:type="simple">https://doi.org/10.1016/j.ejmech.2020.112337</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0455">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Lockshin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Programmed cell death—II. Endocrine potentiation of the breakdown of the intersegmental muscles of silkmoths</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Insect Physiol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>1964</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>643</sb:first-page>
                              <sb:last-page>649</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/0022-1910(64)90034-4</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">R.A. Lockshin, C.M. Williams, Programmed cell death-II. Endocrine potentiation of the breakdown of the intersegmental muscles of silkmoths, J. Insect Physiol. 10 (1964) 643-649. https://doi.org/10.1016/0022-1910(64)90034-4.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Galluzzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Vitale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Aaronson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Abrams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Adam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Agostinis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.S.</ce:given-name>
                                 <ce:surname>Alnemri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Altucci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Amelio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.W.</ce:given-name>
                                 <ce:surname>Andrews</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Annicchiarico-Petruzzelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Antonov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Arama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.H.</ce:given-name>
                                 <ce:surname>Baehrecke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.A.</ce:given-name>
                                 <ce:surname>Barlev</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.G.</ce:given-name>
                                 <ce:surname>Bazan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Bernassola</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.M.</ce:given-name>
                                 <ce:surname>Bertrand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Bianchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.V.</ce:given-name>
                                 <ce:surname>Blagosklonny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Blomgren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Borner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Boya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Brenner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Campanella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Candi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Carmona-Gutierrez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Cecconi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.K.-M.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Chandel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.H.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Chipuk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Cidlowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ciechanover</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Cohen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Conrad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Cubillos-Ruiz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.E.</ce:given-name>
                                 <ce:surname>Czabotar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>D’Angiolella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.M.</ce:given-name>
                                 <ce:surname>Dawson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.L.</ce:given-name>
                                 <ce:surname>Dawson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.D.</ce:given-name>
                                 <ce:surname>Laurenzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.D.</ce:given-name>
                                 <ce:surname>Maria</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.-M.</ce:given-name>
                                 <ce:surname>Debatin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>DeBerardinis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Deshmukh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.D.</ce:given-name>
                                 <ce:surname>Daniele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.D.</ce:given-name>
                                 <ce:surname>Virgilio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Dixit</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Dixon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.S.</ce:given-name>
                                 <ce:surname>Duckett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Dynlacht</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.S.</ce:given-name>
                                 <ce:surname>El-Deiry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Elrod</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Fimia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fulda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>García-Sáez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Garg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Garrido</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Gavathiotis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Golstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Gottlieb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Green</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Greene</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Gronemeyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gross</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Hajnoczky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Hardwick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.S.</ce:given-name>
                                 <ce:surname>Harris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.O.</ce:given-name>
                                 <ce:surname>Hengartner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hetz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ichijo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jäättelä</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Joseph</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Jost</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.P.</ce:given-name>
                                 <ce:surname>Juin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Kaiser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Karin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kaufmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Kepp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kimchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.N.</ce:given-name>
                                 <ce:surname>Kitsis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Klionsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Knight</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Lemasters</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Levine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Linkermann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Lipton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Lockshin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>López-Otín</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Lowe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Luedde</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Lugli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>MacFarlane</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Madeo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Malewicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Malorni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Manic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-C.</ce:given-name>
                                 <ce:surname>Marine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Martin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-C.</ce:given-name>
                                 <ce:surname>Martinou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Medema</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Mehlen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Meier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Melino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Miao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Molkentin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.M.</ce:given-name>
                                 <ce:surname>Moll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Muñoz-Pinedo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nagata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Nuñez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Oberst</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Oren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Overholtzer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Pagano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Panaretakis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Pasparakis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Penninger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Pereira</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pervaiz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Peter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Piacentini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Pinton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.M.</ce:given-name>
                                 <ce:surname>Prehn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Puthalakath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Rabinovich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Rehm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Rizzuto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.P.</ce:given-name>
                                 <ce:surname>Rodrigues</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Rubinsztein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Rudel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Ryan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Sayan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Scorrano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Shao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Silke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.-U.</ce:given-name>
                                 <ce:surname>Simon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sistigu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.R.</ce:given-name>
                                 <ce:surname>Stockwell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Strasser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>zabadkai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.G.</ce:given-name>
                                 <ce:surname>Tait</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Tavernarakis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Thorburn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tsujimoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Turk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.V.</ce:given-name>
                                 <ce:surname>Berghe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Vandenabeele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.V.</ce:given-name>
                                 <ce:surname>Heiden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Villunger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.W.</ce:given-name>
                                 <ce:surname>Virgin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.H.</ce:given-name>
                                 <ce:surname>Vousden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Vucic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.F.</ce:given-name>
                                 <ce:surname>Wagner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Walczak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wallach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Wells</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zakeri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Zhivotovsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zitvogel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Melino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Kroemer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Death Differ.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>486</sb:first-page>
                              <sb:last-page>541</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/s41418-017-0012-4</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">L. Galluzzi, I. Vitale, S.A. Aaronson, J.M. Abrams, D. Adam, P. Agostinis, E.S. Alnemri, L. Altucci, I. Amelio, D.W. Andrews, M. Annicchiarico-Petruzzelli, A.V. Antonov, E. Arama, E.H. Baehrecke, N.A. Barlev, N.G. Bazan, F. Bernassola, M.J.M. Bertrand, K. Bianchi, M.V. Blagosklonny, K. Blomgren, C. Borner, P. Boya, C. Brenner, M. Campanella, E. Candi, D. Carmona-Gutierrez, F. Cecconi, F.K.-M. Chan, N.S. Chandel, E.H. Cheng, J.E. Chipuk, J.A. Cidlowski, A. Ciechanover, G.M. Cohen, M. Conrad, J.R. Cubillos-Ruiz, P.E. Czabotar, V. D’Angiolella, T.M. Dawson, V.L. Dawson, V.D. Laurenzi, R.D. Maria, K.-M. Debatin, R.J. DeBerardinis, M. Deshmukh, N.D. Daniele, F.D. Virgilio, V.M. Dixit, S.J. Dixon, C.S. Duckett, B.D. Dynlacht, W.S. El-Deiry, J.W. Elrod, G.M. Fimia, S. Fulda, A.J. Garcia-Saez, A.D. Garg, C. Garrido, E. Gavathiotis, P. Golstein, E. Gottlieb, D.R. Green, L.A. Greene, H. Gronemeyer, A. Gross, G. Hajnoczky, J.M. Hardwick, I.S. Harris, M.O. Hengartner, C. Hetz, H. Ichijo, M. Jaattela, B. Joseph, P.J. Jost, P.P. Juin, W.J. Kaiser, M. Karin, T. Kaufmann, O. Kepp, A. Kimchi, R.N. Kitsis, D.J. Klionsky, R.A. Knight, S. Kumar, S.W. Lee, J.J. Lemasters, B. Levine, A. Linkermann, S.A. Lipton, R.A. Lockshin, C. Lopez-Otin, S.W. Lowe, T. Luedde, E. Lugli, M. MacFarlane, F. Madeo, M. Malewicz, W. Malorni, G. Manic, J.-C. Marine, S.J. Martin, J.-C. Martinou, J.P. Medema, P. Mehlen, P. Meier, S. Melino, E.A. Miao, J.D. Molkentin, U.M. Moll, C. Munoz-Pinedo, S. Nagata, G. Nunez, A. Oberst, M. Oren, M. Overholtzer, M. Pagano, T. Panaretakis, M. Pasparakis, J.M. Penninger, D.M. Pereira, S. Pervaiz, M.E. Peter, M. Piacentini, P. Pinton, J.H.M. Prehn, H. Puthalakath, G.A. Rabinovich, M. Rehm, R. Rizzuto, C.M.P. Rodrigues, D.C. Rubinsztein, T. Rudel, K.M. Ryan, E. Sayan, L. Scorrano, F. Shao, Y. Shi, J. Silke, H.-U. Simon, A. Sistigu, B.R. Stockwell, A. Strasser, zabadkai, S.W.G. Tait, D. Tang, N. Tavernarakis, A. Thorburn, Y. Tsujimoto, B. Turk, T.V. Berghe, P. Vandenabeele, M.G.V. Heiden, A. Villunger, H.W. Virgin, K.H. Vousden, D. Vucic, E.F. Wagner, H. Walczak, D. Wallach, Y. Wang, J.A. Wells, W. Wood, J. Yuan, Z. Zakeri, B. Zhivotovsky, L. Zitvogel, G. Melino, G. Kroemer, Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018, Cell Death Differ. 25 (2018) 486-541. https://doi.org/10.1038/s41418-017-0012-4.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Jouan-Lanhouet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.I.</ce:given-name>
                                 <ce:surname>Arshad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Piquet-Pellorce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Martin-Chouly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Le Moigne-Muller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Van Herreweghe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Takahashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Sergent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Lagadic-Gossmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Vandenabeele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Samson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.-T.</ce:given-name>
                                 <ce:surname>Dimanche-Boitrel</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Death Differ.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2003</sb:first-page>
                              <sb:last-page>2014</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/cdd.2012.90</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">S. Jouan-Lanhouet, M.I. Arshad, C. Piquet-Pellorce, C. Martin-Chouly, G. Le Moigne-Muller, F. Van Herreweghe, N. Takahashi, O. Sergent, D. Lagadic-Gossmann, P. Vandenabeele, M. Samson, M.-T. Dimanche-Boitrel, TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation, Cell Death Differ. 19 (2012) 2003-2014. https://doi.org/10.1038/cdd.2012.90.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Le Cann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Delehouzé</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Leverrier-Penna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Filliol</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Comte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Delalande</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Desban</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Baratte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Gallais</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Piquet-Pellorce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Faurez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bonnet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Mettey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Goekjian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Samson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Vandenabeele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.-T.</ce:given-name>
                                 <ce:surname>Dimanche-Boitrel</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>FEBS J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>284</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3050</sb:first-page>
                              <sb:last-page>3068</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1111/febs.14176</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">F. Le Cann, C. Delehouze, S. Leverrier-Penna, A. Filliol, A. Comte, O. Delalande, N. Desban, B. Baratte, I. Gallais, C. Piquet-Pellorce, F. Faurez, M. Bonnet, Y. Mettey, P. Goekjian, M. Samson, P. Vandenabeele, S. Bach, M.-T. Dimanche-Boitrel, Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis, FEBS J. 284 (2017) 3050-3068. https://doi.org/10.1111/febs.14176.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Delehouzé</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Leverrier-Penna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.L.</ce:given-name>
                                 <ce:surname>Cann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Comte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jacquard-Fevai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Delalande</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Desban</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Baratte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Gallais</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Faurez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Bonnet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hauteville</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.G.</ce:given-name>
                                 <ce:surname>Goekjian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Thuillier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Favreau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Vandenabeele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Hauet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.T.</ce:given-name>
                                 <ce:surname>Dimanche-Boitrel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bach</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>6E11, a highly selective inhibitor of Receptor-Interacting Protein Kinase 1, protects cells against cold hypoxia-reoxygenation injury</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>12931</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1038/s41598-017-12788-4</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">C. Delehouze, S. Leverrier-Penna, F.L. Cann, A. Comte, M. Jacquard-Fevai, O. Delalande, N. Desban, B. Baratte, I. Gallais, F. Faurez, M.C. Bonnet, M. Hauteville, P.G. Goekjian, R. Thuillier, F. Favreau, P. Vandenabeele, T. Hauet, M.T. Dimanche-Boitrel, S. Bach, 6E11, a highly selective inhibitor of Receptor-Interacting Protein Kinase 1, protects cells against cold hypoxia-reoxygenation injury, Sci. Rep. 7 (2017) 12931. https://doi.org/10.1038/s41598-017-12788-4.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Necroptosis in health and diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Semin. Cell Dev. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>14</sb:first-page>
                              <sb:last-page>23</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.semcdb.2014.07.013</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">W. Zhou, J. Yuan, Necroptosis in health and diseases, Semin. Cell Dev. Biol. 35 (2014) 14-23. https://doi.org/10.1016/j.semcdb.2014.07.013.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Degterev</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Boyce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Jagtap</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Mizushima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.D.</ce:given-name>
                                 <ce:surname>Cuny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Mitchison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Moskowitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>112</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.1038/nchembio711</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">A. Degterev, Z. Huang, M. Boyce, Y. Li, P. Jagtap, N. Mizushima, G.D. Cuny, T.J. Mitchison, M.A. Moskowitz, J. Yuan, Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury, Nat. Chem. Biol. 1 (2005) 112. https://doi.org/10.1038/nchembio711.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Vandenabeele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Grootjans</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Callewaert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Takahashi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Necrostatin-1 blocks both RIPK1 and Ido: consequences for the study of cell death in experimental disease models</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Death Differ.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>185</sb:first-page>
                              <sb:last-page>187</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/cdd.2012.151</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">P. Vandenabeele, S. Grootjans, N. Callewaert, N. Takahashi, Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of cell death in experimental disease models, Cell Death Differ. 20 (2013) 185-187. https://doi.org/10.1038/cdd.2012.151.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Teng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Degterev</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Jagtap</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Xing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Denu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.D.</ce:given-name>
                                 <ce:surname>Cuny</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure–activity relationship study of novel necroptosis inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5039</sb:first-page>
                              <sb:last-page>5044</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmcl.2005.07.077</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">X. Teng, A. Degterev, P. Jagtap, X. Xing, S. Choi, R. Denu, J. Yuan, G.D. Cuny, Structure-activity relationship study of novel necroptosis inhibitors, Bioorg. Med. Chem. Lett. 15 (2005) 5039-5044. https://doi.org/10.1016/j.bmcl.2005.07.077.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhuang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small-molecule inhibitors of necroptosis: current status and perspectives</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>63</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1490</sb:first-page>
                              <sb:last-page>1510</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.9b01317</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">C. Zhuang, F. Chen, Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives, J. Med. Chem. 63 (2020) 1490-1510. https://doi.org/10.1021/acs.jmedchem.9b01317.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Harris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bandyopadhyay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.B.</ce:given-name>
                                 <ce:surname>Berger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Campobasso</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Capriotti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Cox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Dare</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.N.</ce:given-name>
                                 <ce:surname>Finger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Hoffman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Kahler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Lehr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Lich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Nagilla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.T.</ce:given-name>
                                 <ce:surname>Nolte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.T.</ce:given-name>
                                 <ce:surname>Ouellette</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.S.</ce:given-name>
                                 <ce:surname>Pao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Schaeffer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Smallwood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.H.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.A.</ce:given-name>
                                 <ce:surname>Swift</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.D.</ce:given-name>
                                 <ce:surname>Totoritis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ward</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.W.</ce:given-name>
                                 <ce:surname>Marquis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bertin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Gough</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of small molecule RIP1 kinase inhibitors for the treatment of pathologies associated with necroptosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1238</sb:first-page>
                              <sb:last-page>1243</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/ml400382p</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">P.A. Harris, D. Bandyopadhyay, S.B. Berger, N. Campobasso, C.A. Capriotti, J.A. Cox, L. Dare, J.N. Finger, S.J. Hoffman, K.M. Kahler, R. Lehr, J.D. Lich, R. Nagilla, R.T. Nolte, M.T. Ouellette, C.S. Pao, M.C. Schaeffer, A. Smallwood, H.H. Sun, B.A. Swift, R.D. Totoritis, P. Ward, R.W. Marquis, J. Bertin, P.J. Gough, Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis, ACS Med. Chem. Lett. 4 (2013) 1238-1243. https://doi.org/10.1021/ml400382p.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Harris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>King</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bandyopadhyay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.B.</ce:given-name>
                                 <ce:surname>Berger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Campobasso</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Capriotti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Cox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Dare</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.N.</ce:given-name>
                                 <ce:surname>Finger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.C.</ce:given-name>
                                 <ce:surname>Grady</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Hoffman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.U.</ce:given-name>
                                 <ce:surname>Jeong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Kasparcova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Lakdawala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Lehr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>McNulty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Nagilla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.T.</ce:given-name>
                                 <ce:surname>Ouellette</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.S.</ce:given-name>
                                 <ce:surname>Pao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Rendina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Schaeffer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Summerfield</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.A.</ce:given-name>
                                 <ce:surname>Swift</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.D.</ce:given-name>
                                 <ce:surname>Totoritis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ward</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.W.</ce:given-name>
                                 <ce:surname>Marquis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bertin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Gough</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>DNA-encoded library screening identifies benzo[b][1,4]oxazepin-4-ones as highly potent and monoselective receptor interacting protein 1 kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>59</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2163</sb:first-page>
                              <sb:last-page>2178</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.5b01898</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">P.A. Harris, B.W. King, D. Bandyopadhyay, S.B. Berger, N. Campobasso, C.A. Capriotti, J.A. Cox, L. Dare, X. Dong, J.N. Finger, L.C. Grady, S.J. Hoffman, J.U. Jeong, J. Kang, V. Kasparcova, A.S. Lakdawala, R. Lehr, D.E. McNulty, R. Nagilla, M.T. Ouellette, C.S. Pao, A.R. Rendina, M.C. Schaeffer, J.D. Summerfield, B.A. Swift, R.D. Totoritis, P. Ward, A. Zhang, D. Zhang, R.W. Marquis, J. Bertin, P.J. Gough, DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors, J. Med. Chem. 59 (2016) 2163-2178. https://doi.org/10.1021/acs.jmedchem.5b01898.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Weisel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.E.</ce:given-name>
                                 <ce:surname>Scott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Tompson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.J.</ce:given-name>
                                 <ce:surname>Votta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Madhavan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Povey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Wolstenholme</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Simeoni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Rudo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Richards-Peterson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sahota</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.G.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Finger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Verticelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Reilly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Gough</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Harris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bertin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.-L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Res. Perspect.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:article-number>e00365</sb:article-number>
                           <ce:doi>10.1002/prp2.365</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">K. Weisel, N.E. Scott, D.J. Tompson, B.J. Votta, S. Madhavan, K. Povey, A. Wolstenholme, M. Simeoni, T. Rudo, L. Richards-Peterson, T. Sahota, J.G. Wang, J. Lich, J. Finger, A. Verticelli, M. Reilly, P.J. Gough, P.A. Harris, J. Bertin, M.-L. Wang, Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers, Pharmacol. Res. Perspect. 5 (2017) e00365. https://doi.org/10.1002/prp2.365.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yoshikawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Saitoh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Katoh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Seki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.V.</ce:given-name>
                                 <ce:surname>Bigi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shimizu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ishii</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Okai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kuno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hattori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Watanabe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Saikatendu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Nakakariya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Tatamiya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Nakada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yogo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of 7-Oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine derivatives as potent, orally available, and brain-penetrating receptor interacting protein 1 (RIP1) kinase inhibitors: analysis of structure–kinetic relationships</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <ce:doi>10.1021/acs.jmedchem.7b01647</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">M. Yoshikawa, M. Saitoh, T. Katoh, T. Seki, S.V. Bigi, Y. Shimizu, T. Ishii, T. Okai, M. Kuno, H. Hattori, E. Watanabe, K.S. Saikatendu, H. Zou, M. Nakakariya, T. Tatamiya, Y. Nakada, T. Yogo, Discovery of 7-Oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure-Kinetic Relationships, J. Med. Chem. (2018). https://doi.org/10.1021/acs.jmedchem.7b01647.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.B.</ce:given-name>
                                 <ce:surname>Berger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Harris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Nagilla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Kasparcova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hoffman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Swift</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Dare</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Schaeffer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Capriotti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ouellette</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>King</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wisnoski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Reilly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.W.</ce:given-name>
                                 <ce:surname>Marquis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bertin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Gough</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Characterization of GSK’963: a structurally distinct, potent and selective inhibitor of RIP1 kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Death Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <ce:doi>10.1038/cddiscovery.2015.9</ce:doi>
                        </sb:host>
                        <sb:comment>15009–15009</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0100">S.B. Berger, P. Harris, R. Nagilla, V. Kasparcova, S. Hoffman, B. Swift, L. Dare, M. Schaeffer, C. Capriotti, M. Ouellette, B.W. King, D. Wisnoski, J. Cox, M. Reilly, R.W. Marquis, J. Bertin, P.J. Gough, Characterization of GSK’963: a structurally distinct, potent and selective inhibitor of RIP1 kinase., Cell Death Discov. 1 (2015) 15009-15009. https://doi.org/10.1038/cddiscovery.2015.9.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Harris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Faucher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>George</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>Eidam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>King</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.V.</ce:given-name>
                                 <ce:surname>White</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.A.</ce:given-name>
                                 <ce:surname>Anderson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bandyopadhyay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Beal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Beneton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.B.</ce:given-name>
                                 <ce:surname>Berger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Campobasso</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Campos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Capriotti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Cox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Daugan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Donche</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.-H.</ce:given-name>
                                 <ce:surname>Fouchet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.N.</ce:given-name>
                                 <ce:surname>Finger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Geddes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Gough</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Grondin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.L.</ce:given-name>
                                 <ce:surname>Hoffman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Hoffman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Hutchinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.U.</ce:given-name>
                                 <ce:surname>Jeong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Jigorel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Lamoureux</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.K.</ce:given-name>
                                 <ce:surname>Leister</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Lich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Mahajan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Meslamani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Mosley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Nagilla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>Nassau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.-L.</ce:given-name>
                                 <ce:surname>Ng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.T.</ce:given-name>
                                 <ce:surname>Ouellette</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.K.</ce:given-name>
                                 <ce:surname>Pasikanti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Potvain</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Reilly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Rivera</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sautet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Schaeffer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Sehon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Thorpe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.D.</ce:given-name>
                                 <ce:surname>Totoritis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ward</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Wellaway</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.D.</ce:given-name>
                                 <ce:surname>Wisnoski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Woolven</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bertin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.W.</ce:given-name>
                                 <ce:surname>Marquis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and lead-optimization of 4,5-dihydropyrazoles as mono-kinase selective, orally bioavailable and efficacious inhibitors of receptor interacting protein 1 (RIP1) kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5096</sb:first-page>
                              <sb:last-page>5110</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.9b00318</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">P.A. Harris, N. Faucher, N. George, P.M. Eidam, B.W. King, G.V. White, N.A. Anderson, D. Bandyopadhyay, A.M. Beal, V. Beneton, S.B. Berger, N. Campobasso, S. Campos, C.A. Capriotti, J.A. Cox, A. Daugan, F. Donche, M.-H. Fouchet, J.N. Finger, B. Geddes, P.J. Gough, P. Grondin, B.L. Hoffman, S.J. Hoffman, S.E. Hutchinson, J.U. Jeong, E. Jigorel, P. Lamoureux, L.K. Leister, J.D. Lich, M.K. Mahajan, J. Meslamani, J.E. Mosley, R. Nagilla, P.M. Nassau, S.-L. Ng, M.T. Ouellette, K.K. Pasikanti, F. Potvain, M.A. Reilly, E.J. Rivera, S. Sautet, M.C. Schaeffer, C.A. Sehon, H. Sun, J.H. Thorpe, R.D. Totoritis, P. Ward, N. Wellaway, D.D. Wisnoski, J.M. Woolven, J. Bertin, R.W. Marquis, Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase, J. Med. Chem. 62 (2019) 5096-5110. https://doi.org/10.1021/acs.jmedchem.9b00318.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pushpakom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Iorio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Eyers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Escott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hopper</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Wells</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Doig</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Guilliams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Latimer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>McNamee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Norris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sanseau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Cavalla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Pirmohamed</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Drug repurposing: progress, challenges and recommendations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>41</sb:first-page>
                              <sb:last-page>58</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nrd.2018.168</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">S. Pushpakom, F. Iorio, P.A. Eyers, K.J. Escott, S. Hopper, A. Wells, A. Doig, T. Guilliams, J. Latimer, C. McNamee, A. Norris, P. Sanseau, D. Cavalla, M. Pirmohamed, Drug repurposing: progress, challenges and recommendations, Nat. Rev. Drug Discov. 18 (2019) 41-58. https://doi.org/10.1038/nrd.2018.168.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hofmans</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Devisscher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Martens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Van Rompaey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Goossens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Divert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Nerinckx</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Takahashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>De Winter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Van Der Veken</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Goossens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Vandenabeele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Augustyns</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tozasertib analogues as inhibitors of necroptotic cell death</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <ce:doi>10.1021/acs.jmedchem.7b01449</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">S. Hofmans, L. Devisscher, S. Martens, D. Van Rompaey, K. Goossens, T. Divert, W. Nerinckx, N. Takahashi, H. De Winter, P. Van Der Veken, V. Goossens, P. Vandenabeele, K. Augustyns, Tozasertib Analogues as Inhibitors of Necroptotic Cell Death, J. Med. Chem. (2018). https://doi.org/10.1021/acs.jmedchem.7b01449.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.B.</ce:given-name>
                                 <ce:surname>Bharate</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.D.</ce:given-name>
                                 <ce:surname>Sawant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.P.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Vishwakarma</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Kinase inhibitors of marine origin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>113</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6761</sb:first-page>
                              <sb:last-page>6815</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/cr300410v</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">S.B. Bharate, S.D. Sawant, P.P. Singh, R.A. Vishwakarma, Kinase Inhibitors of Marine Origin, Chem. Rev. 113 (2013) 6761-6815. https://doi.org/10.1021/cr300410v.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Appenzeller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Tilvi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.-T.</ce:given-name>
                                 <ce:surname>Martin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-F.</ce:given-name>
                                 <ce:surname>Gallard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>El-bitar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.-T.</ce:given-name>
                                 <ce:surname>Huu Dau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Debitus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Laurent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Moriou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Al-Mourabit</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Benzosceptrins A and B, with A unique benzocyclobutane skeleton and nagelamide S and T from the pacific sponges</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Org. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4874</sb:first-page>
                              <sb:last-page>4877</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/ol901946h</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">J. Appenzeller, S. Tilvi, M.-T. Martin, J.-F. Gallard, H. El-bitar, E.-T. Huu Dau, C. Debitus, D. Laurent, C. Moriou, A. Al-Mourabit, Benzosceptrins A and B, With A Unique Benzocyclobutane Skeleton and Nagelamide S and T from the Pacific Sponges, Org. Lett. 11 (2009) 4874-4877. doi.org/10.1021/ol901946h.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sheng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structural simplification of natural products</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <ce:doi>10.1021/acs.chemrev.8b00504</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">S. Wang, G. Dong, C. Sheng, Structural Simplification of Natural Products, Chem. Rev. (2019). https://doi.org/10.1021/acs.chemrev.8b00504.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Frei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Breitbach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.E.</ce:given-name>
                                 <ce:surname>Blackwell</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>2-Aminobenzimidazole derivatives strongly inhibit and disperse Pseudomonas aeruginosa biofilms</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Angew. Chem. Int. Ed.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5226</sb:first-page>
                              <sb:last-page>5229</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/anie.201109258</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">R. Frei, A.S. Breitbach, H.E. Blackwell, 2-Aminobenzimidazole Derivatives Strongly Inhibit and Disperse Pseudomonas aeruginosa Biofilms, Angew. Chem. Int. Ed. 51 (2012) 5226-5229. https://doi.org/10.1002/anie.201109258.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Verma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.N.</ce:given-name>
                                 <ce:surname>Acharya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ghorpade</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Pratap</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.P.</ce:given-name>
                                 <ce:surname>Kaushik</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A DBU–diheteroaryl halide adduct as the fastest current N-diheteroarylating agent</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>RSC Adv.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>18783</sb:first-page>
                              <sb:last-page>18786</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1039/C3RA43179G</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">S.K. Verma, B.N. Acharya, R. Ghorpade, A. Pratap, M.P. Kaushik, A DBU-diheteroaryl halide adduct as the fastest current N-diheteroarylating agent, RSC Adv. 3 (2013) 18783-18786. https://doi.org/10.1039/C3RA43179G.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ju</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Death Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>13</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/s41419-019-1735-6</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">J. Hou, J. Ju, Z. Zhang, C. Zhao, Z. Li, J. Zheng, T. Sheng, H. Zhang, L. Hu, X. Yu, W. Zhang, Y. Li, M. Wu, H. Ma, X. Zhang, S. He, Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis, Cell Death Dis. 10 (2019) 1-13. https://doi.org/10.1038/s41419-019-1735-6.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Belmokhtar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hillion</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Ségal-Bendirdjian</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3354</sb:first-page>
                              <sb:last-page>3362</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/sj.onc.1204436</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">C.A. Belmokhtar, J. Hillion, E. Segal-Bendirdjian, Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms, Oncogene. 20 (2001) 3354-3362. https://doi.org/10.1038/sj.onc.1204436.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Esser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ehrengart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.P.</ce:given-name>
                                 <ce:surname>Ignatow</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cyclic guanidines. Part 6. 1 Synthesis of benzimidazoles by intramolecular vicarious nucleophilic substitution of hydrogen</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Soc. Perkin.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1153</sb:first-page>
                              <sb:last-page>1154</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1039/A900553F</ce:doi>
                        </sb:host>
                        <sb:comment>0</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0155">F. Esser, P. Ehrengart, H.P. Ignatow, Cyclic guanidines. Part 6. 1 Synthesis of benzimidazoles by intramolecular vicarious nucleophilic substitution of hydrogen, J. Chem. Soc. Perkin 1. 0 (1999) 1153-1154. https://doi.org/10.1039/A900553F.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ha Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hyun An</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Hyun Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.-Y.</ce:given-name>
                                 <ce:surname>Park Choo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A facile synthesis of 2-acyl and 2-alkylaminobenzimidazoles for 5-lipoxygenase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Heterocycles</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>70</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>571</sb:first-page>
                           </sb:pages>
                           <ce:doi>10.3987/COM-06-S(W)25</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">G. Han, J. Ha Lee, M. Hyun An, E. Hyun Choi, H.-Y. Park Choo, A Facile Synthesis of 2-Acyl and 2-Alkylaminobenzimidazoles for 5-Lipoxygenase Inhibitors, Heterocycles. 70 (2006) 571. https://doi.org/10.3987/COM-06-S(W)25.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Krishnamurthy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Senanayake</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A practical synthesis of 2-(N-substituted)-aminobenzimidazoles utilizing CuCl-promoted intramolecular cyclization of N-(2-aminoaryl)thioureas</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Tetrahedron Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>45</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7167</sb:first-page>
                              <sb:last-page>7170</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.tetlet.2004.07.042</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">X. Wang, L. Zhang, Y. Xu, D. Krishnamurthy, C.H. Senanayake, A practical synthesis of 2-(N-substituted)-aminobenzimidazoles utilizing CuCl-promoted intramolecular cyclization of N-(2-aminoaryl)thioureas, Tetrahedron Lett. 45 (2004) 7167-7170. https://doi.org/10.1016/j.tetlet.2004.07.042.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>PubChem</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>N-Cyclohexyl-6-methyl-1H-benzimidazol-2-amine</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2019</sb:date>
                           </sb:book>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intref0035" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/71190137" xlink:type="simple">https://pubchem.ncbi.nlm.nih.gov/compound/71190137</ce:inter-ref>
                              <sb:date-accessed day="6" month="8" year="2019"/></sb:date-accessed>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">PubChem, N-Cyclohexyl-6-methyl-1H-benzimidazol-2-amine, (2019). https://pubchem.ncbi.nlm.nih.gov/compound/71190137 (accessed August 6, 2019).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>PubChem</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>6-Chloro-N-cyclohexyl-1H-benzimidazol-2-amine</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2019</sb:date>
                           </sb:book>
                        </sb:host>
                        <sb:host>
                           <sb:e-host>
                              <ce:inter-ref id="intref0040" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/33697394" xlink:type="simple">https://pubchem.ncbi.nlm.nih.gov/compound/33697394</ce:inter-ref>
                              <sb:date-accessed day="6" month="8" year="2019"/></sb:date-accessed>
                           </sb:e-host>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">PubChem, 6-Chloro-N-cyclohexyl-1H-benzimidazol-2-amine, (2019). https://pubchem.ncbi.nlm.nih.gov/compound/33697394 (accessed August 6, 2019).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zegzouti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zdanovskaia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hsiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Goueli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>ADP-Glo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A bioluminescent and homogeneous ADP monitoring assay for kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Assay Drug Dev. Technol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>560</sb:first-page>
                              <sb:last-page>572</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1089/adt.2009.0222</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">H. Zegzouti, M. Zdanovskaia, K. Hsiao, S.A. Goueli, ADP-Glo: A Bioluminescent and Homogeneous ADP Monitoring Assay for Kinases, ASSAY Drug Dev. Technol. 7 (2009) 560-572. https://doi.org/10.1089/adt.2009.0222.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Verdonk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Cole</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Hartshorn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Murray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.D.</ce:given-name>
                                 <ce:surname>Taylor</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Improved protein–ligand docking using GOLD</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proteins Struct. Funct. Bioinforma.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>52</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>609</sb:first-page>
                              <sb:last-page>623</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/prot.10465</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">M.L. Verdonk, J.C. Cole, M.J. Hartshorn, C.W. Murray, R.D. Taylor, Improved protein-ligand docking using GOLD, Proteins Struct. Funct. Bioinforma. 52 (2003) 609-623. https://doi.org/10.1002/prot.10465.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Šali</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Blundell</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Comparative protein modelling by satisfaction of spatial restraints</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Mol. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>234</sb:volume-nr>
                              </sb:series>
                              <sb:date>1993</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>779</sb:first-page>
                              <sb:last-page>815</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1006/jmbi.1993.1626</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">A. Sali, T.L. Blundell, Comparative Protein Modelling by Satisfaction of Spatial Restraints, J. Mol. Biol. 234 (1993) 779-815. https://doi.org/10.1006/jmbi.1993.1626.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Surpateanu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.I.</ce:given-name>
                                 <ce:surname>Iorga</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Evaluation of docking performance in a blinded virtual screening of fragment-like trypsin inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Aided Mol. Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>595</sb:first-page>
                              <sb:last-page>601</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/s10822-011-9526-x</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">G. Surpateanu, B.I. Iorga, Evaluation of docking performance in a blinded virtual screening of fragment-like trypsin inhibitors, J. Comput. Aided Mol. Des. 26 (2012) 595-601. https://doi.org/10.1007/s10822-011-9526-x.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Colas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.I.</ce:given-name>
                                 <ce:surname>Iorga</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Virtual screening of the SAMPL4 blinded HIV integrase inhibitors dataset</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Aided Mol. Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>455</sb:first-page>
                              <sb:last-page>462</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/s10822-014-9707-5</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">C. Colas, B.I. Iorga, Virtual screening of the SAMPL4 blinded HIV integrase inhibitors dataset, J. Comput. Aided Mol. Des. 28 (2014) 455-462. https://doi.org/10.1007/s10822-014-9707-5.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.Y.</ce:given-name>
                                 <ce:surname>Martiny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Martz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Selwa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.I.</ce:given-name>
                                 <ce:surname>Iorga</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Blind pose prediction, scoring, and affinity ranking of the CSAR 2014 dataset</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Inf. Model.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>996</sb:first-page>
                              <sb:last-page>1003</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jcim.5b00337</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">V.Y. Martiny, F. Martz, E. Selwa, B.I. Iorga, Blind Pose Prediction, Scoring, and Affinity Ranking of the CSAR 2014 Dataset, J. Chem. Inf. Model. 56 (2016) 996-1003. https://doi.org/10.1021/acs.jcim.5b00337.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Selwa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.Y.</ce:given-name>
                                 <ce:surname>Martiny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.I.</ce:given-name>
                                 <ce:surname>Iorga</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular docking performance evaluated on the D3R Grand Challenge 2015 drug-like ligand datasets</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Aided Mol. Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>829</sb:first-page>
                              <sb:last-page>839</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/s10822-016-9983-3</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">E. Selwa, V.Y. Martiny, B.I. Iorga, Molecular docking performance evaluated on the D3R Grand Challenge 2015 drug-like ligand datasets, J. Comput. Aided Mol. Des. 30 (2016) 829-839. https://doi.org/10.1007/s10822-016-9983-3.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Selwa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Elisée</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zavala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.I.</ce:given-name>
                                 <ce:surname>Iorga</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Blinded evaluation of farnesoid X receptor (FXR) ligands binding using molecular docking and free energy calculations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Aided Mol. Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>273</sb:first-page>
                              <sb:last-page>286</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/s10822-017-0054-1</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">E. Selwa, E. Elisee, A. Zavala, B.I. Iorga, Blinded evaluation of farnesoid X receptor (FXR) ligands binding using molecular docking and free energy calculations, J. Comput. Aided Mol. Des. 32 (2018) 273-286. https://doi.org/10.1007/s10822-017-0054-1.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chaput</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Selwa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Elisée</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.I.</ce:given-name>
                                 <ce:surname>Iorga</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Blinded evaluation of cathepsin S inhibitors from the D3RGC3 dataset using molecular docking and free energy calculations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Aided Mol. Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>93</sb:first-page>
                              <sb:last-page>103</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/s10822-018-0161-7</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0220">L. Chaput, E. Selwa, E. Elisee, B.I. Iorga, Blinded evaluation of cathepsin S inhibitors from the D3RGC3 dataset using molecular docking and free energy calculations, J. Comput. Aided Mol. Des. 33 (2019) 93-103. https://doi.org/10.1007/s10822-018-0161-7.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Elisée</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Gapsys</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Mele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chaput</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Selwa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.L.</ce:given-name>
                                 <ce:surname>de Groot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.I.</ce:given-name>
                                 <ce:surname>Iorga</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Performance evaluation of molecular docking and free energy calculations protocols using the D3R Grand Challenge 4 dataset</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Aided Mol. Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1031</sb:first-page>
                              <sb:last-page>1043</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/s10822-019-00232-w</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0225">E. Elisee, V. Gapsys, N. Mele, L. Chaput, E. Selwa, B.L. de Groot, B.I. Iorga, Performance evaluation of molecular docking and free energy calculations protocols using the D3R Grand Challenge 4 dataset, J. Comput. Aided Mol. Des. 33 (2019) 1031-1043. https://doi.org/10.1007/s10822-019-00232-w.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.F.</ce:given-name>
                                 <ce:surname>Pettersen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.D.</ce:given-name>
                                 <ce:surname>Goddard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Couch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Greenblatt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.C.</ce:given-name>
                                 <ce:surname>Meng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.E.</ce:given-name>
                                 <ce:surname>Ferrin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>UCSF Chimera—a visualization system for exploratory research and analysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1605</sb:first-page>
                              <sb:last-page>1612</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/jcc.20084</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0230">E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, T.E. Ferrin, UCSF Chimera-A visualization system for exploratory research and analysis, J. Comput. Chem. 25 (2004) 1605-1612. https://doi.org/10.1002/jcc.20084.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>